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Abstract
Recruitment to randomised trials: strategies for trial enrolment
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MK Campbell,1* C Snowdon,2 D Francis,3 D Elbourne,2 AM McDonald,1 R Knight,2
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Objectives: To identify factors associated with good
and poor recruitment to multicentre trials.
Data sources: Part A: database of trials started in or
after 1994 and were due to end before 2003 held by
the Medical Research Council and Health Technology
Assessment Programmes. Part B: interviews with
people playing a wide range of roles within four trials
that their funders identified as ‘exemplars’. Part C: a
large multicentre trial (the CRASH trial) of treatment
for head injury. 
Review methods: The study used a number of
different perspectives (‘multiple lenses’), and three
components. Part A: an epidemiological review of a
cohort of trials. Part B: case studies of trials that
appeared to have particularly interesting lessons for
recruitment. Part C: a single, in-depth case study to
examine the feasibility of applying a business-
orientated analytical framework as a reference model
in future trials. 
Results: In the 114 trials found in Part A, less than
one-third recruited their original target within the time
originally specified, and around one-third had
extensions. Factors observed more often in trials that
recruited successfully were: having a dedicated trial
manager, being a cancer or drug trial, and having
interventions only available inside the trial. The most
commonly reported strategies to improve recruitment
were newsletters and mailshots, but it was not
possible to assess whether they were causally linked to
changes in recruitment. The analyses in Part B
suggested that successful trials were those addressing
clinically important questions at a timely point. The
investigators were held in high esteem by the
interviewees, and the trials were firmly grounded in
existing clinical practices, so that the trial processes
were not alien to clinical collaborators, and the results
could be easily applicable to future practice. The
interviewees considered that the needs of patients
were well served by participation in the trials. Clinical
collaborators particularly appreciated clear delineation
of roles, which released them from much of the
workload associated with trial participation. There was
a strong feeling from interviewees that they were
proud to be part of a successful team. This pride fed
into further success. Good groundwork and excellent
communications across many levels of complex trial
structures were considered to be extremely
important, including training components for learning
about trial interventions and processes, and team
building. All four trials had faced recruitment
problems, and extra insights into the working of trials
were afforded by strategies invoked to address them.
The process of the case study in Part C was able to
draw attention to a body of research and practice in a
different discipline (academic business studies). It
generated a reference model derived from a
combination of business theory and work within
CRASH. This enabled identification of weaker
managerial components within CRASH, and initiatives
to strengthen them. Although it is not clear, even
within CRASH, whether the initiatives that follow from
developing and applying the model will be effective in
increasing recruitment or other aspects of the success
of the trial, the reference model could provide a
template, with potential for those managing other
trials to use or adapt it, especially at foundation 
stages. The model derived from this project could 
also be used as a diagnostic tool if trials have difficulties
and hence as a basis for deciding what type of
remedial action to take. It may also be useful for
auditing the progress of trials, such as during external
review. Conclusions: While not producing sufficiently definitive
results to make strong recommendations, the work
here suggests that future trials should consider the
different needs at different phases in the life of trials,
and place greater emphasis on ‘conduct’ (the process
of actually doing trials). This implies learning lessons
from successful trialists and trial managers, with better
training for issues relating to trial conduct. The
complexity of large trials means that unanticipated
difficulties are highly likely at some time in every trial.
Part B suggested that successful trials were those
flexible and robust enough to adapt to unexpected
issues. Arguably, the trialists should also expect agility
from funders within a proactive approach to
monitoring ongoing trials. Further research into
different recruitment patterns (including ‘failures’) may
help to clarify whether the patterns seen in the
‘exemplar’ trials differ or are similar. The reference
model from Part C needs to be further considered in
other similar and different trials to assess its
robustness. These and other strategies aimed at
increasing recruitment and making trials more
successful need to be formally evaluated for their
effectiveness in a range of trials.
Abstract
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Background
Randomised controlled trials are widely accepted
as the gold standard for evaluating healthcare
interventions. If, however, the target sample 
size is not achieved, the trial’s results will usually
be less reliable. If recruitment has to be 
extended to reach the required sample size, 
this will delay the use of the results in clinical
practice, and usually cost more, so fewer trials can
be conducted within the limited resources
available. 
Objectives
It is unclear why certain trials recruit well whereas
others do not. The aim was, therefore, to identify
factors associated with good and poor recruitment
to multicentre trials. 
Methods 
The study used a number of different perspectives
(‘multiple lenses’), and three components: Part A:
an epidemiological review of a cohort of trials
funded by the UK’s Medical Research Council
(MRC) and Health Technology Assessment (HTA)
Programme; Part B: case studies of trials that
appeared to have particularly interesting lessons
for recruitment; and Part C: a single, in-depth
case study of a large multicentre trial to examine
the feasibility of applying a business-orientated
analytical framework as a reference model in
future trials. 
Part A was based on 114 multicentre MRC and
HTA Programme trials that started in or after
1994 and were due to end before 2003. 
Whereas in Part A the planned level of
recruitment was used as a surrogate measure for
the ‘success’ of a trial, Part B was based on in-
depth analyses of 45 interviews with people
playing a wide range of roles within four trials that
their funders identified as ‘exemplars’ (trials which
had met, or were scheduled to meet, agreed
targets and that the funders publicised as
successes). 
Part C complements the emphasis on trial
‘processes’ in Parts A and B in a case study of a
large multicentre trial (the CRASH trial) of
treatment for head injury. 
Results
In the trials found in Part A, less than one-third
recruited their original target within the time
originally specified, and around one-third had
extensions. Factors observed more often in trials
that recruited successfully were: having a dedicated
trial manager, being a cancer or drug trial, and
having interventions only available inside the trial.
However, these findings should be interpreted
cautiously: the confidence intervals were wide;
associations were, at best, only marginally
statistically significant; and the trend for some
factors was towards a negative association. The
most commonly reported strategies to improve
recruitment were newsletters and mailshots, but it
was not possible to assess whether they were
causally linked to changes in recruitment. 
The analyses in Part B suggested that successful
trials were those addressing clinically important
questions at a timely point. The investigators were
held in high esteem by the interviewees, and the
trials were firmly grounded in existing clinical
practices, so that the trial processes were not alien
to clinical collaborators, and the results could be
easily applicable to future practice. The
interviewees considered that the needs of patients
were well served by participation in the trials.
Clinical collaborators particularly appreciated
clear delineation of roles, which released them
from much of the workload associated with trial
participation. There was a strong feeling from
interviewees that they were proud to be part of a
successful team. This pride fed into further
success. Good groundwork and excellent
communications across many levels of complex
trial structures were considered to be extremely
important, including training components for
learning about trial interventions and processes,
and team building. All four trials had faced
recruitment problems, and extra insights into the
working of trials were afforded by strategies
invoked to address them. Teams within trials that
Executive summaryx
were not exemplars were not interviewed, and
hence it is not known to what extent the
perceptions observed in these exemplars differed
from those in trials that were less successful. 
The process of the case study in Part C was able to
draw attention to a body of research and practice in
a different discipline (academic business studies). It
generated a reference model derived from a
combination of business theory and work within
CRASH. This enabled identification of weaker
managerial components within CRASH, and
initiatives to strengthen them. Although it is not
clear, even within CRASH, whether the initiatives
that follow from developing and applying the
model will be effective in increasing recruitment or
other aspects of the success of the trial, the
reference model could provide a template, with
potential for those managing other trials to use or
adapt it, especially at foundation stages. The model
derived from this project could also be used as a
diagnostic tool if trials have difficulties and hence
as a basis for deciding what type of remedial action
to take. It may also be useful for auditing the
progress of trials, such as during external review. 
Conclusions
While not producing sufficiently definitive results
to propose strong recommendations, the work
here suggests that people undertaking future 
trials ought at least to think about the different
needs at different phases in the life of trials, and
place greater emphasis on ‘conduct’ (the process
of actually doing trials). This implies learning
lessons from successful trialists and trial managers,
with better training for issues relating to trial
conduct.
The complexity of large trials means that
unanticipated difficulties are highly likely at some
time in every trial. Part B suggested that 
successful trials were those flexible and robust
enough to adapt to unexpected issues. Arguably,
the trialists should also expect agility from funders
within a proactive approach to monitoring
ongoing trials.
Recommendations for research
Three important areas for further research arise.
First, an extension of Part B to trials with different
recruitment patterns (including ‘failures’) may
help to clarify whether the patterns seen in the
‘exemplar’ trials differ or are similar. Second, Part
C was based around a single large trial with the
unusual feature that patients were mainly
unconscious. Before use as an audit tool for
diagnosing and/or addressing management
factors, the reference model needs to be
considered in other similar and different trials to
assess its robustness. Finally, these and other
strategies aimed at increasing recruitment and
making trials more successful need to be formally
evaluated for their effectiveness in a range of
trials.
Executive summaryBackground
The importance of the randomised
controlled trial
The randomised controlled trial (RCT) is widely
accepted as the gold-standard design for
evaluating healthcare interventions.1,2 Its principal
benefits are widely known; for example, the
groups generated should only differ by chance in
baseline prognostic variables, the potential for
attribution is maximised and the results can be
analysed using standard statistical testing.
Decision-makers are increasingly looking to the
results of RCTs to guide practice, and RCTs are
now a major and increasing component of NHS-
supported research and non-commercially funded
research more generally.3 For example, the UK
Medical Research Council (MRC), in its recent
review of clinical trials, considers that RCTs are
the “most scientifically rigorous, unbiased way of
comparing alternative healthcare interventions”.4
Successful delivery of RCTs
It is important that trials are conducted ethically
and efficiently. However, several issues can hamper
the successful delivery of trials. These include
barriers to patient participation, barriers to
clinician participation, poor design, poor conduct,
poor analysis, poor reporting and other obstacles
such as complex consent procedures.5 One of the
most commonly reported problems with the
conduct of multicentre RCTs, however, is that
recruitment is slower or more difficult than
expected, with many trials failing to reach their
planned sample size within the timescale and
funding originally envisaged.6 If the target sample
size is not achieved, the trial has less statistical
power to detect potentially important clinical
differences between the groups, so the results may
be less useful.7 In addition, if recruitment has to
be extended to reach the required sample size, the
trial will cost more and take longer, delaying the
use of the results in clinical practice. If trials
become more expensive and take longer, fewer
trials can be conducted overall with the limited
funding and resources available, and hence less
information will be available to the NHS. There is
growing policy concern in the UK that trials are
increasingly not achieving planned recruitment
targets.
To recruit successfully to an RCT depends on a
number of factors beyond that of a good design,
including: (1) the formal authorisation of the trial,
for example by research ethics committees (RECs);
(2) the active participation of clinicians or
collaborating researchers; and (3) the participation
of patients. There has been considerable discussion
about whether patients are increasingly less willing
to participate in RCTs.8,9,10 If, however, steps (1)
and (2) are not fulfilled, then patients are unlikely
to be in a position either to refuse or to accept
participation. For the formal authorisation of a
trial, REC and NHS Research and Development
(R&D) approval is generally required, which can
often be a lengthy process. In addition, successful
participation of clinicians generally requires the
fulfilment of a number of key roles: that they agree
to participate in the RCT when invited, offer
participation in the trial to eligible patients, recruit
eligible patients, and comply with the procedures
outlined in the trial protocol.5 Each of these stages
represents a potential barrier to the successful
delivery of a trial.
The reasons why certain trials recruit well while
others do not remain unclear. Several potential
limiting factors have been identified in the
literature,5 including constraints on clinician
time,11,12 lack of available staff,13 impact on clinician
autonomy and complexity of trial procedures.14
Most of these factors were identified from surveys of
researchers or clinicians involved in research, and
are summarised in reviews.5,15 Qualitative work in
selected perinatal trials explored the factors that
influenced doctors’ willingness to propose the trial
to parents.16 Some of the key factors that influenced
the clinicians were their degree of commitment to
the trial, their understanding of the scientific
background to the trial, time factors, confidence
about handling the clinical procedures required, a
sense of ownership and good communication with
senior staff about the trial. The more junior doctors
identified the need for more support from senior
staff, as well as for training.
Specific strategies to improve
recruitment
There are several reports in the literature of
clinical trials and elsewhere where specific
strategies implemented to improve recruitment
Health Technology Assessment 2007; Vol. 11: No. 48
1
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
Chapter 1
Introductionyielded large changes in recruitment rates. A
recent example in clinical trials is that of the
ORACLE (Role of Antibiotics in Curtailing Labour
and Early Delivery) trial,17 where the introduction
of a number of research midwives had a dramatic
effect on subsequent recruitment rates. The use of
data from these ‘natural experiments’ may provide
particularly useful lessons for the formulation of
strategies to counter failing recruitment. A
systematic review of trials of strategies to increase
recruitment in research studies was recently
published in which a total of 18 trials was
identified, including a total of 39,516
participants.18 The effectiveness of six different
strategies aimed at participants was evaluated.
Seven trials evaluated the effect of providing
potential participants with additional information,
four examined the relative effectiveness of different
consent procedures, three evaluated the effect of
prewarning, two the use of incentives, one the
effect of using a placebo and one trial evaluated
the effect of different types of invitation letter.
There were, however, no trials of interventions to
improve recruitment in multicentre studies, nor
trials on how to ensure that study participation is
routinely offered to patients.
Lessons from research other than
healthcare
The studies mentioned above have all been
conducted within the healthcare environment;
however, many other organisations have sought to
influence and enrol others. For example, in
business some firms have sought to develop long-
term, mutually advantageous relationships with
partners, customers and clients, often with
beneficial results. Indeed, improving
interorganisational relationships is so well
established that ‘relationship marketing’ and
‘partnering’ are extensively discussed in current
business literature. Thus, the application of
analytical frameworks from outside the healthcare
environment may shed new light on the challenge
of recruiting and sustaining trial sites.
The commissioned research
It was against this background that the National
Coordinating Centre for Research Methodology
(NCCRM) (through funding from both the
Department of Health and the MRC)
commissioned research to identify the factors that
are associated with good and poor recruitment to
multicentre trials. Particular emphasis was placed
in the commissioning brief on the participation of
collaborating researchers. 
The research project
Reflecting the commissioning brief, the research
project outlined in this monograph aimed to
identify the factors associated with good and poor
recruitment to multicentre trials, concentrating
particularly on the participation of collaborating
researchers. It also considered the wider issue of
what counts as a successful trial, broadening the
debate from recruitment alone. 
Research approach adopted
To try to understand the potential factors associated
with good and poor recruitment more fully, this
project undertook to examine recruitment from a
number of different perspectives: a ‘multiple lens’
approach. Multiple lens approaches have been used
widely in social science for the examination of
complex phenomena, organisations or processes.
The concept behind the multiple lens approach is
that individual perspectives give interesting insights
into the situation or procedure under examination,
but implicitly lead us to interpret the issues in
distinctive yet partial ways. When taken together,
however, they give a much wider and insightful
vision of the underlying issues. An example of this
approach from the field of organisational behaviour
was the research undertaken by Morgan19 to
examine the ways in which organisations function.
He viewed organisational behaviour from a number
of different perspectives (e.g. from the perspective
of organisations as machines, organisms and
cultures). These perspectives, when considered
individually, gave interesting and different insights
into the organisation, but when taken together gave
a much wider and more rounded insight into the
underlying issues. As recruitment to trials is a
complex process, the present authors decided to
adopt this multiple lens approach to their
investigation. 
Individual components of the research
Reflecting this innovative approach, the project,
known as STEPS (Strategies for Trials Enrolment
and Participation Study), had three distinct
components (all of which could stand alone but
which, when taken together, might provide insights
greater than the sum of the individual parts).
Part A: An epidemiological review of a cohort of
trials funded by the MRC and the NHS HTA
Programme
The aim of this component of the study was to
explore documentation held by funders on a
cohort of trials. These documents provide a rich
description of factors that may influence
recruitment to multicentre trials, as progress
Introduction
2towards recruitment targets is explicitly monitored
and any problems with recruitment are
highlighted, together with any strategies adopted
to improve recruitment. The aims were to describe
the characteristics of the trials in terms of factors
that may affect the success of recruitment (e.g.
level of funding, complexity of trial design,
involvement of a trials support unit), to describe
patterns of recruitment observed; and to describe
trialists’ reports of factors perceived to be
associated with good or poor recruitment (e.g.
delays in obtaining funding or ethics approval)
and strategies attempted to improve recruitment.
Part B: Case studies of trials that appeared to
have particularly interesting lessons for
recruitment
The aim of this component was to explore in more
depth trials that may be considered to be
‘exemplars’ with regard to recruitment. The aims
were to examine these exemplars from a variety of
internal perspectives; to consider the impact of
the unique conditions of the individual trials on
recruitment; and to make comparisons across trials
with regard to a wide range of factors that might
affect recruitment.
Part C: A single, in-depth case study of a large
multicentre trial
The aim of this component was to examine, in a
single ongoing multicentre trial [the MRC
Corticosteroid Randomisation After Significant
Head Injury (CRASH) trial], the feasibility of
applying a business-orientated analytical
framework to trial recruitment (i.e. if the trial were
a business, what policies, practices and capabilities
would be needed for the marketing challenges to
be met). The aim was to develop a reference
model for potential use in future trials.
The STEPS group
The research in the STEPS project was undertaken
by a collaborative group, the majority of whose
members had significant experience of conducting
large multicentre RCTs. The group was
multidisciplinary in background, including trial
managers, epidemiologists, statisticians and social
scientists. Although separate components of the
research were each led by a subgroup of the
collaboration (Part A: AM, RK, MC, AG; Part B:
CS, JG, DE; Part C: DF, IR), the STEPS group met
on several occasions to discuss the work in
progress as a whole, and all contributed to the
whole project.
Outline of report
Reflecting the aims and objectives outlined above,
Chapter 2 describes the epidemiological review of
trials funded by the MRC and HTA Programme.
An epidemiological description of the cohort of
trials is outlined together with the exploration of
specific hypotheses of factors that may affect
recruitment. Chapter 3 describes the results of four
case studies (two funded by the MRC and two
funded by the HTA Programme) of trials that were
deemed to have particularly interesting lessons for
recruitment. The synthesis of interviews
integrating the perspectives of a number of
different trial members [e.g. the principal
investigator (PI), the trial manager or equivalent,
the lead clinical investigator, and other clinicians
involved directly in recruiting at local centres] is
described. Chapter 4 describes the application of a
business-orientated analytical framework to the
MRC CRASH trial. A reference model that could
be used to assess the sales and marketing
capability of a trial is proposed. In Chapter 5 the
project is discussed as a whole, finishing with
recommendations for practice and for further
research.
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For every trial funded by the UK MRC and the
UK NHS HTA Programme, the PI and co-
applicants must initially submit a full scientific
application to the funder outlining the rationale
for the trial, the required sample size and the
expected recruitment rate. Once the trial is
underway, regular progress reports, annually for
MRC trials and 6-monthly for HTA Programme
trials, must be submitted to the funder outlining
the progress of the trial against the original
timeline and expected milestones. Within these
reports, progress against recruitment targets is
explicitly monitored and any problems with
recruitment are highlighted, together with any
strategies adopted to improve recruitment. If
further funding or an extension in time, or both,
is requested, a formal application is made. The
application and reporting documents submitted by
trial teams to funders provide a rich description of
recruitment to multicentre trials and factors that
may influence recruitment.
This component of the project aimed to draw on
these documents to describe recruitment to a
cohort of multicentre trials funded by the MRC
and the HTA Programme, and to explore factors
that may have influenced good or poor
recruitment.
Aims
The specific aims and objectives of this component
of the research were:
● to describe the trials in terms of broad study
characteristics such as population, intervention
and outcomes
● to describe patterns of recruitment observed
such as to original plan or better, slower start
than anticipated, recruitment with identifiable
change-points, etc.
● to characterise the trials in terms of factors that
might affect the success of recruitment, such as
level of funding, complexity of trial design or
involvement of a trials support unit
● to describe trialists’ reports of factors perceived
to be associated with good or poor recruitment
(e.g. delays in obtaining funding or ethics
approval) and strategies attempted to improve
recruitment
● to consider any changes in overall recruitment
pattern over time (based on year in which
recruitment commenced).
Methods
Identification of trials
Trials were identified from the databases of trials
held by the two funding bodies. Trials were
deemed eligible for inclusion in the study if:
● they involved more than one clinical centre;
● recruitment to the trial started on or after
1 January 1994 (this cut-off was chosen as the
HTA Programme was established during 1993);
and
● the planned end-of-recruitment date (as in
application/first protocol) occurred on or before
31 December 2002. Trials where the intention
was that recruitment would close by 
31 December 2002, but were later awarded an
extension to the recruitment phase beyond 
31 December 2002, were included (if they had
subsequently closed to recruitment prior to data
extraction).
Trials were specifically excluded from this study if
they had adopted a cluster randomised design.
Recruitment issues are different for cluster RCTs
as often individual participants are not
approached for consent, rather consent is given
for specific clusters of participants by a cluster
‘guardian’.20 It was, therefore, felt that reasons for
good or poor recruitment would be systematically
different between individually randomised and
cluster randomised trials.
Deviations from the original plan of
work set out in the application form
The original intention was to include multicentre
trials funded from 1997 onwards (when the MRC
reporting structure began). It became evident that
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Chapter 2
An epidemiological review of a cohort of trials 
funded by the MRC and the NHS HTA programmethis would not generate an adequate number of
trials in the cohort. The inclusion criteria were
thus amended to include multicentre trials that
started recruitment on or after 1 January 1994
(this cut-off was chosen as the HTA Programme
was established during 1993).
Access to information
Following discussions with staff at MRC and the
National Coordinating Centre for the HTA
Programme (NCCHTA), it was agreed that the
study researchers would be given access to
application forms and progress report details on
site at each organisation, subject to appropriate
confidentiality safeguards. The structure of current
progress reports is outlined in Appendix 1.
Researchers signed confidentiality agreements at
both sites. The MRC and HTA Programme
contacted all nominated PIs by letter before the
records for their project were reviewed. It was
agreed that any material deemed confidential or
of a sensitive nature that made it irrelevant or
inappropriate to the data extraction exercise
would be removed before the files were passed to
the researchers. This did not prove necessary in
practice.
Data extraction
Data were extracted from trial reports under six
structured headings:
● trial identifying details
● trial administrative details (e.g. date of
application submission, date funding
commenced, date ethics approval received, date
recruitment commenced)
● trial features (e.g. did the trial have a pilot
phase, were the trial team multidisciplinary, was
there a dedicated trial manager, were
consumers involved, trial design, trial setting)
● finance (i.e. overall funding awarded together
with any supplementary awards provided)
● summary of overall recruitment, including
original recruitment target (sample size sought
in specified period as stated in the grant
application), any revisions to recruitment
targets, and final recruitment numbers
● description of components of delay or failure to
reach recruitment target, including factors such
as delays to centre recruitment, delays to
participant recruitment and any strategies
adopted to attempt to improve recruitment.
The data extraction form (Appendix 2) and
procedures were piloted on data from eight trials
funded by the HTA Programme (data from these
trials were also subsequently formally extracted
using the finalised data extraction form). This
enabled the process and contents of the data
extraction form to be refined. Two researchers
(RK, AM) performed the data extraction (each
extracted information from both MRC trials and
HTA Programme trials). For the first few trials, the
researchers worked together on the data
extraction, to agree working rules for the
definition and classification of terms. Following
this, formal definitions of terms (e.g. definition of
multidisciplinary input) were developed to aid the
standardisation of data extraction and are
presented in Appendix 3.
Secondary data sources
For some data items, information was not recorded
or was unclear in some trial reports held by the
funders. In such situations, reports of the specific
trials held on the Current Controlled Trials meta-
register of randomised trials (www.controlled-
trials.com) and the NCCHTA website
(www.ncchta.org) were also searched in an attempt
to augment the dataset. The Current Controlled
Trials meta-register is an international database
combining several registers of ongoing clinical trials
and includes registers of UK-funded trials (e.g.
National Research Register). For some trials, PIs
were also asked to provide additional information.
To avoid overloading PIs, especially for information
about trials that had long since closed, contact was
only made when a ‘core’ item of data, such as the
final recruitment figure, was missing.
Analysis
Classification of recruitment ‘success’
Recruitment was classified as ‘successful’ if a trial
recruited to or over 100% of its original target,
irrespective of time-frame. Further analyses were
based on trials that recruited at least 80% of their
original recruitment target. A sensitivity analysis
was performed, treating trials that stopped early
owing to differential effects as having had
successful recruitment.
Generation of a priori research hypotheses of
factors that might affect recruitment
To protect against being data driven in the
exploration of factors that might affect
recruitment, a number of a priori hypotheses to be
tested was developed. These hypotheses were
generated within the project management group
and were based on issues raised in previous
literature reviews5 and insights gained from the
MRC clinical trials enquiry4 (AG and IR were both
members of the main review panel of the MRC
clinical trials enquiry). The specific hypotheses
were that:
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than a parallel group trial, e.g. factorial trials)
do not recruit as well as simple trials.
● Less well funded trials do not recruit well (this
was initially operationalised as trials with less
than £500,000 funding, but subsequently
operationalised as trials with less than £1000
per planned participant).
● Trials without dedicated trial management
expertise do not recruit as well as those with
trial management expertise (defined as a
person responsible for the day-to-day
coordination).
● Trials with multidisciplinary input recruit better
than those that do not have this input.
● Trials that involve consumers recruit better than
those that do not.
● Trials where the intervention is only available
inside the trial recruit better than those where
the intervention is available outside the trial.
● Trials that have had a successful pilot phase
(defined as either a pilot or feasibility study that
addressed anything to do with recruitment,
including changes to trial documentation)
recruit better than those that do not have a
pilot phase.
● Trials that have dedicated, paid local
coordinators recruit better than those that do
not.
● Cancer trials recruit better than non-cancer
trials.
● Drug trials recruit better than non-drug trials.
● Trials funded through response-mode funding
have different recruitment rates to those funded
through a commissioned process.
Statistical analysis
Data were collated and stored in a specially
created database (MS Access, version 2000) and
analyses were performed using SPSS (version 11).
Frequency tables were generated to summarise the
overall trial characteristics. Associations between
trial characteristics and recruitment success were
generated through the use of 2×2 tables. Odds
ratios (ORs) of recruitment success are presented
together with 95% confidence intervals (CIs).
Statistical levels of association were examined
through the use of the 2 test, or the 2 test for
trend where appropriate.
Results
Description of included trials
Summary of included trials
One-hundred and fourteen trial grants fulfilled
the inclusion criteria. Forty-one (36%) of these
trials were funded through the HTA Programme
and the remaining 73 (64%) trials funded by the
MRC. Some of the trial grants supported more
than one trial: three grants included two subtrials,
one grant had three subtrials and one trial grant
had four subtrials. For the purposes of describing
the trial features, the denominator is based on the
number of trial grants (i.e. 114), whereas for the
analysis of recruitment issues the denominator is
based on all trials (including subtrials) (i.e. 122
trials).
Trial design
Trial designs are summarised in Table 1. Across all
trials (including the eight subtrials) the large
majority were simple parallel group trials
(113/122, 93%). Six trials adopted a factorial
design, and another three adopted a partially
randomised, patient preference approach.
The majority were two-arm (93/122, 76%) trials.
There were 18 (15%) three-arm trials and 12 (9%)
trials with more than three arms (factorial trials
are coded here as multiarm trials; for example a 
2 × 2 factorial would be a four-arm trial under this
coding). 
Trial setting
A wide range of clinical areas was covered (Table 2).
Cancer trials accounted for 20% of the total.
Mental health and orthopaedics/rheumatology
each accounted for a further 17% of the total.
Obstetrics and gynaecology also accounted for a
sizeable percentage of the trials (7%).
Approximately half (64/122, 53%) of the trials
were based in a hospital setting. A further 21%
were based in a general practice setting, 6% in a
community setting and 13% in a mixed setting
(Table 2). Across these different settings, just over
half (52%) involved recruiting centres that were
geographically spread out over a number of
regions. Twenty-five (22%) trials involved
recruiting centres that were outside the UK.
Trial interventions
Trial interventions are summarised in Table 3.
Nearly one-third of the trials involved drugs
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TABLE 1 Design of Part A trials (N = 122) categories 
Design n (%)
Parallel 113 (93)
Factorial 6 (5)
Partially randomised patient preference 3 (2)(excluding chemotherapy) (37/122, 30%). There
were 12 (10%) trials in which the intervention was
based on a form of behavioural therapy.
Chemotherapy, different types of surgical
interventions, new service provision and radiology
also accounted for sizeable percentages of the
interventions.
For the majority of trials (77%), trial interventions
were available outside the study; for only 18 trials
was it clear that one or more interventions were
not available outside the trial.
Trial funding
Trial funding ranged from £16 per planned
participant to £4522, with a median of £641 per
planned participant. Trial funding was classified as
‘good’ if applicants were awarded more than
£1000 per planned participant for the conduct of
the trial. Using this assumption, 24 (24/89, 27%)
trials were awarded a ‘good’ level of funding.
Pilot phase
Sixty (53%) trials had a pilot phase, of which 58%
(35/60) were funded pilots (Table 4). Of these, 32
trials indicated that the recruitment strategy was
changed as a result of the pilot study. The most
common changes noted on the basis of pilot
studies were that written trial materials were
modified (eight trials), the trial design was
changed (six trials), changes were made to the
inclusion criteria (four trials), the recruitment
target was changed (six trials), and the number of
sites was increased (four trials).
Trial coordination and disciplinary representation
Eighty-nine (78%) trials were coordinated from a
trials support unit and 86 (75%) trials had a
An epidemiological review of a cohort of trials funded by the MRC and the NHS HTA programme 
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TABLE 2 Setting of Part A trials
Nn (%)
Clinical areas 122
Cancer 25 (20.5)
Mental health (including neurosciences/psychiatry/psychology) 21 (17.2)
Orthopaedics/rheumatology (including back pain) 21 (17.2)
Obstetrics and gynaecology 9 (7.4)
Primary care 8 (6.6)
Cardiology 5 (4.1)
Gastroenterology  5 (4.1)
Incontinence/urology 5 (4.1)
HIV/AIDS 5 (4.1)
Vascular 4 (3.3)
Minor surgery 3 (2.5)
Respiratory disease 3 (2.5)
Dermatology 2 (1.6)
Dental 2 (1.6)
Gerontology 1 (0.8)
Cerebrovascular 1 (0.8)
Hearing research 1 (0.8)
Ophthalmology 1 (0.8)
Setting 122
Community 7 (5.7)
General practice 26 (21.3)
Hospital 64 (52.5)
Mixed 16 (13.1)
Missing 9 (7.4)
Geographical spread 122
Regional 51 (41.8)
Multiple regions 63 (51.6)
Missing 8 (6.6)
Any recruiting centres outside UK 114
Yes 25 (22.0)
No 88 (77.2)
Missing 1 (0.8)dedicated trial manager (Table 4). Seventy-five
(75/86, 87%) of those trials with a dedicated trial
manager were coordinated from a trials unit.
Ninety-two per cent (104/113) of trials had
multidisciplinary involvement (defined as
medical/dental/nursing expertise plus at least one
other discipline) across the trial applicants
(Table 5), with statistics (73%) and economics (58%)
the highest represented disciplines after clinical
expertise.
Nine trials indicated that they had some form of
consumer involvement, although no trial had a
consumer as a grant applicant. Trialists most
commonly identified that they had access to
appropriate consumer bodies/patients with the
relevant condition (five trials), although in some
cases specific roles for the consumer were noted:
representation on the trial steering committee
(one trial), reviewer of trial literature (one trial)
and referee of the final report (one trial).
Recruitment in included trials
Summary of overall recruitment
Recruitment target varied widely across trials, from
a minimum of 60 to a maximum of 66,000.
Recruitment in the trials is summarised in Table 6.
Thirty-eight (31%) trials were assessed to have
recruited ‘successfully’ (i.e. ≥100% of their original
target). A further 29 (24%) of trials achieved a
recruitment rate of at least 80% but less than
100% of their original target. Thirteen trials
recruited to their original target after a time
extension. Fifty-five (45%) trials recruited below
80% of their original recruitment target. In 42
(34%) trials the recruitment target was revised over
the course of the trial. The target was revised in an
upward direction in six of these trials. Of the 42
trials that revised their target, 19 (45%) recruited
100% or more of their revised target, 15 (36%)
trials recruited at least 80% but less than 100% of
revised target, and eight trials did not achieve
even 80% of the revised target. Six trials recruited
Health Technology Assessment 2007; Vol. 11: No. 48
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TABLE 3 Interventions in Part A trials (N = 122)
n (%)
Medical (drugs, including chemotherapy) 47 (38.5)
Behavioural therapies (e.g. CBT with or without conventional drugs) 12 (9.8)
Different types of surgical intervention (including laparoscopic) 12 (9.8)
New services/treatment policy/information provision (e.g. support programmes) 9 (7.4)
Radiology (including ultrasound) 8 (6.6)
Medical instruments (e.g. metal stents, pacemakers, bandage types) 7 (5.7)
Surgery versus alternative (e.g. conservative management, radiotherapy) 4 (3.3)
Alternative therapies (including complementary medicines, water-based therapies) 4 (3.3)
Radiotherapy and/versus chemotherapy 3 (2.5)
Radiotherapy 3 (2.5)
Physiotherapy 3 (2.5)
Anaesthesia/ventilation 3 (2.5)
Pharmacy-led reviews/repeat prescribing 2 (1.6)
Best management of a medical situation  2 (1.6)
Surgery: primary care versus secondary care 1 (0.8)
Telemedicine 1 (0.8)
Management in primary care versus secondary care 1 (0.8)
CBT, cognitive behaviour therapy.
TABLE 4 Descriptive features of Part A trials (N = 114)
Trial feature Yes No Not known
n (%) n (%) n (%)
Trial had pilot study 60 (53) 41 (36) 13 (11)
Was pilot funded? (N = 60) 35 (58) 4 (7) 21 (35)
Was there a change in recruitment strategy because of pilot study? (N = 60) 32 (53) 5 (8) 23 (39)
Trial coordinated from trials unit  89 (78) 25 (22) –
Trial had dedicated trial manager  86 (75) 14 (12) 14 (12)
Trial had paid local staff available 61 (54) 31 (27) 22 (19)to their revised target within the original time-
frame. Enrolment was halted before the formal
end of the recruitment period in 14 trials. In 11 of
these, this decision was related to poor
recruitment. In the three others, early termination
followed a recommendation from a data
monitoring committee (DMC) that there were
clear differences between the trial groups.
However, in two of these, the recruitment period
had already been extended beyond that originally
specified.
Extensions to trials
Sixty-six (54%) trials requested an extension to 
the trial grant to complete the original trial; 
in all but one of the cases either a time-only
extension or a supplementary grant was awarded.
Where an extension was awarded, in 42 (64%)
cases this was for both a time extension and a
supplementary grant. For the remainder, 15 
(23%) were for a time-only extension and eight
(12%) were for a supplementary grant only. Only
19 (45%) trials whose targets were revised were
known to have successfully recruited to their new
target.
Delays at different phases of recruitment 
Delay to overall start of recruitment
In 47 (41%) trials, the overall start to the
recruitment was delayed (Table 7). The main
reasons cited were: delays related to central trial
staff (11 trials), delays related to local research
staff (11 trials) and delays related to local clinical
arrangements (seven trials) (Table 8). Other
reasons identified included a range of issues, such
as delays with ethics, the supply of study
drugs/placebo, the development of clinical
guidelines, which then impacted on the trial, the
PI moving, adverse publicity about research and
the publishing of conflicting research (Table 8).
Recruitment of centres
Eighty-six (75%) trials indicated that they had
preidentified centres in the application for
inclusion to the trial. In 17 of these, however,
there was some level of failure in bringing in some
of the preplanned centres (Table 9). There
appeared to be no common reason for these
failures, although the issue of problems with time
delays resulting in technology advances was
identified (three trials), as were cost issues (raised
in two cases).
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TABLE 5 Disciplines represented amongst trial investigators
listed as applicants in Part A trials (N = 113a)
Yes No
n (%) n (%)
Multidisciplinary 104 (92) 9 (8)
Disciplines represented
Consumer – 113 (100)
Economics 66 (58) 47 (42)
Health Services Research 35 (31) 78 (69)
Medical/dental 109 (96) 4 (3)
Nursing  22 (19) 91 (80)
Statistics 83 (73) 30 (26)
Other 17 (15) 96 (85)
a Data were missing for one trial.
TABLE 7 Delays to different stages of recruitment in Part A
trials
Nn (%)
Overall start to recruitment delayed 114
Yes 47 (41.2)
No 64 (56.1)
Missing 3 (2.6)
Early participant recruitment 
slower than expected 122
Yes 77 (63.1)
No 35 (28.7)
Missing/not clear 10 (8.2)
Late participant recruitment 
slower than expected 122
Yes 46 (37.7)
No 60 (49.2)
Missing/not clear 16 (13.1)
TABLE 6 Recruitment in Part A trials (N = 122)
n (%)
Recruited successfully
Yes 38 (31.1)
No 84 (68.9)
Was recruitment target revised?
Yes 42 (34.4)
No 76 (62.3)
Missing 4 (3.3)
Final recruitment figure
Original target (N = 122)
≥100% 38 (31.1)
≥80% but <100%  29 (23.8)
<80% 55  (45.1)
Revised target (N = 122)
≥100% 19 (45.2)
≥80% but <100% 15 (35.7)
<80% 8 (19.1)Health Technology Assessment 2007; Vol. 11: No. 48
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TABLE 8 Reasons for delays to overall start of recruitment (N = 47a)
n
Central staff 11
Local research staff 11
Local clinical arrangements: 7
Merging/reorganisation of trusts 2
Concern that workload and costs would increase as patients with the condition would be identified and would 
require treatment 1
Problems with implementation as clinic visit did not facilitate discussing trial participation 1
Major relocation of services 1
Centres did not have experience in skin testing 1
Indemnity 1
Funding issues 6
MREC 5
LREC 5
Supply of drugs/placebo (including costs/supply) 4
R&D 1
Development of evidence-based guidelines took longer than anticipated 1
Adverse publicity about medical research 1
Administrative delays  1
Clarification about information to be collected for health economics  1
Setting up GP practices took longer than anticipated: many extra practices in each region had to be recruited 1
Simultaneous other local research projects 1
Lack of national service framework in disease area 1
Delay new IM&T strategy for the NHS in England ‘Information for Health’ as team aspired to use the NHS-wide 
network as the means of data transmission 1
Had anticipated starting at a major holiday period (Christmas) 1
Contract agreement between university and trust 1
Following pilot, discussions on changing trial design 1
Changes in data legislation resulted in delay in mailing prospective participants 1
In a fast-moving field, technical aspects included in initial proposal had to be revisited to ensure that the most 
appropriate technology available was being used 1
a More than one reason for an overall delay to start of recruitment was reported by several trials.
IM&T, Information Management and Technology; LREC, local research ethics committee; MREC, multicentre research ethics
committee. 
TABLE 9 Reasons why trials failed to sign up some of the preidentified centres (N = 17)
n
No specific reasons for failure recorded in reports 4
Technologies/techniques had moved on, resulting in changing views about treatment (in at least one case this was 
due to time delay between application and recruitment starting) 3
Local staff issues/changes/shortages 2
Support costs (lengthy process of applying for Culyer funding resulted in some surgeons not participating in one trial) 2
Equipoise (problems with recruiting fully cooperating multidisciplinary teams willing to randomise patients 
between at least two of the management policies) 2
Complete change in trial base (PI moved) 1
Changed end-point (brought forward), which meant that some sites never started 1
Costs (of intervention) 1
Costs (could not compete with commercial studies in same disease area) 1Similarly, 37 (32%) trials indicated that they
encountered some form of delay in bringing in
some of the preidentified centres. As before,
reasons for this varied. The most commonly
reported reasons included problems with
costs/funding (13 trials), delays in the recruitment
of research staff (12 trials) and changes with the
MREC system (six trials).
Fifty-two (45%) trials reported that they had to
recruit new centres to ensure the delivery of the
trial. 
‘Early’ participant recruitment
Once centres were enrolled into the trials, early
(within the first approximately 25% of recruiting
time) recruitment was reported to be slower than
anticipated in 77 (63%) trials (Table 7). The most
common reasons noted for this are outlined in
Table 10, and included fewer eligible patients than
expected (19 trials), internal problems (e.g. staff)
(18 trials) and a smaller percentage of patients
agreeing to participate than expected (16 trials).
Other problems included: issues with
procedures/interventions (e.g. randomisation,
placebo (five trials), the absence of perceived
clinical equipoise (four trials) and conflicting
workload pressures (three trials).
‘Later’ participant recruitment
There were also delays to later (within the last
approximately 75% of recruiting time) recruitment
reported in 46 (38%) trials (Table 7). The most
common reasons noted in this phase (outlined in
Table 11) were internal problems (e.g. staff) (ten
trials), a smaller percentage of patients agreeing to
participate than expected (nine trials), and fewer
eligible patients than expected (seven trials).
Other problems were numerous, and included
issues such as conflicts with other trials (five trials)
and long waiting lists (three trials).
Recruitment rates related to year recruitment
started
Data describing recruitment rates for all years
when recruitment started are summarised in
Figure 1. Six of the 15 trials (40%) that
commenced recruitment in 1994 recruited at least
100% of their original recruitment target. Lower
proportions of trials achieved their targets among
those begun in the late 1990s. 
Association between trial features and
recruitment ‘success’
As indicated above, 38 (31%) trials were deemed
to have recruited successfully (i.e. ≥100% of the
original recruitment target). Potential relationships
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TABLE 10 Reasons for early participant recruitment problems (N = 77a)
n
Fewer eligible than expected 19
Internal problem (e.g. staff) 18
Smaller percentage agreeing to participate 16
Eligible people missed 10
External problem (e.g. publicity) 8
Funding (e.g. payment to sites considered too low, cost of intervention) 5
Issues with procedures/interventions (e.g. length of recruitment procedure, use of placebo) 5
Absence of perceived clinical equipoise 4
Complexity of trial/design/materials 4
Changing referral patterns 3
Competing research 3
Conflicting workload pressures  3
Long waiting lists 2
Time delay since grant application (treatment for condition had changed) 2
Service support/treatment costs 2
Recruitment started during major holiday period 1
Local restrictions on use of intervention 1
No perceived individual gain to justify participation 1
Service pressures 1
LREC delays 1
Problems with supply of intervention 1
Language/written English difficulties  1
Introduction of internal market 1
Trial process too demanding 1
a More than one reason for early recruitment problems was reported by several trials.Health Technology Assessment 2007; Vol. 11: No. 48
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TABLE 11 Reasons for late participant recruitment problems (N = 46a)
n
Internal problem (e.g. staff) 10
Smaller percentage agreeing to participate 9
Fewer eligible than expected 7
External problem (e.g. publicity) 7
Funding difficulties (including payment to local investigators considered too low, problems with funding intervention) 5
Conflict with other trials 5
Long waiting lists 3
Treatment preferences 2
Eligible people missed 1
Department policies 1
Recruitment targets too ambitious 1
Trial fatigue 1
No local access to intervention 1
Trial methodology considered too complex 1
Delays in LREC approval 1
Decline in surgical procedures 1
Problems with R&D approval 1
Research not considered a priority by GPs (no career incentive) 1
Additional theatre time required 1
a More than one reason for late recruitment problems was reported by several trials.
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FIGURE 1 Recruitment success related to start year in Part A trialsbetween trial features that were prespecified as
likely to enhance the chances of successful
recruitment are presented in Table 12. An
association suggesting that the factor increased the
chances of successful recruitment is indicated by
an odds ratio of greater than unity. For each
comparison, only trials for which the information
was known were included (i.e. trials where the
information was unclear or missing were
excluded). Subtrials were included. Ninety-five per
cent confidence intervals are presented for all
odds ratios.
As Table 12 shows, the confidence intervals around
the odds ratio estimates were all wide, reflecting
the maximum sample size (122). Some of the
comparison cells had very few data (e.g. number
with a complex design and number with consumer
input). There were marginally statistically
significant associations with being funded by the
MRC, being a cancer trial and not having paid
local trial coordinators.
Strategies to improve recruitment
Seventy-three trials reported the use of at least one
strategy (range one to five strategies) aimed at
improving recruitment (Table 13). A variety of
strategies was reported; the most commonly
reported strategy was the use of newsletters and
mailshots, both to participants and to clinical staff,
to promote the trial. There were reports of
advertisements in newspapers and journals.
Posters and information leaflets were displayed in
appropriate clinics and wards and these were
sometimes backed up by regular phone calls and
visits. Several trials reported that sites had been
supplied with resource manuals and that specific
training had been held for staff recruiting
patients. Another commonly reported strategy was
the trial being presented to appropriate clinical
groups and presentations at relevant national and
international meetings. Ten per cent of the trials
reported that the trial inclusion criteria were
changed or the protocol was amended in an effort
to improve recruitment. Less commonly reported
strategies included provision of training videos for
sites and appropriate special interest groups being
asked to inform patients about the study.
Specific recruitment patterns
Trials were examined for any identifiable change-
points in recruitment. Unfortunately, no trial was
found to display particularly marked changes in
recruitment rates and no analyses based on
specific recruitment patterns were possible.
Discussion
This description of a complete historical cohort of
trials has shown that failure to achieve projected
targets for participant recruitment has been
common in multicentre trials supported by the two
main funders of trials in the UK. Well over half
failed to recruit to 100% or more of their original
target, and 45% failed to recruit to within 80% of
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TABLE 12 Associations between features of Part A trials and recruitment success
Feature Valid N No. with  No. that  OR 95% CI p-Value
feature that  did not have 
had feature  that 
successfula had 
recruitment successfula
n (%) recruitment
n (%)
Simple design  122 35/116 (30) 3/6 (50) 0.43 0.06 to 3.41 0.374
Good level of funding 89 7/24 (29) 17/65 (26) 1.16 0.41 to 3.29 0.776
Multidisciplinary input 113 34/104 (33) 3/9 (33) 0.97 0.19 to 6.36 0.615
Consumer input 107 4/9 (44) 26/91 (29) 2.00 0.36 to 10.05 0.446
Interventions only available  112 7/18 (39) 26/94 (28) 1.66 0.58 to 4.76 0.338
inside the trial 
Pilot phase 109 18/66 (27) 11/43 (26) 1.09 0.46 to 2.61 0.845
Dedicated trial manager 107 32/91(35) 2/16 (13) 3.80 0.79 to 36.14 0.087
Local recruitment coordinators 100 15/69 (22) 14/31 (45) 0.34 0.14 to 0.84 0.017
Support from a trials unit 122 27/94 (29) 11/28 (39) 0.62 0.26 to 1.50 0.289
Cancer trial 122 12/24 (50) 26/98 (27) 2.77 1.11 to 6.93 0.026
Drug trial 122 19/53 (36) 19/69 (28) 1.47 0.68 to 3.18 0.326
Funded by the MRC 122 28/74 (38) 10/48 (21) 2.31 1.00 to 5.36 0.048
a 100% original target.the original target. For around half of the trials
the recruitment period was extended, usually
supported by a supplementary grant. Reasons
varied, but delays were experienced at all stages.
Some trials experienced delays to starting
recruitment; many had delays during recruitment,
both during the early phase and later once the
trial had been established. Analyses to explore
factors that it was thought in advance might be
associated with successful recruitment were
relatively uninformative. The confidence intervals
around the estimated odds ratios were all wide
and too imprecise to allow judgement about
possible causal relationships.
The strength of the study was that it included a
systematically identified, complete cohort of trials
funded by the two major UK public funding
bodies in the field of healthcare and drew on
previously confidential routine progress reports
submitted over the course of a trial by the
investigators. The large majority of trials were
parallel group trials, with only a small number of
trials with more complex designs. The trials
represented a wide spectrum of clinical areas,
clinical settings and geographical centres. Cancer
trials and drug trials were most commonly
represented. This is therefore a thorough
description of the progress of multicentre trials
Health Technology Assessment 2007; Vol. 11: No. 48
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TABLE 13 Reported strategies aiming to improve recruitment in Part A trials (N = 73)
No. of trials
Number of strategies reported
1 25
2 29
3 12
4 6
5 1
Types of recruitment strategy adopted
Newsletters/mailshots/flyers (to participants and/or clinical staff) 26
Regular visits/telephone calls to wards/sites/practices 15
Posters/information leaflets in clinics/wards/notes 13
Inclusion criteria changed/protocol amended 12
Presentations to appropriate groups (e.g. at consultant meetings, community-based physiotherapists) 10
Resource manual for site staff/trained staff in disease area/procedures being investigated/role-play  10
exercises/study day/workshops for recruiters
Advertisement/articles in newspapers/journals; radio interviews 8
Presentations at national/international meetings 6
Employed extra staff 6
Investigators’ meetings/recruiting staff meetings 5
Training/information videos  4
Incentives for recruiters (e.g. prize draw, chocolates) 4
Trial material revised/simplified/customised for specific sites 4
Visits to centres by PIs/senior members of study group 3
Repeated contact by telephone/letter to individuals/sites 3
Increased/changed time-points when information provided to potential participants 3
Supportive statements from opinion leaders 3
Merchandise/desktop reminders with trial logo for site staff 2
Website information 2
Special interest groups (e.g. physiotherapists interest group), asked to publish information about study  2
and request referrals
Use of hospital system to identify potential participants 2
Simplified process of payment 1
Paid incentive to participants 1
Protected time for site staff 1
Randomisation procedures changed 1
Resources for recruiting staff increased in sites that were recruiting well and reduced in those that were not 1
Initial check for eligibility over telephone 1
Focus groups 1
Interpreters available 1
Complete review of recruitment procedures 1
Industry supplied or discounted cost of trial intervention 1
Experienced trial manager enrolled to help with design of promotion material and drive the trial 1over time, and of the extent of the problem of
under-recruitment to trials. 
The study does have weaknesses, however. The
basis of the investigation was that the ‘outcome’ of
recruitment to a predefined target (original sample
size estimate) is a true measure of success. Often
initial sample size calculations are based on limited
information and, as such, the use of this marker as
a sole indicator of recruitment success is rather
unsatisfactory. Initial sample size estimates can be
viewed more as an informed guide, based on
imperfect information (that may change as new
information emerges from external sources) and
considerations such as feasibility and cost. Sample
size targets do, however, contribute to the decision-
making process when funding decisions are made
and, as such, the degree to which a trial delivers to
initial expectations can be viewed as a legitimate
marker of trial success. In an ideal situation,
parameters other than achievement of planned
sample size, such as rates of participant retention
and treatment compliance, should also be taken
into account. Furthermore, recruitment can be
viewed as a surrogate measure of other, less easily
quantifiable, but arguably more significant measures
of success, such as ‘impact on clinical practice’ or
the extent to which the trial question has been
successfully addressed. In terms of recruitment, it
was anticipated that some of the apparent failure to
reach recruitment targets might have been due to a
DMC’s recommendation to halt the trial. In fact, in
only three cases did a DMC recommend closing
recruitment because of clear differences in outcome
between the trial groups; in two of these, however,
there had already been an extension to the
recruitment period because the rate had been
slower than planned. Sensitivity analyses treating
these three as having ‘successful recruitment’ had
little impact on the results, although they did
strengthen somewhat the association between
success and a trial having a dedicated trial manager.
Another limitation is that the operationalisation of
variables used to address the research hypotheses
of factors that might affect recruitment (the
‘exposures’) was based on pragmatic
considerations which could not always reflect
subtle variations in the underlying concepts. For
instance, different trials need quite different levels
of funding and the choice of a standard cut-off of
£1000 per planned participant was arbitrary. 
There are also some worries about the validity of
the data. There was marked variation in the quality
of the reporting across the 114 studies. This was
particularly noticeable between the two funders;
primarily a reflection of the specific requirements
of the reporting form. The reporting form for the
HTA Programme is more extensive and requires
greater detail for correct completion. It is also
completed 6-monthly rather than annually. 
As a result of the variation in reporting quality,
there was a considerable amount of missing data
in the data set following the initial extraction of
the data from the records kept by funders. In an
attempt to maximise the data available for
analysis, several complementary strategies were
used to augment the funder data. The first extra
source of data was electronic registers of trials:
reports of trials held on the Current Controlled
Trials meta-register of randomised trials and 
the NCCHTA website were searched for 
additional information. Second, PIs were asked 
to provide information where core items were
missing. Third, trial managers registered with 
the UK Trial Managers Network (see below) 
were contacted for specific information (where
they were known to have had links with specific
trials). Finally, the STEPS team reviewed each trial
record and provided supplementary information
where it was known (e.g. whether the trial team
had coordinated more than one trial
simultaneously).
This process of supplementary data gathering was
particularly resource intensive. The authors
believe, however, that the final data set is much
richer as a result of this extra work and helped to
provide sufficient information to allow data
analysis to be undertaken. Despite all these extra
efforts, however, a proportion of data items
remained unclear for most trials and this is
reflected in the varying numbers of trials
contributing to each separate analysis.
It had been hoped that the study would identify
factors associated with successful (or unsuccessful)
recruitment to provide a means of predicting or
enhancing the chances of success. The factors
examined were chosen in advance based on
previous research5 and the experience of members
of the research team. It is possible that other
factors, such as characteristics of the trialists that
were not included, might have been more
informative. In the event, the comparative analyses
that were performed were of limited value, both
because of the choice of outcome and exposure
variables, and because of imprecision around the
estimates of association. While a number of these
analyses provide some evidence that some factors
(e.g. the intervention only being available inside
the trial, having a dedicated trial manager, and
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with successful recruitment, these results (although
less so for cancer trials) were also all compatible
with there being no association. Furthermore,
other analyses showed that some features expected
to enhance recruitment were less commonly
observed in ‘successful’ trials than in ‘unsuccessful’
trials. This applied in particular to ‘local paid
recruitment coordinators’, but alternative
explanations for this apparent negative association
are that this comparison is confounded by other
factors such as the complexity of the trial and the
years when it was undertaken (see below). As many
of the variables are potentially correlated, a
multivariable analysis would have been desirable.
There was insufficient power, however, to
undertake this analysis with any degree of
reliability; experts suggest that there should be at
least ten observations in the data set for each
potential explanatory variable to be included in the
model.21 A multivariable analysis was performed
and the results confirmed the lack of power:
coefficients were often in the ‘wrong’ direction and
standard errors for certain coefficients were large,
indicating instability in the model.
There was an apparent difference in recruitment
success rates between the funders, with MRC-
funded trials more likely to recruit to target. This
is potentially a reflection of the different grant-
awarding processes, as the HTA Programme
commissions specific trials, whereas the MRC
operates in response mode and this is reflected in
markedly different portfolios in the two
organisations.3 There was also evidence that this
observation may have been confounded by other
factors. Cancer trials, drug trials and trials with a
dedicated trial manager were all more likely to
have been funded by the MRC (p < 0.001 for all
associations).
Two separate approaches to the analysis of
recruitment success were undertaken. First, only
trials that recruited to their original target were
deemed to have recruited successfully. Thirty-eight
trials (31%) were assessed to have recruited
successfully under this definition. It was felt,
however, that this definition might be overly harsh
to trials that almost achieved their recruitment
target, and therefore all analyses were rerun using
the definition of success as having achieved at
least 80% of original recruitment target. Under
this definition, 68 (55%) trials were deemed to
have recruited ‘successfully’. Findings in respect of
features associated with success (Table 12) were
consistent under the two definitions of recruitment
success.
Under either definition, however, it is clear that
successful recruitment to trials is a problem. Even
under the generous definition of success, only half
of the trials in this study population were deemed
to have recruited successfully and the situation
does not seem to have improved over time (see
Figure 1). This is despite the growing literature
summarising barriers and facilitators to
recruitment published in the 1990s (exemplified
by the HTA review by Prescott and colleagues5).
Changes in the external environment common to
all trials are likely to have contributed. Some
trialists undoubtedly experienced delays around
the time of the introduction of the MREC system
in 1997.22 The climate for research was also
altered by events such as the Bristol inquiry into
paediatric surgery. The proportion of trials failing
to achieve even 80% successful recruitment was
highest in the late 1990s, contemporaneous with
the height of the perceived problems with these
issues. These sorts of changes could have
accounted in part for the reduced recruitment
success between 1997 and 1999.
The overall start to recruitment was found to have
been delayed in 40% of trials. The primary
reasons listed for this were associated with staffing
problems. Research ethics approval delays and
R&D issues did not appear to be a particularly
common reason for delays given in reports to the
funders, which was somewhat surprising given the
weight attributed to these factors anecdotally.23
While staffing issues were seen as particularly
problematic for specific trials, it was apparent that
a wide spectrum of problems was encountered
(reflected by the high level of ‘other’ reasons).
As indicated above, there was evidence that cancer
trials were associated with better rates of successful
recruitment compared with non-cancer trials.
Within the field of cancer, there has been a long-
standing interest in the recruitment of patients into
clinical trials.24 This relatively positive and open
environment for the recruitment of patients into
trials culminated recently in the establishment of
the National Cancer Research Network (NCRN) in
England and Wales, which was created to improve
the infrastructure within the NHS for clinical
research in cancer and to ensure that research is
better integrated with cancer care. The NCRN was
established by the Department of Health in April
2001 to support prospective trials of cancer
treatments and to support research undertaken by
cancer charities (most of the trials included in this
study had completed recruitment before this
initiative was established). The aim of the NCRN is
to improve the speed, quality and integration of
Health Technology Assessment 2007; Vol. 11: No. 48
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care. It hopes to increase involvement and
recruitment into trials through the creation of
cancer research networks across the UK closely
aligned to cancer service networks. Within the
NCRN all trials are conducted through accredited
trials units and recruitment is coordinated through
funded locally based research staff. This process of
trials unit accreditation ensures that all of the core
competencies (e.g. trial management,
programming, statistics) are available at the
coordinating centre, thus minimising the potential
for trial managers to be isolated (see below),
ensuring experience across the entire trial team and
maximising the efficiency of the trial processes.25
This approach has resulted in a doubling of the
recruitment rate to cancer trials since its
inception.26 This approach to centralised trial
coordination is currently being expanded across the
newly formed UK Clinical Research Network, which
aims to coordinate recruitment to clinical research
(initially in six clinical areas) across the UK.
The perception that drug trials may be easier to
recruit to than non-drug trials is perhaps not
surprising given the background of rigour
required by registration agencies and the
methodological problems associated with non-
drug trials. In surgery, for example, the problems
with conducting randomised trials have been well
documented.27 With non-drug interventions, such
as cognitive behaviour therapy and other
operator/therapist-dependent interventions, there
is the additional problem of therapist recruitment
and retention over and above patient recruitment.
Commentators have also indicated that trials that
include innovative operator or therapist-
dependent interventions suffer particularly from
timing issues, where there may be only a very
narrow window of time when a trial can be
successfully mounted. This has been encapsulated
in what has become known as Buxton’s law, where
“it is always too early (to evaluate an intervention),
until unfortunately it’s suddenly too late!”28 Trials
that attempt to evaluate new non-drug
technologies also suffer from other problems, most
notably the handling of the ‘learning curve’ of
operators/therapists within the study, and trialists
have often sought to restrict the involvement of
practitioners to only those most experienced in
the technique.29 By restricting the number of
practitioners available to be included in the trials,
this has in turn restricted the eligible number of
centres, and thus the patient pool available for
study. New approaches to the statistical assessment
of the learning curve should help to address this
problem in the future.
The view that trials that had a dedicated trial
manager would be associated with better rates of
recruitment compared with those that did not was
given some empirical support. In its recent review
of clinical trials, the MRC acknowledged that the
failure of some trials can be due to practical
problems with trial management rather than
scientific problems or problems with the trial
design.4 This had been recognised by the Council
some years earlier and, in response to the desire
to maximise the dissemination of good practice
across trials, they set up a network of those people
responsible for the day-to-day management of
MRC-funded trials, known as the MRC Trial
Managers Network. The primary functions of the
network were to link trial managers together to
ensure the dissemination of expertise and
experience, and to establish a programme of
training and support for its members. The
network, which has recently expanded to include
trial managers from the HTA Programme and
other publicly funded trials (and renamed the UK
Trial Managers Network), aims to facilitate the
development of a well-trained, highly motivated,
effective workforce of trial managers within the
UK healthcare system who will make an important
contribution to the efficient delivery of high-
quality clinical trials. It also aims to establish a
forum to promote best practice in clinical trials,
and provide a focus for the development of skills
and expertise of trial managers as part of the
larger national clinical trial network. Through the
promotion of this type of activity, one might hope
that the standards of recruitment will increase over
the coming years.
Conclusions
Large numbers of publicly funded trials have
experienced recruitment problems in recent years.
Many have had extended recruitment periods,
which have often been supported by additional
funds. Patterns of delay were shown to vary. Many
possible reasons were suggested, and a range of
strategies was adopted in an attempt to improve
recruitment. The simple descriptive analyses
presented in this chapter do not give any 
clear indications of factors that are likely to
predispose to successful recruitment. The
explanation of why some trials consistently recruit
well and others do not would appear to be
complex, and not amenable to analyses of this
type. Therefore, one has to look to the results 
of the other more in-depth components of the
study for more reliable insights into the reasons
for this.
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Many research papers start with the statement that
RCTs are considered to be the gold-standard
method for the assessment of the effectiveness of
interventions. Trials are not, however, simply an
experimental tool, independent of social, political
and moral values. They are complex and dynamic
entities, shaped by disparate internal and external
forces. The conduct and progress of trials can, for
instance, be shaped by some of their own
characteristics, such as the impact of the use of
placebo on recruitment,30,31 the necessity for
certain levels of expertise required to carry out
trial interventions13 and the involvement of a
heavy data collection load for local centres.32,33
They can also be affected by pre-existing factors
such as the beliefs of the collaborating clinicians34
and patient preferences.35,36 Several such factors
have been reported as barriers to recruitment by
trialists37,38 and identified in empirical
studies.15,39,40
These forces create a complex microclimate in
which a trial can flourish, struggle, or do both. In
spite of the likely impact of this microclimate on
the progress of an individual trial, research has
often focused on questions raised by trials more
generally, treating those with some common
factors as a collective (e.g. in oncology32,41–43 or in
neonatology44). While this type of research is
useful for mapping out broad areas of concern,
the particular circumstances in which an
individual trial operates, which may be crucial in
promoting or inhibiting the successful working of
the research, cannot be considered where trials are
treated as a collective.
There is, however, a developing body of literature
that uses a variety of methods, which examines the
workings of individual trials and strives to
understand their specific contexts. A number of
single trials assesses the impact of attitudinal
factors for a single trial.45–47 There are several
reports by trialists that describe their experience
of recruitment in their own trials.48–50 Gillan and
colleagues23 unusually describe the impact of
external forces such as “national clinical, economic
and political factors” on recruitment to two
multicentre trials. 
These publications are pointers to a potentially
fruitful area for research. It is the present authors’
contention that a careful empirical exploration of
the factors that shape a number of individual
trials, to consider their unique challenges and the
responses of their research teams to those
challenges, could afford important insights that
are likely to be to the benefit of those developing
other trials. It is argued that an assessment of 
the microclimate will promote greater
understanding of the complexity of factors
involved in progress in trials, and greater
sensitivity to the importance of the interplay of
such factors. It will also afford the opportunity to
make comparisons between trials from a more
informed position, to look for common ground
even where the trials may be rather different. Any
common factors in progress highlighted in this
way are likely to be more instructive than those
identified either from one trial or from an
undifferentiated collective.
It is also suggested here that a search for 
common factors in the success of quite disparate
trials that might be considered to be ‘exemplars’
(see the next page for a definition) is a positive
approach that is largely missing from the available
literature. Studies that have examined the
performance of trials have mainly concentrated on
situations where there are problems in order to
understand or explain why things have gone
wrong.34,49,51–53 The present study therefore
concentrates on trials that have, by and large,
recruited well and so could be defined as
successful. It is possible that a search for common
factors in quite disparate exemplar trials may
provide constructive data that could be used to
guide and shape the development of further
research.
In summary, this chapter is grounded in a drive to
understand the influence of highly complicated
microclimates on the success of a small number of
exemplar trials and of the impact of any features
that they may have in common, in spite of their
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Chapter 3
Case studies of trials that appeared to have 
particularly interesting lessons for recruitmentinherent dissimilarity. Unlike a number of papers
in the literature, it is carried out from an
independent outsider perspective.
Aims
Part A of STEPS used reported information 
to give insights into features of trials and the
strategies that they involved. Part B builds on this,
but works with the concept that different parties
who are internal to the trials will be able to offer
additional role-specific and location-specific
insights that are not available in these official
accounts. By interviewing individuals with
different internal perspectives, the possibility of
producing more sensitive data is increased.
Nurses, for instance, may be privy to patient
reactions to the offer of trial enrolment that are
unavailable to more senior doctors. Different
levels of exposure may shape their views, and so
their practices, within the research context. Trial
managers may describe intended modes of
operation, and local collaborators may explain
why those procedures do or do not work well in
their local circumstances. The aim is not to
present a detailed analysis or a comparison of
these different viewpoints. Instead, the variety of
interviewee perspectives is used to produce a
multivoiced, more detailed and more nuanced
account of each trial.
The aims of Part B of STEPS are to use these 
data to describe the characteristics of individual
‘exemplar’ trials, in addition to information
available from protocols, trial materials and
through the reports of those closely involved 
with the running of the trials. Analysis of the
interview data enables the exploration of the
unique circumstances potentially relevant to
recruitment for each trial. This element of the
research aims to understand, through the opinions
of the interviewees, how recruitment may be
affected in a very broad sense, and so focuses on
their progress, any challenges that arose and any
adaptations that were made. Finally, the data were
used to compare the trials in order to highlight
common factors potentially relevant to
recruitment.
The four Part B trials were chosen to represent a
variety of clinical situations, each with its own
particular challenges. As previously stated, it is
precisely this variety that is of interest. Although it
is not possible here to prove exactly which
common factors did promote recruitment (as
opposed to the perception that they did so), it is
possible to use the informed testimonies of those
closely connected to the trials to generate likely
factors that may be considered empirically. 
Materials and methods
The trials
Definition of ‘exemplars’
It was intended that an examination of trials that
have recruited well would produce innovative and
positive data. The initial challenge for the
research team was to develop and refine a
definition of the type of trials that should be the
subject of the study. The use of the term ‘exemplar
trials’ arose during a STEPS meeting. Although an
exemplar can be taken to mean something that is
typical or representative (an example), it can also
refer to something that is worthy of imitation (a
model). It is in the latter sense that this term is
employed here. 
What in practice constitutes exemplar trials was
not, however, immediately clear. Initially it was
considered that in keeping with Part A, these trials
should have recruited to their initial target.
Furthermore, it was felt that they should have
reached this target in the time-frame initially
specified. Given the emerging findings from Part
A, however, it became clear that such a rigid
definition would be problematic. Therefore, trials
were considered that had met or were on schedule
to meet targets agreed with their funders (MRC
and HTA Programme) and, most importantly, that
the funders considered to be successful. If the
funders of the trials categorised, and in some cases
publicised, the trials as a success or as an example
for other trials, then for the present purposes they
could be viewed as exemplars.
Access to the Part B trials
The funders were asked to recommend a number
of trials that they considered to be successful. Four
trials were selected, two from each funder, and the
PIs were approached to assess their interest in
participation in STEPS. The PI for one trial
originally selected declined because of the trial
team’s plans to publish details of their recruitment
strategies at some point in the future. A further
trial from the same funder was chosen as a
replacement. 
Descriptions of the trials
For simplicity, the trials selected (FOCUS,
TOuCAN, HPS and ELEVATE) are often referred
to in this chapter as ‘the Part B trials’. Brief details
are given in Table 14. The trials represent a variety
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T
ABLE 14
Characteristics of the P
art B trials
F
ull title
The Heart P
rotection Study
T
rial of Chemotherapy for Bowel Cancer
[Fluorouracil, Oxaliplatin and Irinotecan
(CPT11), Use and Sequencing]
T
rial of Outcome for Child and
Adolescent Anorexia Nervosa
A pragmatic single-blind RCT and
health economic evaluation of
leukotriene receptor antagonists in
primary care at steps two and three of
the National Asthma Guidelines
T
rial acronym
HPS
FOCUS
TOuCAN
ELEV
A
TE
Clinical speciality
Cardiovascular
, health
promotion
Cancer
Adolescent psychiatry
Asthma management
F
unders
MRC/BHF/industry
MRC/industry
HT
A
HT
A/industry
Eligible patients
Aged 40–75 years with
increased risk of coronary
heart disease based on past
medical history (e.g.
coronary diseases, diabetes
mellitus)
Advanced metastatic colorectal cancer
Adolescents (aged 12–18
years) with
anorexia nervosa referred to (but
before assessment by) general and
specialist providers of CAMHS
P
atients in primary care who have
asthma which requires regular
preventive treatment or an increase in
therapy
Eligible centres
69 UK hospitals
Oncology centres meeting criteria
specified in the protocol (in UK and
Cyprus)
CAMHS in north-west England
General practices in East Anglia and
southern England
Design
Four
-arm randomised trial 
(2 
×
2 factorial)
Five-arm randomised trial
Three-arm randomised trial (with
option to switch treatments
postrandomisation, and parallel non-
randomised ‘naturalistic’ cohort for
patients refusing randomisation)
T
wo severity strata (steps) with two
arms at each step
continued
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ABLE 14
Characteristics of the P
art B trials (cont’d)
Interventions
1. 
Simvastin tablet and
antioxidant vitamin
capsules (C, E and 

-carotene)
2. 
Simvastin tablet and
placebo capsules 
3. 
Placebo tablet and vitamin
capsules 
4. 
Placebo tablet and
placebo capsules
All have MdG with fluorouracil 
1. 
MdG, followed by irinotecan as second-
line therapy (after the initial treatment
had failed)
2. 
MdG with oxaliplatin, as first-line
therapy
3. 
MdG with irinotecan, as first-line
therapy
4. 
MdG, followed by MdG + oxaliplatin as
second-line therapy
5. 
MdG, followed by MdG + irinotecan as
second-line therapy 
When the trial started, cross-
over to the
‘other
’ drug (irinotecan or oxaliplatin) after
completing the trial plan was discouraged,
but the protocol was later amended to
encourage cross-
over
, so surviving patients
have access to all three drugs (fluorouracil,
irinotecan and oxaliplatin) during the
disease course
1. 
Intensive inpatient treatment
2. 
General outpatient in their local
service
3. 
Specialist outpatient service at one
of two centres, Chester or Salford
Step 2:
1. L
TRAs
2. ICSs
Step 3 (all ICS):
1. L
TRAs
2. LABs
Outcomes
Cause-specific mortality
,
stroke, cardiovascular
events, cancer
, cataract,
fractures, cognitive
impairment (5-year follow
up)
Survival and quality of life, toxicity
, patient
acceptability and health economics
Effectiveness, cost-effectiveness and
patient acceptability
Quality of life, clinical outcomes such
as asthma symptoms, hospitalisation
and daily inhaled steroid dose, costs
(at 2
months and over 2
years)
Management
Clinical T
rial Service Unit,
Oxford
MRC Clinical T
rials Unit, London
Universities of Liverpool, Manchester
and Y
ork. Base is Chester Y
oung
P
eople’s Centre
School of Medicine, University of East
Anglia
Sample size
Original aim
R
evised
Achieved
20,000
NA
20,536
2100 patients
NA
2135 patients
210 (+70 in naturalistic cohort)
165 (+75 in naturalistic cohort)
167 (+48 in naturalistic cohort)
712 (178 in each of the 4 arms)
NA
356 step3; step2 ongoing
continued
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rial acronym
HPS
FOCUS
TOuCAN
ELEV
A
TEHealth Technology Assessment 2007; Vol. 11: No. 48
T
ABLE 14
Characteristics of the P
art B trials (cont’d)
Duration of
recruitment 
Original aim
Actual
P
eriod of recruitment
Extension
Time only (no cost)
Time and costs
Pilot phase in 1987
18 months
36 months
1994–1997
Ye
s
36 months
42 months 
May 2000–December 2003
No extension required: extra 6 months of
recruitment absorbed into 5-year 
time-frame for the trial
24 months
42 months
April 2000–December 2003
Ye
s
7 months
18 months step 3; step 2 ongoing
May 2002–November 2003 (step 3);
May 2002 to at least December 2004
(step 2)
Extension of time and costs (and
reduced length of follow
-up for 
step 2)
BHF
, British Heart Foundation; CAMHS, Child and Adolescent Mental Health Services; ICS, inhaled corticosteroid; LAB, long-actin
g beta-agonist; L
TRA, leukotriene receptor
antagonist; MdG, modified de Gramont; NA, not applicable. 
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T
rial acronym
HPS
FOCUS
TOuCAN
ELEV
A
TEof settings, methods and clinical specialities. Two
are hospital based (FOCUS and HPS), one
involved a comparison of inpatients and
outpatient services (TOuCAN) and another
assessed primary care (ELEVATE). None of the
trials is a simple two-arm parallel group trial; they
range from a five-armed trial with cross-over
(FOCUS), to a three-armed patient preference
trial (TOuCAN), a stratified trial (ELEVATE) and
a factorial trial (HPS). The clinical specialities
involved are cardiovascular health promotion
(HPS), oncology (FOCUS), adolescent psychiatry
for anorexia nervosa (TOuCAN) and asthma care
(ELEVATE). All of the trials are multicentre. In
three of the four trials there are drug
interventions. One trial (HPS) involves the use of
placebo. The possible outcomes of the trial
interventions reflect the different settings and
patient populations involved, with two of the trials
involving assessment of mortality (HPS and
FOCUS). In two cases (HPS and FOCUS), the
trials are managed by large clinical trials units, in
one by an academic unit (ELEVATE) and in
another, management is shared by two branches of
a regional service (TOuCAN). The absolute
sample sizes for the trials may be less relevant
than the fact that in each case the trials were
intended to be the largest in the world for their
population. All of the trials involved an extended
period of recruitment, of which one required a
time-only extension (HPS) and two required
additional funding (ELEVATE and TOuCAN).
Target sample sizes were revised for the TOuCAN
Study. Recruitment is complete and the planned
numbers are exceeded for two trials (HPS and
FOCUS), and recruitment is ongoing for the other
two with targets likely to be achieved.
Access to interviewees
RECs and trust R&D requirements
At the time of the original application to fund
STEPS, REC approval for interviews with NHS
staff was not normally required. However, new
regulations were instituted and it became
necessary to submit a full REC application for this
component of the research. As MREC approval
under ‘no local researcher guidelines’ was given,
there was no need for applications to LRECs, but
the new research governance guidance, also
instituted since the start of STEPS, caused further
delays. The study was not viewed uniformly by the
R&D staff. The researcher consulted with 12 R&D
offices and was advised to make applications in
each instance to conform to local requirements.
While some centres had rigorous requirements,
including applications for honorary contracts,
provision of references, completion of
occupational health forms and a police check
(requested, but later waived after some discussion
on receipt of the study paperwork), three R&D
offices revised their opinion that an application
was necessary. The formal process of negotiating
ethical and R&D approval took a disproportionate
amount of researcher time for this short study, and
has negative implications for conducting such
research in future.
Recruitment of interviewees
Before the start of interviews, a broad model of
the likely candidates for interview was drawn up,
reflecting the researchers’ concept of the relevant
protagonists in the running of clinical trials. It was
considered important to include those with a
range of roles, not to characterise the views of
different professional groups, but on the
assumption that those with different
responsibilities and experiences will have different
insights into the four trials. There is little research
that assesses the views of such various
contributors. Although there are some reports of
the views of nurses54,55 and some of the views of
GP recruiters,37,56–58 the research samples available
are largely comprised of senior doctors involved in
trials, with a strong bias towards oncology
trials.32,41–43,45,59,60–62 No research was identified
that describes the attitudes of coordinating staff
[although see Rico-Villademoros and colleagues63
for a survey-based description of the role of the
clinical research coordinator (data manager) in
oncology trials].
The original aim was to carry out 32 interviews,
eight per trial, with a split between the central
coordinating staff and the staff from the recruiting
centres. The sample was constructed to represent
key players who could describe the workings of
each of the trials. The intended interviewees were
PIs, trial managers, local lead consultants and
local recruiters (doctors or nurses according to the
trial procedures). As understanding of the
processes involved in each trial increased, the list
of likely interviewees was expanded to fit the
unique circumstances of that trial. For the
ELEVATE trial it became clear that there were
both research assistants and agency-employed
research nurses with key roles in recruitment who
could not be omitted from the study. For two of
the trials there were two joint PIs. For the
TOuCAN study there was no research nurse
involvement in the trial and recruitment was
carried out by non-clinical trial staff who had not
been included in the original list of interviewees.
Ultimately there were 45 interviews in total
(Table 15). 
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trials with a combination of purposive selection
methods, and elements of snowball sampling.
Access to the PIs was facilitated by the funders.
The PIs in turn facilitated access to the central
trial team. For the local centres, letters
(Appendix 4) including information sheets
describing the research (Appendix 5) and consent
forms (Appendix 6) were sent out directly by the
trial teams either by e-mail or by post to the trial
mailing lists. Those interested in taking part in the
research were invited to respond by replying to the
researcher rather than to the trial team, thus
maintaining a degree of confidentiality for those
respondents in relation to the central trial team.
Where more people responded than were needed,
interviewees were selected randomly. On some
occasions, individuals advised the researcher that
it would be appropriate to speak to a colleague. In
these instances the informant was asked either to
make contact on behalf of the study, or to check
with their colleague that they were happy for the
researcher to make direct contact. In a small
number of cases the researcher made an
unmediated direct approach to individuals who
were detailed in the trials literature who seemed to
be potentially important to the study. It is not
possible to give a response rate as it is not known
how many individuals were contacted initially.
Table 15 shows the broad division of interviews
between central coordinating staff (N = 21) and
clinical staff in recruiting or referring centres 
(N = 24). These two categories do not, however,
reflect a simple split between recruiters and non-
recruiters. Recruitment was not carried out
exclusively by the staff in the recruiting centres,
and within the recruiting centres not all staff had a
role in recruitment. In the FOCUS trial the PI had
a clinical caseload from which trial participants
can be recruited, and for ELEVATE and TOuCAN
there were members of the central office team who
had specific duties to recruit to the trial. In the
recruiting centres there were some staff whose role
was to facilitate rather than to carry out
recruitment. The distribution of recruiters
(N = 16) and non-recruiters (N = 29) is also
indicated in Table 15, with recruiters marked with
the heaviest highlighting.
Interview structure
All interviews were carried out by telephone in the
period from December 2003 to May 2004. They
were tape-recorded with the consent of the
interviewees and fully transcribed. The discussions
typically took between 20 and 80 minutes,
depending on respondents’ degree of involvement
in a trial. The interviews were semi-structured and
explored respondents’ opinions about the Part B
trial in which they were involved (Appendices 7
and 8). The interviews did not include discussion
of individual patients. They were wide ranging,
highlighting individual responsibilities and their
attitudes to and experiences of the trials.
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TABLE 15 Sample structure for Part B
FOCUS ELEVATE TOuCAN HPS Totals
Central coordinating staff
PIs ✓✓ ✓ ✓ ✓ ✓
Trial managers ✓✓✓✓ ✓
Central recruiters ✓✓ ✓✓
Administrative support ✓
Statistician  ✓
Clinical support ✓✓ ✓ ✓
46742 1
Clinical staff in recruiting/referring centres
Local lead investigators ✓✓ ✓✓✓ ✓✓✓✓✓✓ ✓✓
Recruiting doctors ✓✓
Recruiting nurses ✓✓✓ ✓✓✓ ✓✓✓
766 52 4
Total staff 11 12 13 9 45
Key to shading:  , recruiting staff;  , central coordinating staff;  , clinical staff in recruiting/referring centres.Interviewees were also asked to rate the
importance of the question addressed by their trial
and the quality of the design on a 0–5 Likert scale. 
The very detailed discussions were not only
designed to promote a full and reflective account
of their involvement, but also aimed to promote in
the interviewees a deeper state of engagement
with the issues raised. When, at the end of the
interviews, respondents were asked to identify key
factors in the success of their trial, and if there
were any issues that were important and had not
been discussed, the researchers were confident
that their accounts and their final summaries were
well considered and reliable. Because the study
involved professionals with a variety of roles within
the trials, the questions were to some extent varied
for each of these individuals. The lines of
questioning were also modified and developed
over the period of the fieldwork, in response to
the insights gained.
Analysis
All of the interviews were conducted, read and
analysed by one of the researchers for Part B (CS),
with research colleagues (JG and DE) reading a
sample of the interview transcripts and
commenting on significant portions of data as
requested. Data analysis was conducted with the
assistance of the qualitative package Atlas-ti. The
analysis was shaped by the research aims to
provide descriptive, exploratory and comparative
data.
To some extent, the data are a product of the
questions that were asked and could be said to be
influenced by the research team’s pre-existing
perception of what was likely to be important
rather than pure themes that arose from the data.
However, many issues arose in response to the
direction of the interviewees, and the organisation
and refinement of the data are very much a result
of the analysis. In his ‘adaptive theory’, Layder64
values the role of pre-existing researcher
knowledge and concepts, in comparison to
grounded theory approaches in which the data
collected are primary and from which themes are
said to emerge. He suggests an approach to
analysis in which existing models are adapted in a
process of modification and refinement as
experience and understanding of a phenomenon
grow. In this way, for Part B, an initial line of
questioning was drawn up for the interview
schedule; it was developed in interview as
interesting lines of information were introduced by
respondents, and then explored in analysis.
Analysis commenced with codes based on a
mixture of the interview schedule and insights
gained from the interviewer’s experience of the
interviews. The codes were expanded and
collapsed as each interview was processed.
Eventually no new codes were introduced and the
researcher was satisfied that the data had been
adequately explored. 
The findings from the descriptive, exploratory and
comparative data are presented in three parts.
They are first organised as four case studies in
which the structure, history and progress of each
trial is described. The data are then presented as
key chronological stages in the development and
conduct of the trials, ordered thematically within
and across the four trials. Finally, possible
common factors in recruitment success, as
suggested by the interviewees, and generated by
the data analysis, are presented.
Where appropriate, quotations are attributed to
particular trials and ‘type’ of respondent.
However, in some instances, no attribution is
given, to protect anonymity.
Results
Brief histories of individual ‘exemplar’
trials
The FOCUS trial
The FOCUS trial was developed to address the
issue of how best to treat patients with advanced
metastatic colorectal cancer, in the light of the
development of two drugs, irinotecan and
oxaliplatin. These drugs were evaluated in
previous trials but had not been directly
compared, nor had there been direct comparison
of the same drug used in first- or second-line
therapy. 
The developmental period for this trial was
lengthy, in part because of a process of clinical and
academic consultation with colleagues and
professional bodies. Negotiations with industry for
access to, and funding for, the study drugs were
protracted and added to the delays in set-up. A
potential consequence of such delays was a shift in
the evidence base, which would disrupt the trial at
a later stage.
In 2002 the National Institute for Health and
Clinical Excellence (NICE) argued that existing
and emerging data on the improvements in
survival times for the drugs used in the FOCUS
trial did not warrant the costs involved with their
routine use in first-line therapy, and issued
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to the drugs.65 NICE recommended that
irinotecan should be used, but only after the
failure of a first-line treatment, and that the use of
oxaliplatin be restricted to a small subcategory of
patients. There were two consequences of the
guidelines. First, except for that subgroup,
oxaliplatin was now available only via the trial, to
which NICE recommended recruitment. Second,
NICE had recommended the use of second-line
irinotecan when first-line treatments had failed,
when two of the arms in the trial did not employ
irinotecan. The NICE guidance caused a furore in
the oncology community, with some oncologists
arguing in a letter to a newspaper66 that NICE
had misinterpreted the available data. 
After another period of consultation with the
professionals involved in the trial, the trial team
adapted by amending the protocol to remove the
existing discouragement to post-trial cross-over
and introducing a balanced cross-over policy. All
surviving trial patients would then have equal
access to either oxaliplatin or irinotecan
depending on the trial arm, after completing their
initial trial treatment. In response to public debate
following NICE guidance, the independent trial
steering committee (TSC) took the unusual step of
publishing a letter defending the trial
management group’s decision to continue accrual. 
The letter67 included a statement that the data
monitoring and ethics committee (DMEC) had
reported no safety or ethical reasons to close the
trial, and also included current overall median
survival data for the trial as a whole. The aim was
to assuage concerns that patients were being
deprived of the opportunity of improved survival.
The recruitment rate remained steady in this
period. 
The trial exceeded its aim to recruit
approximately 2100 patients, accruing 2135
patients, but over 3.5 years rather than the
planned 3-year period.
The ELEVATE trial
The ELEVATE trial was developed in response to
a call for applications by the HTA Programme. It
compares the role and cost of a relatively new class
of orally administered drugs, LTRAs, to ICS and
LABs (see Table 14) for primary care patients who
have asthma that requires regular preventive
treatment or an increase in therapy. LTRAs have
been available for around 7 years and can be
prescribed for asthma patients, but more often
LABs are used. Although LTRAs are more
expensive than conventional drugs, they are in
tablet form and may prove to be more acceptable
than inhalers, so promoting better disease control. 
The ELEVATE trial is framed by the five ‘steps’ of
the British Thoracic Society National Asthma
Guidelines. Eligible patients are those judged
either to have progressed in their condition or to
have poor control of their symptoms and so need
an increase in their medication: they need to be
‘stepped up’. As the trial is pragmatic, aiming to
produce ‘real-life data’, it includes patients who
would be traditionally excluded from asthma trials,
such as smokers or those affected by other
conditions. 
The trial was very much shaped by its location in
general practice. Trials in this area are known to
be difficult.47,58,68 There was, however, an
important advantage for the trial in that GP
contracts require that a high proportion of
patients with asthma are regularly reviewed, and
that poor control of asthma is addressed.
Participation in the ELEVATE trial offered
practices a valuable degree of support with this
potentially onerous task.
Recruitment was initially very slow. The trial team
had expected to provide some administrative
support to the practices, but it became clear that
much greater involvement in the recruitment
process was required. The entire approach to
recruitment was revised. Funds were granted by
the HTA Programme to provide a more intensive
level of assistance and additional staff costs, and to
permit an extension to the recruitment period.
Money from a pharmaceutical company supported
baseline practice audits and excess drug costs. At
the time of this research (July 2004), recruitment
to one stratum is complete and is ongoing for the
remaining stratum. A reduction in the length of
follow-up for this stratum has enabled the
recruitment period to be further extended without
an additional extension of the amount or period
of the funding.
The TOuCAN study
For some time the senior researchers for the
TOuCAN study had wished to carry out a trial
assessing the efficacy of approaches to care for
adolescents with anorexia nervosa. They were keen
to understand whether it was better to have
intensive inpatient treatment at an earlier stage in
the condition, or whether this should be reserved
for the more difficult, entrenched cases. They also
wished to assess the possible value of a recently
developed specialist outpatient service. RCTs are
Health Technology Assessment 2007; Vol. 11: No. 48
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attempts to bring about a trial had been
unsuccessful. There were many practical and
attitudinal obstacles to be overcome to set up the
TOuCAN study. In a setting where there are
deeply held lay and professional beliefs about
approaches to treatment, the researchers had to
work hard to meet colleagues’ concerns and to
promote support for the development of a trial.
Once funds were awarded there were several
practical and attitudinal obstacles to be addressed.
These were a highly complicated mix of local
concerns over responsibilities for patients, about
delivery of care and about the impact of the trial
upon professional standards and autonomy.
Despite this rather difficult climate, the trial did
gain the support needed. In addition to the efforts
made by the central team to maintain the profile
of the trial and to gain access to potential
participants, an important element in securing
professional support seems to have been the
opportunity for hard-pressed clinicians to access
expert assistance with an often intractable, time-
consuming and anxiety-provoking condition.
Some clinicians were uncomfortable with passing
over control of their patients in the trial context,
but others welcomed the opportunity to free up
local time and resources.
It became clear that although a very impressive
90% of cases were entered into either the trial
arms or the naturalistic arm, the recruitment
targets of 210 in the RCT and 70 in the
naturalistic arm were not going to be met. With
new power calculations the targets were revised to
165 and 75, respectively, and a funded extension
was awarded. These targets were reached in
3.5 years instead of 2 years.
The MRC/BHF Heart Protection Study
The HPS was based at the Clinical Trial Service
Unit (CTSU) in Oxford. It aimed to evaluate
cholesterol-lowering therapy (statins) and
antioxidant vitamins for a diverse group of
patients at increased risk of coronary heart disease
(previous coronary disease, other occlusive arterial
disease, diabetes, hypertension). The trial grew
out of a pilot study which was funded by industrial
sponsors and started recruitment in 1987. As a
result of this work the trial team concluded that a
much larger and more ambitious trial was needed
than had been previously anticipated. There were
questions about the role and safety of statins, in
particular whether they would reduce mortality
and morbidity even in those with cholesterol levels
that were below average for the UK population. In
addition it was considered important to explore
the impact of dietary supplementation with
antioxidant vitamins. At that time they were
thought to have a potential role in protecting the
body from the adverse effects of high cholesterol.
With the initial sponsors unwilling to fund such a
trial, it was necessary to bring together a
consortium of funders. The trial eventually cost
£21 million and was funded by the MRC, the
British Heart Foundation (BHF) and two
pharmaceutical companies who manufactured the
statins and the vitamins. Securing this degree of
funding, while maintaining academic
independence and control of the research
questions, was hugely difficult and time
consuming, and the main trial suffered major
delays as a consequence, finally starting
recruitment in 1994. The delay may have led to a
dilution in the difference in cholesterol levels
between the statin arm and non-statin arms as
clinicians increasingly prescribed statins as results
from other studies became available during the
course of the HPS.
The trial was randomised and double-blind, and
used a 2 × 2 factorial design; around 5000 people
were allocated to each of four treatments: 
(1) active statin and active vitamins, (2) active
statin and placebo vitamins, (3) placebo statin and
active vitamins, and (4) placebo statin and placebo
vitamins.
The trial was thought to be well timed in terms of
clinical awareness of the need for an answer to
important questions about management of
cholesterol, but the feature that shaped the
progress of this trial was its size. Many
management issues were focused on how best to
control and direct human and other resources. For
instance, 69 UK hospitals participated in the trial.
In all, 131,000 invitations were issued and 63,603
people between the ages of 40 and 80 years were
screened. Of these 32,145 agreed to enter the 
2-month run-in to the study and 20,536 finally
took part (15,454 men and 5082 women). Loss to
follow-up was less than 1%. Identification of
potential participants was carried out by the
central trial coordinating team and this was
recognised as critical to the success of the study;
local consultants and research nurses would simply
not have had the time to do this. It also allowed
the central trial team to target categories of
patients whose participation they wanted to
increase, such as women and older patients. Study
clinics in the hospitals were run by specially
recruited senior nurses and participants attended
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the trial. The nurses were trained centrally and
given considerable autonomy.
The trial succeeded in its aim to recruit around
20,000 patients between the ages of 40 and
80 years over the period 1994–1997 and has
reported its results.69–71 HPS gives STEPS an
example of a successful, large, ‘simple’ or
‘streamlined’ clinical trial with important,
internationally significant results. 
Exploration of the key stages of the
trials processes
As these descriptions of the trials suggest, there is
a number of phases in the course of trials, each
involving different challenges that the trial teams
have had to address. It would seem that it is
important to consider how these different stages
contribute to the level of recruitment to a trial.
Four key stages of the trials that may affect
recruitment were identified through the analysis.
They are:
● key stage 1: Foundation work (engagement of
collaborators; establishing
scientific rigour; funding and
financial considerations)
● key stage 2: Recruitment processes
● key stage 3: Delivery of care
● key stage 4: Delivery of research.
These stages are analytical constructs, rather than
chronological stages, and involve a certain degree
of overlap.
Key stage 1: Foundation work: engagement of
collaborators
Trials take place in clinical settings in which the
professionals involved are autonomous or can act
within a firmly integrated community. Within the
broader clinical communities, a research
community can be more, or less, well developed at
the start of a trial. Even where research is carried
out, it may or may not involve RCTs. The
interviews with the PIs and some of the staff who
had been associated with the early stages of the
Part B trials involved discussion of the preparatory
or foundation work that they carried out to
enthuse and engage their community in their
research, and to maximise the support of potential
collaborators. 
The professionals on whom they depended had
varying degrees of research experience and
enthusiasm for the trials. For the TOuCAN study
(anorexia nervosa) and the ELEVATE trial
(asthma), there were limited pre-existing clinical
networks in which some individuals had been
associated with earlier research collaborations, but
there was work to be done in bringing the wider
community together as a collective with a
committed research identity. The HPS
cardiovascular and the FOCUS trial (colorectal
cancer) were, by contrast, conducted in the context
of rolling programmes of trials, where professionals
were familiar with trial rationale and procedures
and in which there were established networks of
research collaboration. Some of the “work behind
the scenes” (TOuCAN study interviewee) described
in the interviews was to establish the clinical and
scientific basis of the trials and was carried out
before funds were awarded, and some took place in
the early postfunding stage. Typically, it involved
senior professionals in the field. How the trials
were received appeared to be very much a product
of the degree of research experience held by these
communities.
The TOuCAN study drew on the support of what
was described as the “small world” of adolescent
psychiatry in the north-west of England and was
carried out by a newly developed research team.
From the start there was a number of major
obstacles to overcome in order to bring about this
“difficult”, “mammoth trial”, but one of the
interviewees described how they felt that it offered
an important chance to develop the research
experience and profile of their community:
Adult mental health services hadn’t been very
successful in treatment trials in this area and here was
an opportunity for child psychiatry, [which is] a bit of
a Cinderella speciality, to come up with some good
research.
Although there are academic units in the area, and
some interviewees who were linked to these
described themselves as “pro-research” and “very
research orientated”, the image generated by the
TOuCAN study interviewees was a community that
was not naturally drawn to RCT methods. RCTs
are seldom used in connection with anorexia
nervosa and so there was not widespread
experience with trials. One interviewee stated that
“up here it’s unusual for people to be in treatment
trials” and another felt that the trial focus on the
care of children and adolescents further
complicated things:
Child psychiatry is a very young branch [so there is
not as much research] as you have in other branches
of medicine. There are [also] some people who don’t
believe in quantitative research. In psychiatry there is
much more [support] for qualitative research.
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TOuCAN study that went beyond research
methods and these constituted a major challenge
to establishing the trial. There were concerns
about limitations on professional autonomy and
erosion of skills in a system where cases of
anorexia nervosa are randomised away from local
care. Although the primary aim was to delineate
appropriate services, the way in which inpatient
and outpatient care was used within the trial
caused much professional anxiety. Inpatient care
involves removal of anorexic adolescents from
home, school and family to a difficult environment
and exposure to a range of highly problematic
psychiatric conditions. Although this approach is
traditionally reserved for urgent cases, it can still
be difficult to find inpatient beds. Randomisation
meant that patients in far less extreme
circumstances may be allocated to inpatient care,
and that some in a more advanced condition be
allocated to outpatient care. Although the trial was
premised on uncertainty over the value of these
different approaches, some clinicians found it
difficult to countenance this situation. Some
concern was expressed in interviews that if urgent
inpatient care was requested, beds could be
blocked by “more robust” trial patients.
These concerns highlight a major difficulty faced
by the trial team. To answer the research questions
necessitated recruiting the vast majority of cases of
adolescent anorexia nervosa in the area. To
achieve this ambitious aim it was crucial that this
clinical community, in which there was a
significant degree of ambiguity over the proposed
research, should work collectively and efficiently
towards that end. Although the interviews
indicated that there are some enduring areas of
unease, the trial has in fact been well supported.
This may have been due in part to the efforts
made by the trial team to address any community
concerns through meetings and provision of
information, and it seems that some concerns may
also have been offset by the very localised setting
for the research. Although the PI had not
previously conducted a trial himself, he had
worked in a number of key centres in the area, had
established treatment programmes and had
worked with many of the local senior adolescent
psychiatrists. Along with other senior clinicians
involved in the TOuCAN study, he was aware of
local politics and sensitivities and was familiar with
his colleagues’ concerns about a trial for this
condition. Most importantly, he had a clinical load
and often took referrals of difficult cases from
CAMHS colleagues in the area. He argued that
this active clinical position was crucial in terms of
engendering trust and professional relationships.
He felt that a trial in such a setting would be
doomed to fail without the support of pre-existing
clinical networks:
It would be difficult for an academic to propose this
sort of trial without having the clinical standing. We
here are very embedded in the [local] clinical service,
and so I think if an academic proposed the research
and just hoped to get clinicians on board, they
wouldn’t be successful. I think you have to have
referrers’ confidence that patients are going to be
managed by somebody with expertise in the field.
The interviews with the local CAMHS
professionals involved in the TOuCAN study
amply supported this statement. Despite some
difficulties, the interviewees were keen to
contribute to research in their area, and to
support a colleague whom they either knew
personally or admired professionally. He was said
to have “a name” in the field and interviewees said
that they were “impressed with what [he] was
trying to do”, and that “a lot of people would want
to try and support the trial partly because of [the
PI] being the one who’s leading the trial”. One of
the CAMHS professionals said: “I felt favourable
towards the trial at the beginning because I know
[the PI] and like him and because he had helped
me to think about how to manage anorectics.”
Similarly, the GPs interviewed in connection with
the ELEVATE trial of asthma therapy were aware
of the work and profile of the PI and welcomed
the fact that he was himself a GP. His name was
said to carry “a huge amount [of weight]” by one
of the GPs. This was particularly important in this
setting as general practice is a hard-pressed area
of medicine in which trials can be difficult for
practical, methodological and ethical reasons.68
The ELEVATE trial was no exception to this and
GPs who were interviewed talked about the need
for assurance that the research would not adversely
affect their workload, their finances and their
patients. The active presence of a GP as the PI, and
a process of consultation with a small GP research
consortium carried out to guide the development
of the trial, had promoted an influential sense that
the trial had emerged from within primary care
and so would be sensitive to its particular
priorities and limitations. The interviewees who
were members of the consortium felt that they
were part of a research network and felt a degree
of loyalty to the trial, even though it was not
considered to be the easiest of research areas:
[We were] very much involved in the design of it at
the beginning so we had a lot of ownership of the
Case studies of trials that appeared to have particularly interesting lessons for recruitment 
30project and obviously we were going to be happy to
go ahead and recruit for it and very actively support
it. … Had it been [anyone else as PI] I think we
wouldn’t have done it because we felt our asthma
patients had already been approached three or four
times in the last four years. But [we did] because we’d
been involved in this and we’d thought things through
and it’s made as easy as possible for the practice.
Although the ELEVATE trial drew some
advantages from the GP research consortium, it
still proved to be quite a task to pull together a
sufficiently large group of practices to conduct the
trial. One GP explained some of the possible
reasons why research that requires active GP input
can be problematic:
There is a very strong feeling among grass root GPs
that they don’t see why they should do it themselves,
in their time and why they should be [subsidising]
it.… [It has to involve] questions that the GPs are
interested in and that are relevant to general practice
and often research projects come up with questions
that actually seem particularly irrelevant. There’s a
slight suspicion of academia and research in general
practice. A lot of people feel that you should be out
there on the front line seeing the patients and are
very sceptical about research in general.
The trial team ultimately had to extend the
geographical area for the trials, and to contact
over 300 practices to find the 55 that went on to
become recruiting centres.
By contrast, the remaining two trials were located
within nationally based networks of experienced
and convinced research collaborators. The HPS
followed on from earlier trials and from a funded
pilot study. One of the consultants interviewed
argued that his previous experience with the
standard of administration and the quality of trials
run by the CTSU was highly influential in his
decision to collaborate with HPS. Collaborators
from the pilot study were available to the main
study and additional centres were brought on
board through a process of visiting new centres
and building up networks. The set-up period for
the 69 centres that went on to collaborate with the
trial proved to be “more time consuming” than
had been anticipated. For the earlier collaborating
centres there was thought to be a pre-existing
“trial ethos”, but in some of the new centres there
were actually very few trials taking place. 
For this trial a range of professional groups was
targeted as potential collaborators. Interest in the
research was a more important factor than
speciality and so collaborators included, for
instance, neurologists, diabetologists and
biochemists, as well as cardiologists. The trial team
were very much aware of the need to promote a
strong sense of enthusiasm for the trial among
their recruiting centres as their contact had to take
on a role as a local representative of the trial, and
the recruiting centres were required to act rather
independently from the central office (see below
for more details of recruitment):
[It] was very important to establish that connection
because with HPS, unlike some of the other trials we
do, … where we were getting data from the hospitals,
there were patients under consultants … other than
the doctor that we had as our contact. … Having
them on side was critical.
A balance had to be struck, however, as the trial
team were not in the “luxurious position” of
selecting only the most committed centres, but
they did feel that a “friendly relationship was
critical”.
A possible obstacle to the engagement of
collaborators for HPS was the anxiety among
some potential collaborators that lowering
cholesterol, the primary aim of the trial, was
potentially hazardous. It was therefore important
that such areas of concern could be addressed at
an early stage. This was done through meetings in
which the team presented the evidence and
rationale for the trial, and through setting up a
telephone information help-line for any queries
that collaborators might have. 
The advantages of being able to draw on a
substantial existing research community were
particularly evident in accounts of the
developmental period for the FOCUS trial, a trial
with a very different starting point from those just
described. The trial was run by the MRC Clinical
Trials Unit and was introduced into the cancer
research community, which has a well-developed
infrastructure and a shared history of successful
and committed collaboration within oncology.
Where a sense of academic loyalty and shared
research experience already exists, this was
considered to be an important advantage, as
described by one of the central team members:
[It] very much built on what we’ve done in the past.
One of the advantages of having a trials office like us
who run a series of trials in a certain disease, is that
we build up contacts and we build up rapport with the
clinicians. So we had a very successful trial
[previously] in the same group of patients and it was
all the same clinicians basically. So having built that
kind of community, when we started to promote the
idea of having the next trial for the same group of
Health Technology Assessment 2007; Vol. 11: No. 48
31
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.patients, we had all the mailing lists for that group of
clinicians, and they were the same group of clinicians
who turned up at all the meetings etc etc. So that was
a very good foundation for starting off. We were
starting from quite a high level of interest.
There was very much a sense that the
development of the FOCUS trial was fostered by
an experienced and professional community. The
set-up period for this trial involved a process of
consultation with many senior clinicians and
professional bodies. The aim was not only to
produce a trial of sound design, which would
reflect the concerns and interest of many of the
senior figures in the field, but also to promote a
sense of commitment to recruitment among
potential collaborators. This resulted in a trial that
was described very positively and characterised by
collaborators in interview as “democratic” and
“very smooth”.
For the FOCUS trial there was a sense of
enthusiasm and opportunity that was clear in the
interviews. Trial participation was largely seen as
important for developing strategies of care for
future patients, but also as offering potentially
important options for existing patients, especially
in terms of the chance to access “cutting-edge”
drugs. It was seen as a “win–win situation”. A
number of interviewees described the enthusiasm
of this research community and a sense of
excitement felt at the launch meetings for the
trial. The collaborators were said to be very keen
to start to use the study drugs and to be involved
in a trial that was “groundbreaking”. The
enthusiasm has largely continued through the
trial. It appeared both to promote and to maintain
levels of support for the trial, possibly a major
factor in successful recruitment, which was
commented upon by one of the trial coordinating
team:
[For] trials that don’t recruit so well, [it must be]
difficult to try and drum up attention when it’s falling
on deaf ears. Whereas it’s ever increasing circles when
people are responsive and you’re enthusiastic. It just
builds momentum.
Key stage I: Foundation work: establishing
scientific rigour
Part of the process of promoting and engaging
collaborators is to gain their confidence and
intellectual support. The research focus and the
methods used are defining elements of a trial. It
was clearly of value to the trial teams interviewed
here to feel that their research was asking an
important question in a methodologically sound
way. The importance was not only for the team
and funder’s confidence in the trial: perceptions
of the quality or research have been shown to have
directly affected clinicians’ willingness to recruit
their patients.51,72 A crucial part of the foundation
work for the trials was therefore to establish the
scientific credentials of the trial. The interviews for
STEPS included discussion of the importance of
the research question and the level of scientific
rigour of the trials.
Importance of the research question
It was striking that when the interviewees were
asked for their views on the importance of the
research question, they frequently responded in
terms of its clinical rather than academic
relevance. It was obviously important to the
interviewees that the trials should be practical and
applicable and the hope behind a comment made
in connection with the FOCUS trial was echoed
throughout the interviews across the trials: “It
could change the course of the treatment of GI
[gastrointestinal] cancers.” For the ELEVATE trial
an important factor in terms of the applicability of
the trial results was the common nature of the
disorder. A research assistant commented on this:
“it’s very important because lots and lots and lots
and lots of people have asthma … so I think the
question’s very relevant, and very real.” Similarly,
there was considerable enthusiasm among the
interviewees for HPS, because of the relevance of
the research to a large clinical population. A nurse
who described the question addressed by HPS as
“exceptionally important” explained:
It’s such a high risk to the population, all of these
conditions, and especially the cardiovascular
conditions, that if we could find a way of reducing the
risk to people, then you know we could certainly
reduce the mortality and incidence within Britain,
because it has been gradually increasing.
In contrast, the TOuCAN study focused on a quite
rare condition, for which the available approaches
to care are not currently evidence based. Its value
lay not in a broad application but as an empirical
starting point. One interviewee commented that
the question was “a very crucial [one] because no-
one knows and there are no trials”. Similarly,
another said: “there’s a big hole in the literature
in regard … to the treatment of anorexia nervosa
in adolescents … so it is going to be highly
useful.”
For all of the trials there was also appreciation of
and interest in the more challenging aspects of the
research questions, such as accessing populations
that are under-represented in research (TOuCAN,
ELEVATE and HPS) and assessing interventions
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(FOCUS, HPS). The trials were often seen as
“ambitious”, “difficult” and “cutting edge”.
While the PIs and their supporting team were not
surprisingly enthusiastic and very clear about the
value of their research questions, they were aware
that support for their research could not be taken
for granted. In each trial the trialists knew that in
the initial stages some colleagues were not
convinced of the need for information, or were
happy with their existing approaches to care, and
they had to work to address this problem. For HPS
there was “quite a lot of resistance in the medical
world”, which this interviewee said had been
“overcome enormously”. Similarly, where there was
support for the FOCUS trial it was said to be
“clear and unequivocal”, although the trial also
had its objectors. For the ELEVATE trial there was
discomfort among some GPs as they were being
asked to consider working outside the approved
national strategies for asthma care. The teams
therefore put a great deal of effort into promoting
understanding for the need for research evidence
in their specific areas. The PI for the TOuCAN
study had a policy of telephoning colleagues who
had queries, to address personally any concerns
that they might have about the research. The four
trial teams also hosted or attended clinical
meetings, ran training days and made visits to
recruiting centres. The interviewees who had
attended trial events were very enthusiastic about
both the educational and the social aspects. HPS
offered residential study days and these appeared
to be particularly popular. 
Even though the Part B trials involved quite
different types of research questions, the
interviewees seemed to be equally enthusiastic
about the value of the research question. Each of
the trial questions was regularly described as being
“important”, “good” and “interesting”. The
importance of the question addressed by their trial
was rated by interviewees on a 0–5 Likert scale. All
gave a rating of 4 or 5. One interviewee
commented on the value and influence of a well-
considered research question for their trial:
It seemed to be the question that people wanted
answering. It’s quite interesting that if you get the
question right, everything else seems to sort of be so
much more smooth.
Design of the trial
All four Part B trials were viewed very favourably
by the interviewees in terms of their
methodological quality. When the interviewees
described the importance of the research question
it was frequently and spontaneously expressed in
connection with their confidence in the design of
the trial to deliver results; essentially they felt that
the trials were scientifically robust. As with the
importance of the question addressed by the trial,
the quality of the design was rated by interviewees
on a 0–5 Likert scale. Almost all interviewees gave
a rating of 4 or 5.
For some of the interviewees, such as the PIs and
other senior trialists, this response was from a
more informed perspective, not only because they
knew the trial intimately, but also because they
were familiar with factors such as power
calculations and the implications of elements of
design such as permitting cross-over. For some
other interviewees, it related in part to their faith
in the prime movers for the trials. One local
clinician talked about his admiration for the
“fantastic work” done by the PI in producing a
“brilliant trial protocol”. For another trial it was
perceptions of the acuity involved in pitching and
delivering the trial: “Their knowledge about how
to decide which questions to answer is probably
second to none.”
There was a sense for all of the trials of striving to
maintain the quality of the design in the face of
quite onerous challenges. For the TOuCAN study
the referring consultants appeared to appreciate
the difficulties inherent in this trial, and perhaps
this added to their wish to see the research
succeed. When asked to reflect on the design of
the trial, one consultant commented:
I was involved in another study which wanted to
compare inpatient with outpatient treatment and they
never got it off the ground. You know, it just didn’t
deal with the realities of life. [The TOuCAN study]
has dealt with the realities of life. In view of the
difficulty of the task and the importance of work like
this, it seems to me to be pretty damned good.
The PI was clear that this trial only worked in such
a difficult clinical setting because he was prepared
to tolerate a degree of compromise in the design.
He was the only interviewee in the study to give
the quality of the design of their trial a rating of 3.
He was clear, however, that any compromise to the
design was born out of realism in order to make
the aims of the research achievable:
It’s a compromise in terms of the treatments being
evaluated and it’s a compromise in order to maximise
the chances that the patients will consent to take
part. … I think it was the best compromise to
persuade clinical colleagues to take part.
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financial considerations
How financial costs are met and distributed is
possibly one of the most crucial factors in the
success of a trial. Securing the initial funds is a
challenge in itself. Once these have been granted
there are additional areas in which financial issues
can play a part in shaping the research. If the
initial funds are limited, or there are
unanticipated increased costs, there is the inherent
difficulty for the trial team of running a trial with
inadequate funds to consider. There is also the
likelihood that financial considerations will affect
potential collaborators’ decisions about their
involvement. Potential costs or savings are likely to
be factors in their decisions about whether or not
to collaborate in a trial at all, and also how much
effort to put into that collaboration.
Of the four trials studied here, the TOuCAN study
was the only one where it was widely perceived
that recruitment to the trial was not affected
positively or negatively by financial considerations.
The remaining trials faced not inconsiderable
financial difficulties. These were addressed in a
number of dynamic ways. The trial teams acted to
prevent financial difficulties destabilising their
trials, and also intervened successfully to address
financial issues as they arose.
Securing multisourced funds
The four trials had different paths to achieve their
funding, and this related in part to their initial
choice of funder, and in part to their differing
costs of and responsibilities for treatment.
The MRC usually funds research in the ‘response
mode’; that is, the research idea originates with
the applicant as the creative figure who
determines the direction of the research. However,
from time to time the MRC makes ‘calls for
proposals’, which seek to encourage research in
strategically important areas. In contrast, the latter
approach is the norm for the HTA Programme,
which seeks suggestions from the NHS and its
users about possible research priorities, and then
commissions research to answer those questions.
Whichever the funder, the success of the trial
teams in terms of gaining HTA Programme or
MRC support initially was only part of the funding
process. Both the TOuCAN study and the
ELEVATE trial required funding extensions to
achieve their research aims.
In addition, the ELEVATE trial, HPS and the
FOCUS trial all had additional funders. The PI
for one of the trials explains how complicated and
delicate an issue funding can be when researchers
have to deal with a number of potential sources of
funding:
… trials are funded from different sources and
research costs of the trial, which would be the cost of
actually running the trial unit and gathering the data
and doing the data analysis – that’s the element of the
cost for which one applies to charities or MRC. ...
[We] had those costs fully met and [our] application
went through without a hitch. But in any trial like
this, the costs of actually delivering the treatment and
doing all the other stuff that goes along with treating
patients may in fact be very much larger than the
actual research costs. ... There were clearly going to
be issues of how we were going to obtain the drugs
and get them into a trial which would involve a lot of
patients in NHS hospitals around the country. ... So
part of the reason why the trial took an awfully long
time to, to get off the ground initially was that ... we
felt that with trials like this that it was really only
likely to be a success if we could get the drug
companies on board to the extent that they would
provide some free or discounted drugs for the trial.
For the FOCUS trial there was “a difficult and
long drawn out process of negotiation” with
industry and with the NHS to complete the level
of funding needed, an experience echoed in HPS.
For HPS these negotiations were protracted,
despite initial success with a pilot study:
The idea was that we were going to do the study
funded solely by [a drug company] and they
supported a pilot study.… The gap that occurred
between the pilot and the main study was merely an
issue of getting the funding. We had initially been
thinking about a ten thousand patient study but the
more we got into it the more we felt that a bigger
study of twenty thousand patients would make more
sense and we couldn’t persuade [the drug company]
to fund that…So we spent some years pulling
together the funding from a range of different sources
[which] was extremely difficult. [There was] a lot of
enthusiasm for doing the study from people that we
collaborated with on previous trials but what held it
up was just getting the money in place… [Eventually]
we retrieved the [drug company] support and got
support from [another drug company], as well as BHF
and MRC but it was a long process.
As these funding difficulties created a gap of
several years between the pilot and the main study,
there was the potential for damaging effects on
recruitment and the findings of the trial. This was
due to the impact of data emerging from other
trials in the course of the study. One interviewee
explained: “there were some types of patients in
HPS for whom their own doctors wanted to use
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have achieved a bigger LDL cholesterol difference
between the treatment groups if it had been done
earlier.”
Treatment costs
The interviewee quoted above raised the subject of
different avenues of funding for research and
treatment costs. Trials such as HPS and the
FOCUS trial which have MRC funding should in
theory be supported by an agreement with NHS
trusts, known as the Concordat. Under the terms
of this agreement, while the MRC covers research
costs, the NHS trusts are obliged to take
responsibility for ‘legitimate’ service support and
treatment costs associated with MRC-funded
research. Although the trialists involved in the
FOCUS trial had negotiated the provision of some
free drugs from industrial sponsors, the treatment
costs were still described as “significant”. Trusts
vary in the funds that they have available for
research and, in spite of the Concordat, there were
some areas where the treatment costs were not met
and centres were unable to collaborate in the trial.
A similar issue was faced for the ELEVATE trial,
where industry was approached and agreed to
meet excess treatment costs while the HTA
Programme was to meet research costs. There was,
however, for the three drug trials, an important
matter of academic integrity which was raised by
their negotiations with industry.
The senior trialists explained how they had had to
maintain their own vision of the direction and
focus of their research questions. They were clear
that despite differing approaches to research and
“very strong commercial agendas”, the industrial
contributions had to be on a “no strings attached”
basis:
When you negotiate with drug companies over
obtaining drug supplies for trials, you usually find
yourself negotiating with somebody who’s from the
business unit or marketing unit of the company
where, obviously, the priorities and the issues which
they bring to bear … will be commercial and 
business decisions. So we went through quite a
difficult process of negotiating with companies …
trying to decide whether or not we could compromise
on some of the questions which we wanted to ask or
whether we were going to stick by our guns and
potentially end up with a more difficult trial to run
because we didn’t have funding. And we ended up
with a trial design where we had pretty much stuck to
our guns and where the amount of drug company
funding was very much less than we might have
wanted if we had compromised the design a bit 
more.
For the ELEVATE trial their negotiation for
additional resources to fund treatment costs was
essential, not only for the day-to-day running of
the trial, but also to allow them to “head off the
resistance we thought we might encounter from
the primary health costs holding the drug
prescribing budgets for primary care”.
Staffing costs
The staffing costs for these trials varied
tremendously. At one extreme there is HPS, a long-
term trial involving an “army” of administrators
and 69 recruiting centres, each with a funded,
centrally trained, time-dedicated research nurse. At
the other extreme is the TOuCAN study, a trial
carried out in a local setting, and for which
administration and recruitment are controlled by a
small number of central staff.
For the ELEVATE and FOCUS trials, although
research nurses in the recruiting centres were key
members of the trial team, how they were to be
resourced was a matter for negotiation. For the
ELEVATE trial a contribution was made to the
practices to cover the research time contributed by
the practice nurse. For the FOCUS trial, although
payments were made to the recruiting centres to
contribute towards nursing costs, some of the costs
were absorbed by the centres, and decisions had to
be made locally as to how to manage this
situation. In one centre resources were provided
through R&D funding systems, and in another,
nursing costs were met via industry links to
provide protected nursing time for the trial. In
comparison to the payments made to recruiting
centres for their contributions to industrial trials,
the income from academic trials can seem to be
less than lucrative, as discussed by a member of
staff at a recruiting centre:
We have a commitment to the MRC trials first. We
would always recruit to them before an industry
sponsored one. But that’s because we’re an academic
department. If you’ve got issues of paying research
nurses’ wages and you’ve got a study that pays five
thousand pound per patient or one that pays two
hundred pound per patient…! But we’re quite lucky
because we have a huge patient catchment, so we’ve
never got a problem in finding patients for any of our
studies.
This raises an important question of competition
between industry and academic trials, a factor
which was likely to shape the ability to collaborate
with academic trials for smaller, less well-resourced
departments. Competition for patients was also an
issue for the ELEVATE trial (see section ‘Key stage
2: Recruitment processes’, p. 37).
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optimism about staffing issues to permit trial
collaboration. As one collaborator in the FOCUS
trial said:
Now this is improving again…with the NCRN, we’ve
got 12 nurses now and some data managers. And so it
actually does make it easier… there is a definite
improvement, even though things aren’t as you would
wish, because there are still too many patients. But it’s
definitely a good start.
Financial implications for collaborators
Where trials may involve costs to collaborators,
this can be “the final straw” in decisions about
joining a trial. This is a particular concern for
trials in general practice. The ELEVATE trial
worked to avoid costs to their collaborators. In a
highly pressured context it can not only be
irksome for GPs to feel that they are used as an
unpaid extension to a research team, but also
result in poor levels of recruitment. A GP
explained the nature of the problem:
People forget that general practices are actually small
businesses and they are funded in a completely
different way to hospitals. … If you are a teaching
hospital there may be funding in the system for the
idea of supporting research. In general practice
research is not a core thing that is funded at all. …
Even things like sending out letters, stamps on
envelopes and secretarial time, all of that costs money.
The only place that that money will come out of is the
practice profits, which is basically the partners’
income, so unless it is adequately funded you are
actually asking the individual GPs to take home less
money in order to do the research. That is just not
the case in hospitals. It doesn’t affect the doctors’ or
nurses’ incomes at all [if] research goes on. … In a lot
of practices that is a big barrier. Unfunded research is
a real problem.
As the ELEVATE trial was developed by GPs, in
consultation with GPs, there was sensitivity to the
need to protect practices from any costs arising
from their collaboration. The trial team reacted
swiftly to early recruitment problems and radically
modified their administrative procedures,
directing the workload away from the practices.
This required greater human resources than
previously anticipated. Additional funds were
given by the HTA Programme to introduce new
members of staff and to pay for occasional use of
independent agency research nurses, thus
providing the necessary support to the practices.
This changed the requirement for the practices to
carry out time-consuming searches, and the entire
way in which potential participants were identified
and recruited was refined. It was mentioned by
nurses and GPs alike that without this intensive
input from the trial team, the trial would have
been impossible to carry out. 
In addition to a contribution to primary care trust
(PCT) prescribing budgets, the practices that
collaborated with the trial were also given a
contribution to their funds to cover nursing time,
something that was thought to be likely to
promote “a stronger collaboration”. Although one
GP argued that this did not cover the costs
involved, it was still widely viewed as an effective
and essential strategy. The aim was largely to keep
the costs of collaboration “neutral”.
The potential for some costs to the practices was
possibly counterbalanced by one particular
financial benefit of the trial. One GP spoke very
clearly of the balance of any cost to a practice of
participation in the trial and the benefits of
accessing assistance with some of the more difficult
asthma cases. In accordance with their NHS
contracts, GP practices are required to
demonstrate that they have improved the
management of such cases, and this can be a
lengthy, labour-intensive process. The trial could
therefore be seen as an important opportunity for
hard-pressed professionals to gain assistance with
this difficult task, and for their asthma patients to
access a greater degree of support and nursing
time than would usually be offered. 
Clearly, the possibility of costs to collaborators can
be a deterrent to initial involvement in a trial. For
the FOCUS trial this issue had been addressed at
an early stage and the cooperation of the
collaborators had been secured, but a potential
threat to that relationship arose at a later stage.
Halfway through the trial one of the drug
companies withdrew its support, with the result
that treatment costs would subsequently need to
be absorbed by the collaborators. Although this
was very worrisome, by this time the trial, its
community and treatment patterns seem to have
been sufficiently established that it did not impact
upon recruitment:
Respondent: We thought this was going to be an
absolute disaster, and nothing
happened. Nobody really bothered;
they just kept on accruing to the 
trial.
Interviewer:  So the hospitals were basically paying
to recruit people into your trial?
Respondent:  Well yes, you could say that, although
outside the trial they were 
probably getting exactly the same
treatment.
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Respondent:  It didn’t affect recruitment.
Key stage 2: Recruitment processes
Once the engagement of more senior
collaborators had been secured, and appropriate
financial support for the trial and the recruiting
centres established, another tier of professional
involvement was introduced to the trials. Whereas
the TOuCAN study used central trial team
recruiters, recruitment to the other Part B trials
relied heavily on the cooperation of nurses in
recruiting centres. Some of these nurses were in
existing posts and took on additional
responsibilities for the trials, and some were
employed specifically for the purpose of
recruitment. The nurses also took on the role of
motivating and reminding colleagues about
recruitment issues for the trials in which they were
involved. The processes involved in recruitment
show how the different teams have considered
factors that are likely to affect participation in
their particular settings.
The TOuCAN study maintained tight central
control over the process of recruitment, an
approach that in part was driven by an
understanding of the complications inherent in
dealing with their target population of adolescents
affected by anorexia nervosa. Recruitment was
predominantly carried out by a small number of
non-clinical research assistants who became very
experienced in talking to prospective participants
and their families over the course of the trial. 
The protocol suggested that the trial team should
be alerted whenever CAMHS received a new
referral of anorexia, before the professionals
involved met with the young person to make a
clinical assessment. The aim was to retain central
control over the information given to potential
participants, and to avoid establishing a
therapeutic engagement at a local level. Such an
engagement may have made the adolescents or
their families reluctant to consider care in any
other location, thus increasing the chances of
refusal to participate in the trial. It may also have
complicated the experience for those allocated
away from local care. 
Once the trial team had been given contact
details, a researcher visited the family to describe
the trial and take consent if they wished to enrol.
As the adolescents had reached a point where they
were being diagnosed with the condition, they
were already at quite a serious stage in their
illness. This could shape both the tone and
management of the discussions about trial
participation. Although there was a widespread
view in the interviews with clinicians that the
population available to the trial was
predominantly middle-class, high-achieving,
teenage girls, who responded to the interest shown
by the trial team, those who made the home or
hospital visits for the trial described some
situations in which it was very difficult to engage
the adolescents in conversation. Among the
younger patients, or those hospitalised or eating
and drinking very little, poor levels of
concentration or responsiveness could be
significant issues. There were some initial anxieties
about random allocation of treatment in this
context and the response of the team reflects an
understanding of what is feasible against the
backdrop of a condition such as anorexia nervosa.
Where adolescents felt uncomfortable they were
told that they were not obliged to accept the
allocated treatment, an approach that would not
often be encouraged in other trial settings. They
were, however, asked to go along to the service to
which they were allocated for an assessment and to
learn more about what was on offer. If possible,
the team tried to encourage participants to try the
service for a 6-week period before choosing to
swap to one of the other treatments. If they were
still unsure, or if they declined randomisation,
there was the option of allowing data collection in
a naturalistic arm (essentially a patient preference
arm) of the trial. This approach to recruitment, as
well as the inclusion of the naturalistic arm,
offered patients who did not wish to have control
taken away from them an important expression of
autonomy.
This form of patient preference trial was described
as “a compromise between a pure RCT and a
naturalistic study” and was driven by an
understanding of the likely resistance among
anorexic patients to a more rigid approach. The
intention was that in permitting a degree of
clinical and personal autonomy that might not be
tolerated in trials in other settings, the chances of
professional and patient participation in the trial
would be increased. These strategies appear to
have worked as the TOuCAN study is following up
over 90% of the local cases of anorexia nervosa,
with 78% of these randomised and 22% in the
naturalistic arm. Cross-over between the
randomised treatments arms was 33%, which was
less than originally feared.
In the ELEVATE trial and HPS, responsibility for
the recruitment processes was shared between the
central trial teams and collaborating centre nurses.
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procedures involved in trawling records and
databases to identify and book clinic appointments
with potential participants, and then passed
recruitment over to the nurses working at a local
level. For HPS, these nurses were employed in
each collaborating centre specifically to work on
recruitment to the trial. They were trained by the
central trial coordinating centre and were then
given a high degree of local autonomy. It became
their responsibility to find office and clinic space
for recruitment and they regulated their own time.
For the ELEVATE trial, the nurses were largely
existing practice nurses who took on a commitment
to recruitment as part of their general duties, for
which the practices were reimbursed. Where a
practice was not able to supply a nurse, the trial
team employed four independent agency nurses
who were occasionally placed in a practice to
recruit to the trial. The more senior collaborators
in the two trials who had permitted the research to
run in their centres had a minimal role in
recruitment, although opportunistic recruitment,
often at the prompt of the research nurses, could
take place via their own caseloads.
The patients who were eligible for the ELEVATE
trial were those with poorly controlled asthma.
During the course of the trial, a competing
commercial drug trial was established. Potential
participants for this trial were, in the opinion of
two of the interviewees, often those who were
easier to recruit, and their recruitment elsewhere
had implications for the ELEVATE trial. Not only
was the available population reduced, the
perceived characteristics of the remaining
population was thought to have shaped, if not
complicated, the process of recruitment in
important ways. A number of interviewees made
the point that these remaining patients often did
not define themselves as having asthma; rather,
they felt that they had some breathing difficulties
for which they had been prescribed an inhaler. It
was more difficult to persuade such patients of the
relevance of the trial to their situation, and
accepting the offer of recruitment could mean
accepting a (possibly unsettling) status as an
asthmatic, with implications for required drug
regimens. The asthma symptoms for some
patients were poorly controlled as they were not
compliant with their prescribed medication. They
often did not attend for monitoring and they were
a difficult group to recruit. Given the difficulties
associated with this population, the trial team
made enormous efforts to track down as many
potential participants as possible.
Once patients had been identified, similar
recruitment procedures were used by both HPS
and the ELEVATE trial. Clinic appointments were
made by the central teams with patients (in itself a
time-consuming process which, for the ELEVATE
trial, included calling many potential participants
at home in the evenings and weekends), at which
they would be assessed to confirm eligibility for
the trial. The nurses were responsible for
informing patients about the trial and for taking
consent from those wishing to join. For both trials
the recruitment procedures involved several
appointments and typically took place over a 
6-week period for the ELEVATE trial and an 
8-week period for HPS.
For these trials, the clear delineation of
responsibility for identification and recruitment of
potential participants was given by most of the
local health professionals as a condition of their
agreement to collaborate. This was not surprising
as the process of identification for both trials was
daunting. It was estimated that just for one large
general practice, the ELEVATE trial team
identified and wrote to 800 patients in order to
bring 30 to the clinic. For HPS, the trial team
wrote to 131,000 patients and screened over
63,000 in the recruiting centres to achieve their
sample of 20,000 participants. This extraordinary
effort at a central level made the collaborating
centres’ own involvement far less onerous,
allowing the nurses to concentrate on screening
and recruitment. The collaborators who were
interviewed were well aware of the value of the
central identification processes and of having
protected nursing time for recruitment. One of
the HPS interviewees commented on how the
system of recruitment was crucially important for
his centre, both in terms of allowing sufficient
time for the trial processes and for protection of
his own time and duties:
The nurses go down to Oxford, they’re fully trained,
they know how to organise the clinics, so my
involvement in these clinics was minimal. … When we
were recruiting the patients … I was required to put
my signature on the forms, but that was very much a
rubber-stamping job. … If it was in competition with
our service commitment, it would very quickly be
sidelined and we wouldn’t be able to do it.
This point was made repeatedly by recruiting centre
staff for HPS and ELEVATE and was well
recognised by the trial teams; one member of a trial
team described how they had come to recognise
that in order to promote recruitment it was
important that their own research teams should do
“all but the most minimal of processes”.
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recruitment of participants were entirely under
local control. It was usual for a member of the
clinical oncology staff to identify eligible patients.
A consultant would initially explain the trial to the
patients, usually in the context of discussion of the
management of the advancing nature of their
disease. A research nurse would then give further
details of the trial and arrange to see the patient
again some days later, to take consent and initiate
their therapy if they wished to enrol in the trial.
The collaborating centres were given a
contribution towards nursing costs which allowed
for some protected nursing time, but the centres
appeared to vary in the level of resources that were
available. The nurses who were interviewed had a
strong identity both as oncology nurses and as
research nurses, and this was reflected in their
approaches to recruitment. The process of
recruitment to the FOCUS trial could involve
several appointments if the nurse felt that the
patients were overloaded and needed more time
to understand or to consider their decision. This
was important as it could involve patients who had
only just learned that their disease was inoperable.
It was very clear that despite their own
commitment to research generally and to the
FOCUS trial specifically, the research nurses did
see themselves as having primary responsibility to
the patients. The decisions that patients were
asked to make were in the context of the last
months of their life and so the nurses felt that
they needed to draw on their own professional
experience, and on “wider nursing issues”, to
assist this potentially rather vulnerable group
through the trial processes. It seemed to be
important to the nurses that recruitment was
carried out in a supportive, patient-centred
environment. The fact that it was governed locally
appeared to offer nurses an important sense of
professional autonomy, in which they were free to
exercise their own values. One nurse argued that
the nursing perspective was rather different to that
of the doctors and this may shape who enters a
trial, as well as the style of recruitment:
If a patient were to come to a clinic, and the
consultant or doctor [said that] this person would be
feasible to go into FOCUS, say if they’d already had
chemo in the past, or they might not be fit and well,
the medical staff might view it a bit differently to how
we would. We might think they’re not suitable to go
into a study. I think a lot of the time we’re looking at
things from a different perspective, perhaps we’re
looking at things more as an advocate. And although
we are there to recruit, we’re also there to protect the
patients. … They [can] be quite a vulnerable group.
Another nurse explained how the discussion of
recruitment to the trial was potentially shaped by
both the type of patients and the “emotivity of the
disease”. Although among the target population of
patients with advanced metastatic bowel cancer
there is a bias towards older patients, there are
some younger patients and she argued that these
two groups approached both their disease and the
trial very differently. This meant that they needed
a different type of input from their research nurse: 
[The older patients] are not quite as inquisitive as the
younger generation, and probably not as fearful. ...
And maybe there’s something to do with their
perception of the nursing and the medical profession.
They have still got that [view] that the doctor’s the be-
all and end-all, and you [accept] everything what the
doctor says, and that lovely nurse type of thing. You
try to get away from that, [saying] ‘This is about you.
You’ve got as much right to make a decision’. But the
elderly population do hold everybody in a much
higher regard.… The younger age group … are more
fearful, more frightened about the situation they’re in.
They might have a young family and things like that.
You have to usually put a lot more in with them,
because you’ve got to get past the diagnosis, you
know, help them with cope with the diagnosis before
you go onto the treatment.
Clearly, in recruiting to the FOCUS trial the
nurses were required to draw on their professional
skills to manage a particularly difficult situation.
Their degree of specialism, in terms of both their
understanding of research and of the patients’
needs, seemed to produce a very careful and
measured style of recruitment.
Key stage 3: delivery of care 
Concern for patient welfare and for the impact of
trial participation on patients has been shown to be
a major obstacle to professional involvement in
trials in a number of studies. There have been trials
that have caused a degree of professional anxiety;41
professional non-participation72,73 or non-
compliance34 can ensue if the treatment allocation
is not thought to be in the patients’ best interest.
Recruitment, retention and patient compliance may
all be affected in trials that are designed with
insufficient sensitivity to patients’ concerns or
needs,74 and trials where patients may prefer one
arm can be particularly difficult.75 It therefore
seems likely that protecting patient welfare may well
be a factor in promoting recruitment, through
maintenance of professional confidence and patient
satisfaction. The quality of care offered in the
context of the Part B trials, and the subject of what
the trials were thought to offer patients, were
therefore explored with the interviewees.
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professional interest and often took a substantial
portion of the interview time. It was clear that
high standards of patient care within a research
framework were particularly valued and the
interviewees for each of the four trials largely
conveyed a sense of professional satisfaction with
the care offered to their own patients. This
possible impact on the delivery of care in the
context of the Part B trials can be examined in the
context of attitudes to the interventions offered in
the trial, and the perceived effect of association
with the trial on care for patients and for clinical
practice.
Impact of the trial interventions for patients
The interventions being tested in the four trials
were statin therapy and vitamins (HPS),
chemotherapy agents (FOCUS), asthma
medication (ELEVATE) and packages of inpatient
and outpatient psychiatric care (TOuCAN). HPS
was the only study to include placebo. There was a
degree of optimism expressed in the interviews
that the interventions would prove to be effective
and that the trials therefore constituted a means of
accessing a potentially helpful form of care.
Perceptions of the importance of the individual
treatments themselves were, however, quite
different. In the interviews with staff involved in
the ELEVATE trial, for instance, there was less
discussion of the possible impact of the drugs
involved, and more interest in the delivery of
nurse-based supportive care, which was the same
for both groups. A similar issue pertained for
HPS, even though the trial has reported very
persuasive results. The two trials in which the
interventions under consideration were thought to
have a greater impact on patients were the
TOuCAN study and the FOCUS trial.
The planned use of randomisation to determine
the care offered in the TOuCAN study raised
varied responses among the community of
professionals in the development stage of the trial,
as described in ‘Key Stage 2’ (p. 37). As this group
held sway over referrals to the trial, their
perceptions of the possible impact of the trial
treatments for their patients could be an
important determinant of recruitment. The
consultants who had referred their patients to the
TOuCAN study were, however, relatively at ease
with the different treatment options, seeing both
advantages and disadvantages to inpatient and
outpatient care. All described the professional
stresses inherent in dealing with anorexia nervosa,
with sleepless nights and much anxiety, but they
did not suggest that any possible impact of the
different treatments considered in the trial caused
them particular concern. One commented “I am
fairly comfortable with it all really”. The allocation
process seemed to be tolerated even where the
professionals had a degree of preference in one
direction or another:
I’m uncertain about the place and benefit,
particularly of long inpatient admission, so would
always be inclined to have a go at kind of
motivational outpatient treatment first. So having 
to refer people on [at an] earlier [stage in their
illness] has been frustrating, [but] worry is too strong
a word.
When another consultant described a preference
for community rather than inpatient care, he was
also asked whether allocation of patients to
inpatient care caused him concern:
I don’t mind if they try [inpatient care], I’m interested
to see what happens. I’ve got enough people to worry
about without getting too worried [about that]. I’m
not one of the sort of anxious rather conservative
people who [is concerned that] the trial might have
stopped me having a hospital admission [because] you
don’t get them much anyway. And I know I could twist
people’s arms when I want to.
There was an important strand in the interviews
which indicated that at times the ability to use the
trial as a means of strategising the care of the
most difficult cases, with the possibility that they
would in fact be randomised on to those with
greater experience of care for problematic
patients, could be “an absolute Godsend”, “a relief
to get a difficult case off your mind”. One clinician
thought that some professionals who are
particularly “embattled” would be “delighted to
have a trial to refer to” as it offered “an
opportunity to get people a more expert
treatment than they would’ve done otherwise”.
Another interviewee explained:
The children concerned often cause a great deal of
professional anxiety because they can be physically
very ill as well as psychologically ill and so they might
be few children but [they are] very worrying children.
There may be an element that the team felt that it
was helpful to be plugged into a centre of excellence
and to be able to draw on that expertise. I could
imagine there would be some departments which are
much smaller and less well-resourced where they’d be
very grateful for the chance to pass some of their
children on to a centre of excellence.
It was notable that they presented the patients and
families within their care as being very much
individuals with different needs. For some patients
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while for others it was seen as offering a valuable
opportunity to provide some space between
adolescents and their families. The degree of
flexibility afforded to the families and
professionals through the opportunity to decline
or override the allocated treatment seemed to be
essential. It was also suggested that the treatment
options within the trial might in fact be in greater
harmony with the views of the families than with
the professionals:
These families often have a belief in inpatient
treatment and distance centres and specialist centres
and so sort of the idea that two of the three options
are actually specialist options is consistent for these
families with what they think they want.
The professional views of the impact of the
treatments available in the FOCUS trial provide
quite a contrast to those just described. Although
there was recognition in the interviews that cancer
patients do have differing needs, and will make
very personal and individual decisions about the
care that they wish to receive, trial enrolment was
largely seen as offering access to drugs that were
widely thought to be potentially very helpful but
were otherwise not readily available.
This became a hugely important and quite
complicated issue for the FOCUS trial. The
publication of guidelines restricting the use of
irinotecan and oxaliplatin by the NICE in 2002
(see ‘Results’, p. 26) was highly contentious.
Practitioners now faced restricted access to what
were seen by some as “cutting-edge” drugs, and
the FOCUS trial was established as the main
access route for oxaliplatin in the UK. The NICE
debate also brought to the fore discussions about
the differences in availability between the UK and
other parts of Europe and the USA, with the
acknowledgement that patients may learn of the
existence of drugs but then be given the
potentially demoralising information that access in
the UK is restricted.76 It should be noted that it
was not impossible to access these drugs as they
are licensed for use in the UK, but there are
important prescribing costs to be considered that
could effectively prohibit their use for many
practitioners. A nurse described how she
presented this situation to patients when offering
participation in the trial, trying to balance
information giving with avoidance of stress and
pressure in an already difficult situation:
[Now] you don’t want to force a patient to go into
trial, but I do say that by going into the FOCUS
study, there is oxaliplatin available. We don’t have
funding for that outside the study. I think you have to
say that as being honest with the patient; that we
don’t have it. But you don’t want to put it in a way
that ‘Well if you don’t go in this study, you just don’t
get this drug’. 
There was a view that there was some evidence of
efficacy from data from other trials, and some
interviewees felt that there were perceptible
benefits in the survival times for their existing
patients:
If you don’t have chemotherapy your mean survival is
about six to nine months. 5FU is about 12 months.
Irinotecan and oxaliplatin about 15, 16 months. And
then all three of them is 20. So every little step is
important. So I suppose you want people to receive
all drugs, if they can, in a tolerable way.
There were differing opinions among the
interviewees over the impact of this shift on
recruitment to the trial. Some practitioners 
stated that they explicitly and deliberately
recruited to the trial in order to access drugs. A
nurse argued that the impact of the limitations on
the availability of the drugs was probably
disproportionate, with the restrictions being 
felt most keenly by smaller centres where funding
for irinotecan outside the trial would be
impossible. Larger centres did have funding
agreements that made it somewhat easier to access
the drugs. She suggested that it was the limitation
placed on the smaller centres that probably
impacted positively on their levels of recruitment
to the trial. Although the issue of limited
availability of irinotecan for patients allocated to
three of the trial arms was of concern to some
interviewees (before the change in trial design to
permit cross-over), this appeared to be
counterbalanced by the attraction of the
availability of the restricted oxaliplatin within the
FOCUS trial. A consultant articulated a sense of
compromise:
At least in the FOCUS trial you could get all three
drugs at some point. And so I suppose we felt that
every trial isn’t perfect, but even on the control
arm…they could get oxaliplatin afterwards. That trial
was good for that. That’s why we put patients into it.
Two consultants explained that an important
attraction of the trial was the ways in which it
could structure care for patients. Although the
FOCUS trial is undoubtedly complicated, the
design could be seen as a treatment guide, “a plan
for life for patients”, mapping out exactly what
would happen step by step, including
consideration of patients’ care after the trial
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drug would be available on progression of their
disease was described as “positive” as it promoted
patient confidence in their treatment. There was,
however, some degree of compromise. Although
all of the drugs are available within the trial, not
all patients will survive to receive them. A
consultant described how this was balanced with
the search for a way of giving the best treatment in
the most tolerable form:
If you say 100 percent of people get level one, the
first treatment, actually only about 50 percent get the
second level. And probably 10 to 20 percent get the
third level. [You] might find that you get somebody
who’s fighting fit at the beginning, their disease
progresses in the first three or four months, they’re
never fit enough to receive anything more. So there’s
pros and cons of it all. I suppose by giving too much
treatment up front you might make their life
intolerable. And so there’s a happy medium
somewhere there.
Impact of some of the trial processes for patients
Trials can offer more than simply the treatments
in the protocol. Whereas the available literature on
barriers to recruitment suggests many ways in
which patient care can be affected by the offer of
trial participation,15 the interviewees for the trials
studied here often described very positive effects
of patient association with a trial.
All of the trials involved an appreciable level of
human contact and patient support in their
procedures. For the TOuCAN study the attention
paid to the adolescents both in the recruitment
procedures, which involved a visit to their home or
hospital bed, and for follow-up was thought to be
a very positive element of the experience. A
consultant commented:
I think people have, have, quite enjoyed being part of
it really. You know they do get quite a fuss made of
them and, and, they get to go back for the one and
two year follow-ups. I just saw someone last week who
had been back for a two year follow-up and was quite
enjoying that really. 
For FOCUS, ELEVATE and HPS, a significant
degree of patient association with the trials
involved contact with a research nurse. The nurses
had important roles in recruitment to the trials,
but they placed their own duties very much in the
larger context of their duties as a nurse. This
meant acting not only as a patient advocate during
the decision-making process, especially for the
FOCUS trial where those considering enrolment
might be feeling vulnerable and overwhelmed, but
also as a health professional with a chance to
intervene to affect patient well-being.
The ELEVATE trial and HPS both involved an
initial screening visit in the recruitment process,
wherein potential participants underwent a
number of tests and were asked questions about
their health and health management. Several of
the nurses commented that they appreciated the
luxury of long appointments (up to 1 hour) for
each patient, where concerns could be expressed
and a relationship could be built up, a sharp
contrast to the usual constraints on their time. For
both trials the nurses said that at the initial
appointments they included an extra degree of
input that was not required by the study protocol,
such as carrying out blood pressure checks. Some
went to considerable lengths to ensure that GPs
were made aware of any possible problems and
clearly saw their encounter with patients as a
health education opportunity. 
There was reported to be an effect of the
screening appointment for patients who had
poorly controlled asthma who were invited to join
the ELEVATE trial. It seemed that for some
patients the discussion of their symptoms and
asthma management promoted greater use of
preventive medication (rather than simply
symptom relief), and improved their control of
symptoms to a point that they had become
ineligible for the trial by the time of their second
visit. 
Not only were there benefits of patient access to a
nurse, it also seemed that there was a helpful
continuity of care. Participants could establish a
relationship with the research nurse that could
continue throughout their participation in a trial
and beyond. A research nurse from HPS said:
I still see those people locally now and they talk to me
and still recognise me and you know, there’s still that
good relationship there.
Several interviewees articulated a view in which it is
in patients’ best interests to enter the trial because
of the broader package of supportive care. One
nurse linked to the FOCUS trial clearly felt this:
I feel bad for people that don’t go in it because you
think, well who is their nurse if they’re not on a trial,
you know, who’s going to be providing that extra
support? … All they get is the outpatient nurses who
are really stretched and pushed themselves. So I feel
[that] a lot of the time they get extra counselling and
extra one on one support, which people don’t
[usually] get.
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emphasised the importance of patient care, an
element that is likely to appeal to health
professionals, but also de-emphasised the research
element, which can become uncomfortably
disproportionate in some trials in difficult settings. 
Key stage 4: Delivery of research
However great the effort that is put into the
development of a trial and the management of
clinical elements of the research, if a trial is
inefficient and its management poorly thought
out, success is likely to be compromised. Delivery
of the research depends on practical input to
securing patient contact, implementation of trial
procedures, data collection and analysis. This
section considers how this key stage of the trials
was conducted. It is an enormous shared task, and
so it describes not only perceptions of the value of
sound administration, and the ways in which
motivational strategies were employed to maintain
the profile of the trial, but also how those with a
variety of responsibilities to the trials are brought
together as a team with the aim of protecting or
improving recruitment (see also Chapter 4).
Teamwork
For the TOuCAN study it was said that promoting
teamwork and effective communication had been
“a challenge in itself ”. This was not surprising as
the team structures of the trials studied here were
often highly complicated. There seemed to be a
number of teams within their larger frameworks.
The central coordinators operate as a team, as do
groups of doctors and nurses working in recruiting
centres. Even where there is only one individual in
a centre, either making referrals or recruiting to
the trial, there was often an articulation of
membership of a larger team working in a
different way, but in a collective fashion, towards a
shared goal. The relationships between the various
individuals and groups were important, creating
what was described in one interview as “the
chemistry of the team”:
Key factors in success are having a good group of
people who really can figure out what their roles are.
Communicating well and fulfilling promises. [Central
team members need to] understand [recruiting centre
staff ’s] perspectives and their concerns.
If individuals do not fulfil their professional
commitments to other team members or to the
trial, and in turn are pressured or irritated by
requests for action, a trial is unlikely to run
smoothly. Here the interviewees often mentioned
their colleagues within a trial team very positively.
The centres felt supported by the central teams
and frequently said that they were given prompt
answers to any queries. A GP involved in the
ELEVATE trial contrasted his experience of this
team with that of another trial:
I think that the most important thing has been the
support from the researchers [and] the infrastructure
that has been provided. … I contrast that with a study
I was doing for a commercial research organisation
which was overly burdensome with paperwork [and
involved] very poor support from the research
assistants. In the end we didn’t recruit anybody for
their trial.
Working as a team is not, however, something that
happens naturally. It requires particular input
from those involved to maintain and regulate their
own and others’ positions within the trial. One
interviewee argued that without clarity over roles
and expectations of team members, a trial is likely
to fail:
A recipe for a failing trial is to have a committee
designing a trial with a weak PI who isn’t 100 per cent
committed and who leaves the trial office to do the
work.
Multicentre trials are dependent for their success
on the contributions made to recruitment by those
who are, more commonly than not, volunteering
to work on their trials. As described above, the
central teams worked to create a sense of
commitment and loyalty to the trials through
building relationships, giving information and
addressing concerns. The training sessions and
clinical meetings that were offered to all
collaborators for HPS appeared to be particularly
effective on all three fronts. 
The expertise of trial managers and the
inspiration of PIs were highly valued. It was
common for interviewees to describe the
contributions made by particular individuals. In
one trial, central trial team individuals had been
chosen specifically to complement the profile and
skills of the others, mindful of what this would
offer to the local teams and their patients. The PI
described how the role of one, a doctor, was to
bring on board fellow doctors through academic
and shared professional appeal, and of the other,
who had a lot of experience in working with
health professionals, was to act as a diplomat, to
“charm” patients and professionals alike. 
Administration
The administrative workload for a trial can be
extremely heavy, as demonstrated by each of the
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centres require a high level of contact and
support, as in the TOuCAN study and the
ELEVATE trial, or where there are many centres
involved in recruitment. HPS faced a particular
administrative challenge, with a large number of
recruiting centres and a long timescale.
Interviewees from the HPS centres commented on
how well thought out all trial procedures and
documentation were, and how impressed they
were with the trial organisation. Careful planning
and the development of strategies to manage the
administrative load involved in patient contact
and recruitment were seen by some of the
administrative staff as essential for the trial. An
important factor in this area of success, as with the
FOCUS trial, appears to lie in the location of the
trial team within a larger professional clinical trials
unit, centres with a reputation for expertise in the
conduct of trials.
Although there could be a lot of central assistance,
some of the administrative load, especially
provision of follow-up data, fell to the recruiting
centres, and this could cause difficulties. In one
FOCUS trial centre, recruitment to the trial had
slowed down as the backlog of data collection on
previously recruited participants had become
unmanageable. For some months patients were
treated with standard care rather than recruited to
the trial to allow local staff to try to regain some
administrative ground. Funds gained locally from
industry and from R&D were used to fund nurses
and data managers for the department, and one
nurse was specifically appointed to address this
backlog. The centre was then able to pick up
recruitment without the concern of a high
administrative load building up. The difficulties
created by this backlog were mentioned by several
interviewees. One nurse felt that this situation
would not have arisen for an industry-funded trial.
She argued that where nurses’ salaries are funded
by industry, there is an expectation that they will
fulfil an obligation to meet data collection
requirements, and these are more stringent than
in academic trials. It was felt that for academic
trials, stricter monitoring combined with
appropriate support was desirable to keep busy
centres on track.
Motivational strategies
The trials all used standard motivational
techniques such as newsletters, aide-mémoires and
competitions for the highest recruiters. There were
two approaches that seemed to be most effective,
according to the interviewees. The trials
commonly held meetings for professional
collaborators (HPS also held them for their
patient participants), and these combined
educational and social elements. They served to
improve interest in and knowledge of the trials
and aimed to promote a sense of the trial
community. The trial team also often fed back
recruitment figures so that centres could compare
their progress with that of others involved in the
trials. This could stir a competitive spirit,
particularly in larger recruiting centres with the
potential to bring in more participants.
Some of the motivational work was carried out
locally by those with a sense of investment or
ownership of the trial. The nurses who were
interviewed from the ELEVATE trial were well
motivated themselves and placed a lot of emphasis
on their own ability to influence ad hoc
recruitment. This could be by encouraging and
reminding the GPs in their practice to be alert to
the eligibility criteria for the trial when they are
consulting patients, or it could be nurses checking
records themselves. One nurse sent regular e-mails
to her colleagues as reminders and described
herself as “prompting them the whole time”. Even
though the majority of the patients enter the trial
by way of the standard identification processes for
the trial, rather than through ad hoc recruitment,
the value of an enthusiastic nurse was appreciated
by the trial teams.
For the TOuCAN study the success of the trial
depended entirely on the cooperation of the
CAMHS professionals, and therefore much effort
was directed into promoting their participation,
maintaining the trial profile and trying to ensure
that referrals of new cases of anorexia nervosa
were not missed. There was a policy of frequent
contact and each team was telephoned on a
monthly basis to check for new referrals.
Newsletters and other aide-mémoires (bookmarks,
postcards and Christmas cards) were used, as well
as an annual census of all cases of anorexia in
which the teams were asked to state whether or not
they were referred to the trial. Practical assistance
with caseloads was also offered to promote
involvement with the trial, in that those with a
long waiting list for clinical assessments could take
up the option of passing over assessments to the
Eating Disorders Service at Chester. To maintain
good relations, the team observed a policy of
always providing prompt feedback on decisions
about participation and the allocated treatment to
the CAMHS team for each patient seen by the
research team. This was mentioned as something
that was much appreciated by one of the CAMHS
interviewees. When new consultants join CAMHS
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relationship and to make sure that they are aware
of the trial.
Common factors in the successes of the
Part B trials
The four Part B trials have essential internal
differences in their aims, settings and methods.
During the course of the trials they have also been
shaped by external factors, such as the NICE
guidance on treatment for colorectal cancer
patients for the FOCUS trial, and competition
from another asthma drug trial for the ELEVATE
trial. Given their intrinsic and extrinsic
differences, the identification of any possible
common factors in their success may be useful in
terms of the light shed on the running of other
similar and dissimilar trials.
These factors are considered initially in two ways:
first, an analysis of themes from the key stages
presented above where the common factors cut
across at least three of the trials, and which appear
to offer insights that may be used elsewhere; and
second, from the responses of the interviewees to
the specific question that asked them to explain
which factors they thought were the most
significant in the success of their trial. These two
methods for considering factors in success are
then contrasted and compared. 
Common factors in the successes of the Part B
trials based on analysis of themes identified in the
key stages
As might be expected, analysis of the themes
showed that success was thought to be related to
the clinical importance of the research question,
and confidence that the trial design was
scientifically sound. This appeared to be closely
linked to perceptions of the PIs, who were seen as
responsible for the design and direction of the
trials. They were respected not simply as high-
profile academics, but because they were, for
instance, “an OK bloke” or “a good doctor”. They
were seen to have conviction and to be resolute;
one was thought to “never waiver” in his
commitment to the design of the trial. 
In addition to good-quality science and
leadership, it was clear that the interviewees in all
four trials considered that the ‘processes’ involved
were key factors in the success of the trials. They
pointed to the considerable time and effort taken
in getting the foundations for their trials well
established, and felt that this was effective and
time well spent. This process of laying the
groundwork (although facilitated if there was a
pre-existing network of experienced trial
collaborators or an established trials office) helped
to instil a strong sense of commitment to the trial,
regardless of the original climate.
Although the trials varied in their approach to the
recruitment processes, there was a common sense
of their accommodation of the needs of potential
recruits, such that clinical collaborators felt able to
fulfil their own sense of obligation to their
patients, and that the trial was firmly grounded in
their own clinical practice, and so may be useful in
their practice after the trial. 
Expertise for the trials was fostered through
various forms of training, and hence participants
generally appeared to feel well informed. There
was appreciation from the collaborators that they
were protected from some of the workload
associated with involvement in a trial, for instance
by having dedicated research nurses, and that
responsibilities within the trial were well
delineated within an efficient management system. 
The interviewees identified themselves as part of a
successful, hard-working and motivated team, and
this feeling bred greater success and confidence,
such that they were able to adapt to and overcome
even serious problems such as funding crises and
NICE pronouncements. What interviewees in all of
the trials seemed to be pointing to was a climate
in which there was an important sense of
collectivity operating, where central teams and
collaborators were enthusiastic and keen to make
their trials function well and to “deliver”.
Factors identified by respondents as the most
significant for the success of their trials
When, at the end of the interview, respondents
were asked what they felt were the key factors in
the success of their trials, they were not given a list
of possible factors from which to select or any
other form of direction or guidance. 
The responses for each trial are shown in Boxes 1–4.
It should be borne in mind that the interviewees
had already talked about many aspects of the trial
in the course of the interview and so may not have
repeated some of what they had already said was
important for success. It was noticeable that
although respondents from the central trial teams
did select some different features of their trial to
mention, compared with local collaborators, there
was no evidence of strong disagreement within a
trial about the trial’s success and the broad reasons
for that.
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respondents as the most significant for
the success of their trials
In their summing up, some features were
mentioned by respondents across all four trials.
The most obvious were good communication
between the centre and local collaborators and an
efficient and responsive centre. In two of the four
trials (ELEVATE and TOuCAN) interviewees
described a close identification between the PIs
and the collaborating clinicians. In TOuCAN the
work done by the PI in keeping in touch with local
clinicians was specifically mentioned. In ELEVATE
it was clearly very important for the participating
GPs who were interviewed that the trial was
designed and run by GPs. In a third trial, FOCUS,
a parallel set of comments was about the value of
involvement with a respected trials unit and
approval for the trial from NCRN. Another
important common feature of these trials that was
mentioned by interviewees was that they were
designed to minimise the burden on local
collaborators (HPS, ELEVATE) or that
participation had benefits for those who took part
(ELEVATE, FOCUS, TOuCAN). Benefits included
improved local team working, access to training
and meetings and benefits to patients (in
ELEVATE) because of extra attention to their
asthma. 
The importance, interest and timeliness of the
trial question were mentioned in three of the four
trials (not ELEVATE), and good design was
mentioned in two. Specific design features that
were mentioned as encouraging clinicians or
patients to take part included drugs not being
available outside the trial (FOCUS), NHS funding
and contact through a GP legitimising the trial for
patients (ELEVATE), and being able to say to
patients that their GP approved in principle of an
approach to them (in HPS).
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• Important/interesting research question (×2)
• Good design, good protocol
• Clinicians keen to recruit to trial
• Drugs already tested so easier to explain to patients
• Didn’t demand extra effort from patients
• No competing trials for those centres/patients
• Approval from NCRN
• Centre accreditation
• Drugs not available outside the trial (×2)
• Excellent trial management 
• Good communication between trial team and
clinicians
• Trials unit helpful, caring
• Good public relations/feedback/updates/information
for collaborators (×5)
• Annual meetings for all concerned
• Trial steering group played an important role in
defending the trial
BOX 1 FOCUS (comments from ten interviewees)
• Good planning and organisation by CTSU 
• CTSU responsive, efficient
• Central organisation of many aspects of the
research
• Minimising work for health professionals
• Agreement in principle from GP to approach
patients
• Prior screening to make sure patients were eligible
(×2)
• Important question, timely and managed to roll
several questions into one study
BOX 4 HPS (comments from six interviewees)
• Flexibility of trial team and flexibility allowed to
practices (×3)
• GPs involved in design (academic GPs) and practical
side (active GPs)
• Trial team able to see things from GP perspective 
• Pragmatic study
• Good design
• Good funding
• Practices not ‘researched out’ already; not too
stressed; enough willing to take part (×3)
• PI well respected
• Trial run by good team, good infrastructure (×3)
• Trial team communicative, responsive and alert to
problems (×3)
• NHS funding and contact through GP legitimise the
trial for patients
• Patients have done well with their asthma control
• Impact on practice running and costs was minimised
(×2)
• Role of research nurse
BOX 2 ELEVATE (comments from 12 interviewees)
• Communication within team and between team and
collaborating clinicians (×7)
• PIs worked hard to keep collaborators on board
(×3)
• Topic important, urgent need for research (×2)
• Trial good for local staff because it gave them
training, motivated them and improved their
working relationships (×4)
• Good trial team, responsive, good research
assistants (×4)
• Study included everybody
• Team worked hard at how to explain the study to
patients
BOX 3 TOuCAN (comments from ten interviewees)Common factors in the successes of the
Part B trials: summary
Common factors emerged both from analysis of
the broader interviews and from the specific
summary question. 
From both sources it was clear that a key 
feature was the importance and timeliness of a
research question that had the potential to lead 
to real changes in practice. Alongside this was a
view that a trial design that put respect for the
needs of patients and the clinical professionals
within the trial at its centre was likely to be
successful. 
These were seen as necessary but not sufficient
conditions. Respondents also saw the leadership
role of the PIs as crucial, particularly in terms of
their standing in the clinical community. However,
they all recognised that the clinical leader needed
to be backed by a strong and efficient coordinating
team, which was able to take much of the weight of
participation in the trial off the hands of busy
clinicians, and yet use excellent communication
skills to keep all the collaborators on board, well
informed and enthusiastic ambassadors for ‘their’
trial. 
Discussion
This component of STEPS has complemented 
the approach from Part A. Rather than using a
quantitative approach working with
documentation provided for a large number of
trials, four trials were looked at in more detail
using a qualitative approach. Chapter 5 
compares and contrasts the findings from the
three STEPS parts. In the rest of this chapter, the
conclusions of Part B are discussed in the context
of the strengths of this method and also its
limitations.
The available literature is large and complicated
with a lot of methodological variation, but it does
point to a number of potential barriers to
recruitment for professionals. The data from the
interviews described the efforts that teams in these
exemplar trials made to address, adapt to,
mitigate and even prevent the effects of these
potential obstacles from affecting recruitment
rates. It may have been significant that these trials
were not simple and easy trials, but faced
considerable challenges. Where the larger trial
teams were aware of the difficulties inherent or the
obstacles overcome, this seemed to increase
respect and motivation. 
A specific aim of this research was to gain insights
into facilitators to recruitment that are likely to be
relevant to trials in general. Interviewing
individuals in several trial centres with a wide
range of responsibilities, and the exploration of
key stages for the four Part B trials, suggested a
number of factors that seemed to offer useful
lessons and that might be replicable. The
interview process itself conveyed something of the
culture of each trial and offered the opportunity
for insight and reflection. 
The common key factors identified by the
interviewees suggested that high research
standards are extremely influential in their
experiences. This would make sense because if
researchers and collaborators are to invest their
time and effort, not to mention exposing patients
to a trial, then they need to feel confident and
motivated and that a trial is ‘morally right’ to
offer. The discussions for this study suggested that
high research standards were, however, greater
than simply a good question or a scientifically
robust design. Professionals appeared to be most
enthused by a sense of contributing to research
that they perceived as having the potential to
change their clinical world, and that was sensitive
to the needs of patients and professionals alike.
The PIs were highly important, as inspirational
figures at central and local levels. 
These trials also showed how much attention they
paid to getting the foundations right. To the
authors’ knowledge this aspect of trials
management, and the contribution that it makes
to subsequent recruitment, has not been previously
described in the empirical literature. 
The various factors explored here may be tightly
interrelated, and what is expressed in forms such
as “a good team”, “hard work”, “good
communication” and “organisation” do tap in to a
more general ethos, a spirit of enquiry carried out
with a high degree of professionalism. Indeed, this
was evident in the often striking degree of
cooperation offered to the researcher. This sense
of dynamism, clarity and efficiency extended to
the conduct and content of the interviews. There
were strict time constraints for Part B and so
requests were often made with a degree of
urgency. They were met with prompt and efficient
replies to queries and provision of comprehensive
and clear trial material. Some trial managers went
to considerable lengths, writing long e-mails to
ensure that the relevant issues for their trials were
made clear. Not only did the interviewees give of
their time, it was clear that many were deeply
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patient descriptions and enthusiastic engagement
in the issues raised in interview. Although it is
difficult to quantify the impact of this quality of
commitment on recruitment, it is likely that a
culture of motivation, responsiveness and
commitment that prevails at different levels, both
centrally and locally, will be a positive force and a
contributory factor in the success of a trial.
The conclusions from these interviews must be
tentative. This study focused on a small number of
trials and although these covered a range of
specialities, interventions and trial designs, it is
likely that more might be learned by extending
these interviews to a larger number of more
diverse trials. The authors chose to concentrate on
exemplars and these particular trials were
suggested to them by the funders. If we had,
instead, chosen trials that had achieved their
target recruitment within the originally agreed
time-frame, further insights might have been
gained.
The interviews elicited perceptions of the reasons
for the success of the Part B trials. It is plausible,
however, that if interviews had also been
conducted with teams within trials that were not
exemplars in either sense, the study might have
found similar factors operating. 
However, it was clear from the interviewees that
they did see themselves as members of successful
teams. The ways in which trials are organised and
how teams operate are ripe for further research
and are explored in the next chapter.
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The in-depth case studies of four trials in Chapter
3 suggested that management and teamwork play
important roles in a successful trial. However,
many, perhaps most, clinical trials are devised,
managed and reviewed by clinicians and allied
professionals only. This is not surprising since the
purpose of a trial is to advance clinical practice.
However, could it be that conducting a successful
clinical trial requires activities that disciplines
other than medicine are best suited to deliver? In
this chapter it is suggested that clinical trials can
be seen as businesses and that the disciplines of
business management may be relevant to those
who conduct clinical trials.
Businesses find customers and convince them to
buy what is on offer. Clinical trials find doctors
and patients and convince them to sign up. They
thus appear to face similar challenges and may
need to install similar processes. Clinical trials are
not necessarily akin only to small businesses; 
some can be viewed as equivalent to quite large
businesses with revenues running into millions of
pounds and recruitment targets of thousands of
participants.
Clinical trials have several stages, including
designing the trial, obtaining funding, finding
participants, processing results, interpreting the
results and reporting the findings. In all stages the
key requirement is to ‘do good science’. However,
in the recruitment stage the most demanding
activity is to install and operate a range of
effective management techniques, which parallel
those for running a successful business. This
presents new challenges that require a very
different set of competencies to those related to
fulfilling the scientific mission of the trial.
Management and marketing
The modern study of management began with
Frederick Winslow Taylor before the First World
War.77 Taylor realised that effective management
requires a clear set of values, incisive analytical
techniques, evidence-based approaches, and the
use of specially devised methods for control and
coordination. For the purposes of this chapter,
management is defined as ‘getting complex things
done efficiently and effectively’. Taylor became
known as ‘the father of Scientific Management’
and many empirical and theoretical contributions
since then have taken the study and practice of
management forward greatly. Since the 1970s,
management has become a legitimate academic
study, with most universities offering Master of
Business Administration (MBA) degrees and
doctoral programmes.
Some, but not all, managers run businesses. A
business exists because it finds customers and
fulfils their needs, with its costs being lower than
the revenue that it receives. A business needs to be
entrepreneurial, not least because other businesses
compete with it and attempt to capture its
customers. There are special management
challenges in running businesses78 that will be
elaborated upon later in this chapter.
An aspect of management that has developed
markedly over the past 20 years deals with ‘big
picture’ questions such as ‘what should we be
doing?’ and ‘what resources will we need?’
Questions such as these are answered by senior
managers and the field that guides them is known
as strategic management. Strategy is constructed
as decisions are taken about why the organisation
exists (its mission), what it aims to do (vision and
goals), its capabilities (core competencies) and its
guiding principles (values).
An important speciality within management is
marketing, which is the study of what is needed to
win and retain customers. Like management,
marketing has distinctive frameworks, methods
and techniques, many drawn from the social
sciences such as sociology and social psychology.
Since marketing became better understood in the
1960s79 it has become ubiquitous with almost
every large company, and many not-for-profit
organisations, having a director of marketing and
a marketing department. The key tasks of a
marketing function are to define the
characteristics of customer groups (market
segments), to devise ways to signal the benefits of
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Chapter 4
The clinical trial as a business: a single, 
in-depth case study of a large multicentre trialthe company’s offers (marketing strategies) and to
influence the company to meet the needs of the
market (be market driven).
Marketing is a set of technologies for finding
sufficient numbers of people who want to buy what
a company (or not-for-profit organisation) seeks to
sell. Clinical trials need people to buy in; hence,
for all trials, marketing is fundamental. Trialists
cannot avoid being marketers.
A definition of marketing offered by McDonald and
Wilson80 is “a process for defining markets,
quantifying the needs of the customer groups
(segments) within these markets, determining the
value proposition to meet these needs,
communicating these value propositions to all those
people in the organisation responsible for
delivering them and getting their buy-in to their
role, playing an appropriate part in delivering these
value propositions to the chosen market segments
(and) monitoring the value actually delivered”. (A
value proposition is a bundle of benefits offered
that impels a customer to want to buy. For example,
the value proposition for a family car may include
enhanced safety cots for babies, children’s
entertainment in the back seats, ample space and
stain-proof upholstery. One of these benefits, by
itself, will be unlikely to persuade parents to buy.
Taken together, the value proposition offered by the
motor manufacturer may be sufficient to impel a
customer to want to buy.)
McDonald and Wilson’s definition concentrates on
developing processes that provide an offer that
customers consider to be of value. In short, it
focuses on the need to have customers pulling the
organisation to deliver something that they want.
This is the opposite of the conventional view that
marketing is about pushing products or services
that the organisation wants to sell. It can be
argued that pushing a product is a sales, not
marketing, activity.
An initial survey of the literature on clinical trials
shows that the marketing dimension is included
tangentially in many trials.39 For example, trials
are generally stated to need recruitment strategies,
use of media and data tracking systems. However,
the notion of developing and working to achieve a
formal marketing plan that covers all of the areas
in the McDonald and Wilson80 definition is absent
from all the trial management descriptions
examined here.
This is not to suggest that clinical trial managers
consider the topic of recruitment lightly. Indeed, it
is the dominant preoccupation of many trialists.
For example, the Diabetic Retinopathy Awareness
Program study81 undertook many initiatives to
recruit volunteers and concluded that “these
experiences substantiate the need for a
comprehensive coordinated approach, using
planned sources, to achieve recruitment success”.
When looked at from a business management
perspective, it is clear that dimensions of running
a successful trial include marketing, sales and
ongoing client management. It can be argued that
marketing is especially important in clinical trials
since, in most cases, those who need to be enrolled
to support clinical trials are volunteers who may
gain no benefits from participation and can be
asked to undertake activities without reward to
themselves. Participation in a trial is a formal
voluntary act, in that participants need to abide by
a set of rules. Accordingly, not only is it necessary
for people to volunteer, but they also need to sign
up to behave in accordance with a procedure.82 It
has been suggested83 that “competitive pressures
make careful applications of marketing
management tools imperative for the survival of
time-dependent (i.e. working to time-based
targets) non-profit organizations”. This point was
elaborated in the following observation by the
director of investigation services at a contract
research company, who observed that “nowadays,
recruitment is more complex and so there are
increasing requirements around raising awareness
with patients”.84
From a marketing perspective, conducting a
successful trial can be seen as a process with five
main stages (Figure 2). These five subprocesses
follow McDonald and Wilson’s definition (cited
above), but elaborate it significantly. Table 16
amplifies the purposes and content of each of the
stages.
Related to, but distinct from, marketing are sales
activities. Selling is a set of activities intended to
persuade a potential customer to buy. Selling
requires specialised skills, a persuasive case and
the capacity to empathise with potential
customers. Often selling is a face-to-face activity,
but it need not be so. It is possible to sell through
the Internet, by telephone, through word-of-
mouth, by advertising, and so on. It is considered
by some that selling is a base and manipulative
activity. Although this can be true, selling is often
a mechanism for relating a customer’s needs to
products or services that are available. Many
doctors, for example, spend part of their time
selling the benefits of leading a healthier lifestyle.
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marketing and sales. Undoubtedly they undertake
all of these activities in some way. It is possible,
however, that those who define the strategy of a
trial, establish its management processes, devise its
marketing plan and attempt to sell the benefits of
participation may improve their practice by
explicitly engaging with the discipline of
management. Indeed, Farrell85 has argued
persuasively that it is a lack of solutions to
managerial issues that reduces the effectiveness of
trials, and Rowe and colleagues86 suggested that
“to get patients into trials more efficiently pharma
companies must begin to think like marketers”. 
Of particular importance is the need to segment
the market. This requires identifying and listing
the key characteristics of different target
audiences. (It should be noted that a disadvantage
of selecting the CRASH trial for the in-depth case
study was that for this patient population the
aspect of participant engagement could not be
explored.) To some extent each will require a
distinctive marketing strategy. Market segments
vary according to the nature of the trial but,
typically, there will be at least five: the potential
participants, their relatives, the potential
recruiting doctors, senior consultants and nurses
(who play a key role in many cases). It may also be
necessary to have a marketing strategy for the
broader medical community, including opinion
leaders who may be crucial to the success of the
trial. In addition, it may be necessary to ‘sell’ the
trials to R&D departments and other groups that
impact on the feasibility and therefore success of
the trial.
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Set-up
Gaining prestige
and building
robust systems  
Market planning
Segmenting markets
and devising the 
marketing story 
Signalling
Conveying the
message and enrolling
patrons and sponsors  
Learning
Developing market
knowledge and
redirecting strategy  
Reinforcing
Maintaining and
renewing
commitment  
FIGURE 2 Five stages in marketing a trial
TABLE 16 Purposes within the five stages in marketing a trial
Stage Marketing purposes
Set-up 1. To gain the buy-in of the necessary authorities and stakeholders
2. To gain the buy-in of opinion leaders whose explicit approval provides legitimacy and prestige for the
trial
3. To construct a marketing function within the trial and devise robust systems for ensuring that the
marketing (and later sales) activities are undertaken efficiently, effectively and in accordance with the
values and goals of the trial
Market planning 1. To identify and describe the distinctive features of the ‘segments’ of the ‘market’ to be targeted
2. To discover what people in each of the selected market segments value (i.e. what would encourage
them to ‘sign-up’)
3. To develop a ‘value proposition’ (or more than one if required) that can be tested with each of the
targeted segments
4. To enrol the whole trial organisation in working within the trial’s ‘marketing brief’
Signalling 1. To convey, fully and persuasively, the ‘value proposition’ to sufficient numbers of people in the target
market
2. To convey, fully and persuasively, the ‘value proposition’ to intermediaries (e.g. doctors or nurses),
influencing bodies (e.g. ethics committees) and other agents that can either help or hinder the conduct
of the trial
Learning 1. To learn, through doing, about ‘the market’
2. To utilise ongoing learning to develop more effective policies and practices
3. To evaluate, and redirect the strategy of a trial as learning is acquired
Reinforcing 1. To maintain momentum by renewing or upgrading ‘the offer’ made to participants
2. To sustain commitment of interested parties and other agencies whose support will be neededAims
The aims of Part C were to examine a single trial
as if it were a business, to comment on its
marketing strategy, and to help the trial team to
understand and put in place a marketing plan.
Methods
One of the researchers in the STEPS team (DF), a
marketing specialist from the academic business
sector, was invited to work with the MRC CRASH
trial. The CRASH trial is a large-scale, placebo-
controlled trial on the effect of corticosteroid
treatment on death and disability in patients with
head injury. The trial aimed to recruit close to
20,000 head-injured patients from hospitals
worldwide. Because all of the patients included in
the trial were unconscious and thus unable to give
informed consent, the relevant MRECs and
LRECs had in most cases agreed that the
responsible doctor could take the decision to enter
a patient into the trial. For this reason the main
challenge in conducting the trial was to engage
the interest and collaboration of doctors who treat
patients with head injury.
DF was given access to all trial related documents
(apart from confidential patient outcome data)
and interviewed the members of the central trial
management team. He visited three participating
hospitals in England, observed training sessions
and interviewed or facilitated group discussions
with doctors (12), nurses (14) and ancillary staff
(four).
DF’s interview notes were analysed using N-Vivo
qualitative analysis software initially, but manual
analytical methods were used later as a significant
research objective was to highlight what
participating agents were not saying, rather than
what they were saying. The researcher invited a
professor of management to check his
interpretative framework against the raw data. He
presented his findings to the STEPS research team
and also to researchers at the Centre for Research
in Innovation Management. Exposing an
emerging conceptual model to experienced
academic researchers, trialists and trial managers
provided an opportunity to validate the
researcher’s constructs and extended the theory
building process.
Using grounded theory87 a reference model was
developed that could be used to assess the sales
and marketing capability of the trial. A one-day
marketing workshop using an action research
approach was held with the trial team to provide
insights into the extent to which concepts and
practices from the business world might have
relevance to management of clinical trials. Early in
2004 an additional 5-hour workshop was held with
representatives from five trials (one of which was
the CRASH trial) to gain further insight into the
heuristic value of the reference model.
Processes for testing the reference model, using an
action research method, with the full-time staff
conducting the CRASH trial provided additional,
although case-specific, data. For example, a one-
day workshop was held on the strategy of the
CRASH trial. 
In the trial documentation (a form of business
plan) it was stated that the aims of the trial were to
deliver a certain number of cases by a certain
time. In the workshop this statement of goals was
elaborated and it was agreed that the mission of
the CRASH team was “to answer an important
scientific question thereby providing clinicians
with evidence-based knowledge that will help
them to treat head injury patients better by:
● efficiently and effectively conducting the world’s
largest head injury study;
● recruiting and following up 20,000 patients by
2006;
● ensuring that the evidence collected and
conclusions drawn meet the highest standards
of medical and scientific practice.”
At the same workshop, eight core values were
agreed upon:
1. We maintain the highest ethical standards:
maintaining confidentiality and abiding by the
best medical practice.
2. We ensure that data are reliable, valid and
verifiable.
3. We build quality into every activity and into our
system as a whole: ‘quality before quantity’.
4. We are unique, innovative and original: seeking
new ideas and using them to benefit the trial.
5. We are efficient (fast, cost-effective and error
free).
6. We are a collaborative organisation: serving the
needs of all partners and stakeholders.
7. We communicate effectively, openly and fully.
8. We are people-orientated: personal and caring.
The mission and core values elaborated the goals
of the CRASH trial, humanised its tasks and
defined ground-rules or collective norms. From
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proved possible to assess how a trial management
group responded to interventions more commonly
used in commercial organisations.
Results
The researchers considered that it would be
impossible to audit the managerial effectiveness of
a trial without templates of what a well-managed
trial was like. Accordingly, the results presented in
this section are models, not findings. Later
research can test the models and use them as audit
tools.
Two models will be presented. The first is
systemic, dealing with the management issues for
a trial as a whole. The second, and more detailed,
model examines marketing and sales issues for
clinical trials, since these were the areas studied
intensively in the CRASH study.
A tentative systemic model
Since the 1970s, management studies have
emphasised that organisations need to be seen as
systems with interacting activities.88 The
performance of the system as a whole depends, at
least in part, on the appropriateness of the
activities to the performance of the system as a
whole, the efficiency by which the activities are
performed and, crucially, how the activities relate
together to form a gestalt, or whole.89 An example
illustrates the point. In a busy primary care
practice it may be that the clinical activities could
be conducted efficiently as there are sufficient
numbers of trained doctors available. However, if
systems for scheduling the doctors’ workloads are
slow and prone to error the performance of the
practice as a system will be degraded.
A clinical trial requires a sequence of activities to
be completed. Within each activity category many
specific activities generally take place. In
management jargon this is known as a value chain,
since each of the activities should create value (i.e.
provide benefits for one or more of the
stakeholders). The activities listed in a value chain
diagram are very broad in scope, for example,
‘operations’ would be regarded as ‘an activity’. (In
management jargon, ‘operations’ means the work
needed to turn raw materials into finished
products. In a factory, ‘operations’ is the work that
needs to be done, for example, to turn planks of
wood into furniture; in an insurance office
‘operations’ includes work that needs to be done
to turn an enquiry into a proposal. In a hospital,
‘operations’ is the work that needs to be done to
care for patients.) Accordingly, the effectiveness of
the trial is a consequence of the degree to which
each set of activities is appropriate and performed
well, and the activities are integrated together.90
Some activities are core, in that they directly
support trial effectiveness. Other activities are
support, in that they are necessary but do not
directly add value to trial performance.
The researchers were unable to find a systemic or
value chain model of a clinical trial in the
literature and so to understand better the specific
management issues of a trial a speculative value
chain model was developed (Figure 3). The arrow
layout is the conventional format used in
management analysis. This diagram shows the
relationship between the key sets of activities that
deliver value to clinical knowledge. There are six
core activities, shown in the centre of the arrow
diagram, and four non-core activities that enable
the core activities to be performed. The core
activities are likely to be understood, but the value
added by non-core activities is less obvious. This
study found that it was vital for a trial to win
support from the multiple stakeholders, have
strong norms and processes for undertaking ‘good
science’, be able to manage all of the soft and hard
activities involved in managing a complex project
and, lastly, to ensure that funds were spent well
and that expenditure was tracked.
The extent to which a trial delivers its promise 
will be determined by the efficiency and
effectiveness by which the ten activities of the
value chain are performed and the degree of
integration between them. It is to be expected that
the construction of a value chain for a clinical trial
will differ to some extent according to its specific
requirements. It is emphasised that sales and
marketing are limited management activities.
Simply getting sales and marketing right will not
be sufficient.
Workshops held with the CRASH trial team found
that there was a need to upgrade systemic
thinking. Each person working on the trial had
their area of responsibility, but issues that crossed
organisational boundaries were discussed less and
were identified as problematic. Each activity in the
value chain presented a distinct management
challenge. For example, in the CRASH trial many
participating hospitals were overseas and there was
a need to travel extensively to gain stakeholder
support and use web-based communication
methods to maintain communication and
commitment.
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The marketing challenge facing the CRASH trial
team is different to that of a company that is
selling soap or offering package holidays. When
companies sell a product they attempt to convince
a potential customer that they will gain benefits
directly from their purchase. In CRASH the trial
managers were seeking to gain a commitment to
engage from clinical professionals who would
make no material gain for themselves.
Accordingly, the CRASH trial was selling an
opportunity for clinical professionals to participate
in improving future clinical practice, an activity
that can be seen as being akin to a charitable
endeavour.82 A challenge for the CRASH trial was
to sell the notion that if a clinician signed up to
the trial then medicine itself would progress and
the clinician would be fulfilling a professional
obligation.
The complex nature of the sale [of a trial that
requires the participation of staff in accident and
emergency (A&E) departments] is illustrated by
the comments in Box 5.
Another dimension of the marketing challenge
was found to be the difficulty in understanding the
reasons why participants (in this case hospitals)
signed up and what motivated them to fulfil a
commitment that had no sanctions for 
non-performance.91 An analysis of feedback from
participating hospitals concluded that they opted
in for a variety of reasons, including the perceived
merits of the study, the efficacy of the sponsors
and advocates, the status provided to participants
through participation and the affordability of
participation (see section IIa of Figure 4).
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FIGURE 3 Value chain model
• Enrolment happens by word of mouth. Friends talk
to friends
• I need to opt in both in principle and then you have
to remember it when a patient is in front of you
• When someone keen leaves then it can fade out
immediately
• So many things are happening at the same time that
it is difficult to think about the trial
• It can happen in the middle of the night. The people
on duty need to remember that this patient is
suitable for the trial
• It needs someone to be assertive – there’s a lot
going on
• It feels like an optional extra
• A reluctant person can mean ‘no’
• Some A&E departments are just not organised
enough to do anything extra
• Less badly injured patients may be in a side room,
so we just don’t think about them for the trial
BOX 5 The complex nature of the ‘sale’It became clear that the CRASH trial team was not
ignorant of the basic principles of sales and
marketing. Many of the attitudes, concepts and
practices of modern marketing had already been
adopted. Indeed, the trial manager made the
comment in an early interview that “it’s all about
selling”. However, the trial team was unaware that
they were using, at least in part, a distinctive
conceptual framework developed in the business
world; to them it was common sense. Perhaps
because the CRASH team’s marketing approach
was self-invented, some practices were state of the
art, whereas others were weak or absent. 
Working with the CRASH trial team, DF sought to
answer the question, ‘if this was a business, then
what policies, practices and capabilities would be
needed for the marketing challenges to be met?’ 
A reference model was developed to define the
capabilities required for each of these stages
(Figure 4) that offered a systemic ideal type, that
the trial could use to define excellence.92 The
model has four domains and 12 components and
is illustrated as a wheel diagram. The components
and their relevance to the CRASH trial are
outlined below. 
The wheel diagram could be used as the
framework for an auditing tool. The management
team conducting the CRASH trial assessed the
components’ effectiveness and efficiency in
relation to each of the 12 components and
illustrated these as a spider chart on the diagram.
Since all of the components are important, it was
assumed that higher scoring components
represent strengths that should be amplified93 and
lower scoring components are blockages to be
reduced or eliminated.94
The 12 components are described below, with
comments on performance of the CRASH trial
related to each dimension.
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FIGURE 4 Reference model1a. Developing brand values
Brand values define what a brand is and what it is
not; that is, its personality. A clinical trial can be
seen as a brand. Without explicit brand values it is
impossible to communicate a coherent and
persuasive perception of a trial’s promise: what the
trial intends to deliver to medicine, doctors,
patients, and so on. CRASH had developed strong
brand values, including scientific rigour,
inclusiveness, simplicity and high levels of
feedback to participants.
Ib. Gaining legitimacy and prestige
Trials need legitimacy: they need to be positively
tagged by association with prestigious individuals
and institutions (so a hospital doctor may say, “I
know that this is an important trial because
Professor X, whom I know and respect, is
supporting it”). Legitimacy and prestige provide
persuasive credibility, which is key to gaining
access to decision-makers. CRASH benefited
greatly from the public support of leading
authorities, notably the MRC, the CTSU at the
University of Oxford and respected academics.
However, an assessment of the extent to which the
CRASH trial had acquired a full portfolio of
legitimatising agents identified that one important
speciality (neurosurgeons) had never been won
over, and disadvantaged the trial’s persuasive
credibility. This legitimacy gap is now being
addressed.
Ic. Signalling worthiness
It is vital to signal to likely participants that this
trial will create greater value than the costs (time,
effort or money) involved. Buy-in is more likely to
occur when participants realise, and identify with,
the potential benefits that will be delivered by the
success of the trial. CRASH made great efforts to
signal its worthiness, especially through
presentations at conferences, journal publications,
advertising, public relations and training
materials. Anecdotally, it was considered that these
signalling activities had been successful, but no
procedures were in place to gather data
systematically on the extent to which the trial had
achieved an adequate share of voice (i.e. the trial
was known to potential participants).
IIa. Providing simple, complete processes
Trials require participants to undertake additional
work. Providing simple, complete processes
reduces the costs of participation and increases the
chances that involvement will be affordable.
CRASH had developed streamlined processes that
were piloted and improved frequently. However,
some difficulties remained. For example, trial
treatment packs for overseas participants are often
held by overseas customs, requiring considerable
effort from trial collaborators to release them.
Also, filling in data forms and sending them to the
trial office could involve substantial work.
Although the trial team developed better methods
for data collection, they were not in place at the
start of the trial. During 2003 processes were
simplified further with improved online input.
IIb. Devising strategies for overcoming resistance
Potential participants frequently raise objections
(Box 6). It is likely that other trials will have
different perceptions and resistances. An effective
marketing plan will deal with the existential reality
of each of the targeted groups, not bundle them
together into a generalised marketing/sales plan.
Trials should have standard and persuasive
answers to these. Having a persuasive answer for
each objection increases the probability of making
a sale. CRASH has a list of answers to frequently
asked questions, but the team could do more to
deal with unspecific resistance, for example,
potential participants saying “it’s a good trial but
we just don’t have the time”. Again, work is
underway to improve the capacity of the trial staff
to provide accurate, speedy and persuasive
answers to objections.
IIc. Adopting an explicit marketing plan
The marketing of a trial is too important and too
complicated to be done informally. A formal
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Nurses’ comments included:
• Nurses are notoriously resistant to trials: they seem
less than human
• Nurses see themselves as advocates for the patient
• Numbers are not interesting to nurses
• We don’t want research. We want to give the best
treatment NOW
• There’s generally a boss nurse and what s/he says goes
Doctors’ comments included:
• What’s special about this trial?
• Will it involve much work?
• Do I believe in this? Is it right?
• I need my questions to be answered, before I can
commit myself
• One of the problems is to enrol the bigger team,
especially with transfers (i.e. patients that are sent
to other hospitals for further treatment)
• What are likely to be the long-term benefits?
• What’s in it for me?
• Some little things can be difficult – finding the
patient’s phone number, for example. It can put you
off doing it again
BOX 6 Potential participants’ objectionsmarketing plan is required that should include a
definition of target market segments (groups that
need to buy in to the trial) and the trial’s unique
selling points. It is to be expected that the
marketing plan will need to be revised frequently,
probably every quarter. CRASH did not have a
written marketing plan until this study was
undertaken. The trial team had already
appreciated that a major market for the trial
comprised hospitals in countries that had high
rates of head injuries, and identified nine
segments: opinion leaders (national/international)
in neurosurgeons, intensivists, A&E specialists, A&E
nurses, hospital administrators, registrars, ethics
committees, government health departments and
drug manufacturers. Each of these segments
needed a distinctive marketing and sales plan.
A formal marketing plan identified the need for
additional resources to be allocated to winning
participation from such hospitals. The CRASH
team later identified five levels of commitment to
the project by potential participants and defined
strategies for each. The levels and strategies were:
(1) the uninformed (inform and persuade with
targeted stories); (2) the unconvinced (address
concerns point-by-point; get to yes); (3) the
laggards (enrol, cajole, facilitate and target); 
(4) the steady performers (reward, renew, upgrade
and recognise); and (5) the stars (honour, learn
from, exploit and nourish).
IIIa. Engaging active sponsors, champions and
change agents
Selling a trial to prospective participants requires
persuasion. This requires enrolling sponsors
(public advocates), champions (activists) and
change agents (facilitators). Trial managers need a
network of supporters to spread the message.
Persuasion is more likely to occur if the advocate is
respected and known personally to the prospective
participant. CRASH had enrolled sponsors and
sought to encourage champions. However,
performance was patchy. Increased recognition of
the importance of this activity has meant that the
CRASH team is now making systematic efforts to
develop stronger networks of direct influence.
IIIb. Delivering a multiaudience, multilevel
message
Trials need to convey sales messages through
publicity, presentations, training materials, and so
on. These should be tuned to the distinctive needs
of target groups; for example, surgeons are likely
to be persuaded by different messages to
administrators or nursing staff. Speaking in the
language of the person being targeted and
addressing their particular pattern of motivation is
more likely to succeed than a one size fits all
approach. CRASH had gone some way to
developing distinctive ways to communicate with
its intended audiences, but this was insufficient
and the communication was generic, not
segmented. Currently, work is underway to refine
further the communication strategy using the
notion of micromarketing (i.e. tuning messages to
the specific needs of market segments).
IIIc. Achieving buy-in (in public)
Public buy-in requires that intended participants
announce their commitment to join the trial in a
setting where they are heard by others. This is
important because when someone states, in public,
that they are willing to undertake an action, then
they are much more likely to abide by their
commitment than if they take a silent decision,
which can be forgotten easily. CRASH has
achieved a measure of encouraging and
reinforcing buy-in, for example by naming new
participants in its regular newsletter. However,
more can be done and strategies are being
developed to achieve more complete and
memorable buy-in moments.
IVa. Ensuring positive moments of truth
People evaluate organisations (including trial
management teams) on the basis of their
experiences at moments of truth. For example, if a
doctor has a technical question about entering a
patient into a trial he or she will gain a strong
impression of the trial management team’s
competence by the way in which the query is
handled. If an organisation behaves well in a
moment of truth then loyalty grows; if not, loyalty
diminishes. A core value of the CRASH trial was to
be user-friendly and this meant that the trial team
tried to be helpful on all occasions. However,
potential moments of truth had not been
identified systematically and work is underway to
understand better the key moments when
participants come to define the CRASH trial; for
good or ill. Once this assessment has been
completed it will be possible to improve the way in
which moments of truth are handled.
IVb. Providing frequent positive reinforcement
Positive reinforcement for existing participants
should be an important part of a trial’s participant
retention strategy. It is more expensive to recruit
new participants than to retain existing
participants. CRASH had gone some way towards
recognising and rewarding participants, but its
strategy was to honour the highest yielding
hospitals, which could be a disincentive to those
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In 2003, the policy was changed so as to give
positive reinforcement to all contributors.
IVc. Facilitating incorporation into routines
Activities that become embedded as routines are
more likely to be done than one-offs. Trial
procedures should be incorporated into the
routines of units undertaking the work. CRASH
had incorporated this principle into the
development of its training materials, but did not
emphasise it. More can be done to embed CRASH
as a standard operating procedure in hospitals,
and this is being addressed.
Discussion
Statement of principal findings
Farrell, among others, has been arguing for a
greater recognition of the role of management in
the conduct of clinical trials,85 but without spelling
out what this means in detail. This study has
found that it is possible to construct useful
reference models that assess the managerial
capability of a trial, both as a totality and in
relation to marketing and sales activities.
Strengths and weaknesses of the study
The key strength of this study is that, to the
authors’ knowledge, for the first time in academic
literature, it provides two models that give a
conceptual architecture that provides an
opportunity for trial managers to review their
strategic, managerial and/or marketing strengths
and weaknesses.95
The weaknesses of this study are that it was based
on a single case, that tests to prove the validity of
the models were rudimentary, and it has not been
possible to compare trials that use the reference
model approach with trials that do not use it.
Although the researchers consider that there are
considerable benefits in reflecting on trials from a
business perspective, it is important to emphasise
that they are not businesses. Management and
marketing provide frameworks and tools that can
improve the probability that a trial will achieve its
scientific goals. However, it would be damaging if
an interest in developing trials as ‘businesses’ led to
separation of the scientific aspects and trial
management processes. As mentioned above (see
the section ‘Management and marketing’, p. 49),
participation in a trial generally brings no direct
benefit to either clinical teams or participants, as
the likely beneficiaries will be future patients. It is
important to recognise that there are substantial
differences as well as similarities between trials and
most forms of business. Techniques of management
and marketing should not be adopted uncritically,
but they can provide a valuable input into the
emerging theory of trial management practice.
The reference models described above should be
seen as tentative frameworks rather than definitive
templates. They were developed from a theory-
building process from a single trial and are best
considered as a set of provocative hypotheses;
later they may be developed as provisional audit
tools. As indicated above, an audit of the CRASH
trial enabled components that were considered to
be weaker than others to be identified and
initiatives undertaken to improve in these areas. 
A clash of cultures?
Medicine has a basis in scientific method, of which
RCTs are a prime example. Management is
fundamentally different as it is rooted in practice
and can be considered to be a craft in the
medieval sense of the word. “Mastery requires a
combination of science, art, practical experience
and learning from accomplished masters.”96 This
is not a hard and fast distinction, as much clinical
practice is craft based, and some management
tasks (e.g. the statistical analysis of product quality
problems) draw from scientific techniques and are
evidence based.
Henry Mintzberg described the essence of
management when he wrote:97
Science is about the development of systematic
knowledge through research. That is hardly the
purpose of management. Management is not even an
applied science: for that is still a science.
Management certainly applies science: managers have
to use all of the knowledge that they can get, from the
sciences and elsewhere. But management is more
art….
The art of management lies, in part, in the ability
of the manager to respond to the chaotic nature of
the real world.89 The different bases of knowledge
on which medicine and management rest may
present difficulties to scientists who seek
experimental evidence and tend to eschew a
discipline that is based on craft principles.
However, clinical trials are not just medical
activities; they are time-bound businesses that have
two interdependent sets of processes, one clinical
and the other managerial. In the main, since trials
are seen as clinical endeavours, they are
dominated by clinical issues and led by people
The clinical trial as a business: a single, in-depth case study of a large multicentre trial
58with clinical skills. This is essential for certain
policies and practices, but this cultural bias can
result in the managerial aspects of trials being
relatively neglected. If this is true, even if only in
part, it means that the radical improvement of
clinical trials could require different ways of
defining the challenges of running successful
trials; in particular, to ensure that they are seen as
management challenges that can benefit from the
informed use of selected management processes
and techniques.
These considerations suggest that looking within
past trials for the answers to the problem of
underperforming trials is necessary but will not be
sufficient. In order to improve trials it will be
necessary to look outside the world of clinical
practice, into the worlds of business strategy,
management, marketing and sales, to gain a fuller
understanding of what can be done to upgrade
the performance of clinical trials. This insight is
not new. Donovan and colleagues98 state that the
“methodological literature (on trials) is almost
exclusively statistical and epidemiological, and
very little of it is concerned with the conduct or
the particular demands that trials put on trialists
and participants”. 
Meaning of the study: possible
mechanisms and implications for
clinicians or policy makers
This study could begin to change the ways in
which trial managers undertake their work. It also
provides a new and different way to think about
the skill sets needed by those who manage clinical
trials. In essence, the message of this study is
simple, even simplistic. It is that trials are both
complex projects and businesses (they need to find
customers). The key implication for clinicians is
that insufficient attention to management issues
and marketing or sales activities will degrade the
performance of the trial.
There are significant implications for policy
makers and funding bodies as well. If the tentative
conclusions of this study are correct, then the
funders will need to examine more than the
scientific case before sponsoring a trial. They will
need to see a business plan, be assured that all of
the required elements of the business system will
be developed and have a marketing/sales plan.
Since a successful trial requires both good science
and good management, both need to be given
their due weight.
Trials need participants just as companies need
customers. Trials have something to sell, perhaps a
promise that, at some time in the future, other
sick people will benefit from the research being
undertaken. Trials target participants, develop a
story to describe their unique selling points and
attempt to persuade people to buy in. Once a trial
has enrolled a participant it seeks to retain him or
her. In these and many other respects trials are, in
fact, businesses.
But there are differences. Business is about profit.
Medicine is driven by human values. It would be
wrong to suggest that trials need to be more like
businesses; rather, it is suggested that trials may
benefit from using business concepts and business
techniques.
There is a potential benefit for using the reference
models in other trials, especially early in their life
cycle; this can be described as speeding the
learning curve. It took many months of
management effort for the CRASH trial team to
develop their approach to marketing the trial. The
clinical coordinator considered that if they had
had access to an appropriate model at the
beginning it would have accelerated its
development and reduced costs, enabling more
effort to be invested in trial activities.
The world of business has spent more time and a
lot more money than health management in
finding tools for marketing and selling. In the
authors’ opinion, it makes sense for trialists to
learn from business where this could improve trial
performance.
Unanswered questions and future
research
There are five unanswered questions that the
authors consider to be worthy of further research.
These are:
● Are the reference models outlined in this
chapter complete and correct for other trials?
● How can useful audit tools be developed from
the reference models?
● What competencies do trial managers need to
manage the business dimensions of their trial?
● How can third parties such as advisers, assessors
or sponsors intervene successfully in a trial in
order to improve its performance as a business?
● What should funding bodies ask about the
proposed business model, management system
and marketing/sales of a trial requesting
funding?
If there is sufficient commitment to improving the
business management of trials then the reference
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in the context of other trials to assess their validity.
In addition, recognition of concepts common to
more than one trial does not necessarily imply
that their inclusion into a strategy for future trials
will increase recruitment. This strategy needs to be
tested empirically. However, the perspectives given
by this study have proved provocative and have
stimulated much consideration into what it means
for a trial to be well managed.
If this does not happen, then Farrell’s call85 to
address the role of management in the effective
delivery of a trial will have fallen on deaf ears and
some trials will continue to disappoint, despite
their scientific merit. Nevertheless, it is important
to emphasise that ethics must not be compromised
and that improved management and marketing
effectiveness must not be allowed to become
unethical, thereby causing distress to patients and
their families or to healthcare workers by using a
hard sell inappropriately.
Personal reflection
Although some trialists tend to denigrate forms of
knowledge other than that from the hard sciences
(which can be a barrier to cross-disciplinary
learning), the management researcher (DF) found
himself at home in the trials world since the sorts
of issues that trial managers raised were variants
of those that occupy managers in the commercial
world. He felt that the groups that he encountered
had remarkable energy, commitment and sense of
mission, and he saw that the management policies
and practices that he introduced using an action
research approach were not alien: they were
developments of approaches that were already
being used by the trial management team.
As academic researchers we surround our findings
with caveats, but managers from the world of
business can be cavalier and say, “yes, a trial is a
business and a trial needs to employ up-to-date
management practices if it is to achieve its
promise; simply looking within the world of trials
will not provide all the answers. It is time for trial
managers to take as much pride in the
management of their trial as they do in the
medical advance that it delivers”.
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his chapter first refers back to the
commissioning brief and the successful
application from the STEPS team. It then briefly
summarises the main findings from Parts A, B and
C, and their individual strengths and weaknesses.
Finally, the authors consider what has been learnt
from the study overall and what questions remain
unanswered, and suggest areas for future research. 
Background
The commissioning brief for this project followed
from the perspective that although large sums of
money are spent on multicentre trials, the trials
often fail to achieve planned levels of recruitment.
Fast recruitment is desirable as it brings important
benefits in terms of providing knowledge more
quickly and reducing research costs. It is possible
that differences in the design and execution of
these trials could result in better or worse
recruitment rates. The HTA Programme and MRC
therefore jointly prioritised this research to “learn
lessons latent in the existing experience” of such
trials.
The STEPS team adopted both quantitative and
qualitative methods to concentrate on factors that
may affect participation of clinicians and
collaborating researchers (rather than patients)
through three components: an epidemiological
review of a cohort of multicentre trials funded by
the MRC and the HTA Programme; case studies
of four trials that appeared to have particularly
interesting lessons for recruitment; and a single,
in-depth case study to assess the feasibility of
applying business theory to trial recruitment. 
Principal findings, strengths and
weaknesses
Part A: epidemiological review
The results of the epidemiological review of 
MRC and HTA Programme multicentre trials
confirm the concern expressed in the
commissioning brief that failures to achieve
projected targets for participant recruitment,
extensions of the recruitment period and
supplementary grants are indeed common. 
As few as one-third of trials recruited to 100% of
original target and around one-third had
extensions. The analyses within this cohort of
factors associated with successful recruitment
(from the research literature) provide some
support that the intervention only being available
inside the trial, having a dedicated trial manager
and being a cancer trial or a drug trial were
associated with success. However, these findings
should be interpreted cautiously; the confidence
intervals were all wide, at best these associations
were only marginally statistically significant and
the trend for some other factors was towards a
negative association.
The strengths and weaknesses are discussed in
Chapter 2. The main strength was that it included
a systematically identified, complete cohort of
trials from a wide spectrum of clinical areas,
clinical settings and geographical centres. The
data were prospectively collected for other
purposes and so were unlikely to be biased in
respect to the questions being addressed for
STEPS. An important limitation was the number
of trials available for analysis. Although an
attempt was made to include as many studies as
possible, there were fewer than had originally
been anticipated and a sample size of 114 gave
only limited scope for exploratory analyses. As in
the commissioning brief, the planned level of
recruitment was used as a surrogate measure for
the ‘success’ of a trial. As indicated in Chapter 2,
the use of this marker as a sole indicator of
recruitment success is rather limited, as initial
sample size estimates are often more an informed
guide, based on imperfect information and other
considerations such as feasibility and cost.
Arguably more significant measures, such as the
extent to which the trial question has been
successfully addressed, the perception of funders
and other key stakeholders as to whether the trial
was successful, and the impact of the results on
clinical practice, would be more useful. Other
necessary limitations of the epidemiological
approach, such as the secondary use of data
collected for other purposes (including the
misspecification of the ‘exposure’ variables, and
variation in the quality of the reporting), and
interrelationships between possible explanatory
factors, mean that conclusions about causative
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Chapter 5
Discussionfactors must be tentative. Although there were
some attempts to go back to PIs for further details
and understanding, these were limited in scope
owing to restrictions in the STEPS budget. 
This component proved less useful than expected
for exploring factors related to recruitment. No
trial was identified that showed a clear change in
the recruitment rate at a particular point in time.
Hence, although a range of strategies aimed at
improving recruitment was described (Table 13), it
was not possible to assess the extent to which they
were causally linked to changes in recruitment.
The value of this part of the study was therefore
primarily as a descriptor of the problems and of
trialists’ attempts to overcome them, rather than
providing evidence about how useful the strategies
were.
Part B: case studies
The results of the in-depth analyses of interviews
from four trials considered by their funders to be
‘exemplars’ suggested that successful trials were
those addressing clinically important questions at
a timely point. The interviewers highlighted that
the trials were led by investigators who were held
in high esteem by the interviewees, and they were
firmly grounded in existing clinical practices, both
so that the trial processes were not alien to the
clinical collaborators and so that the results could
be easily applicable to future practice. The
interviewees considered that the needs of the
patients were well served by participation in the
trial. Good groundwork and excellent
communication across the many levels of the
complex structures of trials were considered to be
extremely important, including training
components for learning about the trial
interventions and processes, as well as team
building. Clinical collaborators particularly
appreciated the clear delineation of roles which
released them from much of the workload
potentially associated with trial participation.
Although the perception of ‘success’ was not in
terms of the study results (as only HPS had
reported its findings), there was a strong feeling
from the interviewees that they were proud to be
part of a successful team, and that this pride in
itself fed into further success.
The main strength of Part B was that the in-depth
investigation into the four trials took an
independent outsider perspective. By building on
the experience of Part A, the focus shifted from a
restricted definition of success as meeting the
recruitment target within the planned time-frame
to funders’ perceptions of successful trials. The
four trials were all aiming to be the largest 
of their kind in the world, and spanned a range of
clinical and research situations. They were not
chosen as ‘easy’ trials. Indeed, all had faced
recruitment problems, and extra insights into 
the working of trials were afforded by the
descriptions of these problems, and strategies
invoked to address them. The 45 interviewees
performed a range of roles within the trials.
Enabling them to reflect within semi-structured
interviews allowed them to consider their trials as
a whole, not merely in terms of meeting
recruitment targets, and their emphasis on the
necessary foundations for building a trial is a facet
that does not appear to have been previously
reported. 
The main weaknesses of Part B have been
mentioned in Chapter 3. Only four trials were
involved, and this is not merely a small number,
but possibly atypical of successful trials. The
interviews were with people intimately involved
with the trials and therefore did not include the
perspectives of people with more peripheral roles,
such as DMCs and TSCs. No interviews were
conducted with teams within trials that were not
exemplars. These limitations were mainly due to
delays from the RECs and trust R&Ds, and to
restrictions in the STEPS period and budget. 
The implications are that it is not known to what
extent the perceptions of those involved in 
these exemplars differed from those in other 
trials that were less successful. Most, if not all, PIs
are likely to argue that their own trials are
important and timely. The other features
identified that are common to all four exemplars,
such as the importance of good communications,
are likely to be essential for successful trials, but
would not by themselves guarantee success. It 
was planned to extend this component of the
project to address these issues if further funding
had been available, but this funding was not
forthcoming.
Part C: the clinical trial as a business
The main result of Part C was to draw attention to
a body of research and practice in a different
discipline (academic business studies), and
generate a reference model derived from a
combination of business theory and work within
the CRASH trial.
Part C complements the emphasis on trial
processes in Parts A and B. Disciplines often work
on their own, and an important strength of Part C
has been to make explicit connections between the
management of trials and the management of
Discussion
62businesses. In the CRASH trial, this enabled
identification of weaker managerial components
and initiatives to strengthen them. 
The main weaknesses of Part C have been
mentioned in Chapter 4. As with Part B, it is based
on a case-study approach, and the CRASH trial
may be a different case in important ways from
other trials. For example, the CRASH trial
involved patients who were unconscious and hence
recruitment focused on the participation of
clinicians. In contrast, in most trials, efforts are
concentrated on recruitment of patients. In
addition, the management approach has not been
formally evaluated even within business settings,
and it is not clear whether the initiatives that
follow from developing and applying the reference
model will be effective in increasing recruitment
or other aspects of the success of CRASH or other
trials. 
Nevertheless, the authors see the outputs of this
component as potentially the most useful for
addressing the commissioning brief. The reference
model developed for the CRASH trial could
provide a template, with the potential for those
managing other trials to use or adapt it, 
especially at the foundation stages. Parallels 
can be drawn with professional behaviour change
research where psychological models are being
used to address the reasons for unwanted
behaviours and hence to design appropriate
strategies for behaviour change.99 The reference
model derived from this project could be used 
as a diagnostic tool if a trial has difficulties and
hence as a basis for deciding what type of
remedial action to take. It might also be useful 
for audit of a trial’s progress, such as during
external review. 
Discussion of the overall findings
from STEPS
Initially, trials that had recruited to their target
sample sizes were considered as successful, and
Part A has clearly confirmed there is a problem 
in terms of trials not reaching their targets 
within the specified time-frame and budget. 
This therefore seemed a sensible starting point
given that rigorous scientific peer review had
agreed what sample sizes were appropriate, 
and recruitment is a key element for trials, 
and it may be a sine qua non for a successful 
trial. None of the STEPS components was,
however, able to provide definitive answers about
what exactly are the causes of or the solutions 
to the problem of not achieving recruitment
targets.
Rather, the research has pointed to some of the
complexities in trials and cast light on the
question by asking: ‘what makes a trial a success?’
It was concluded that recruitment is only one
aspect of success and what matters is whether the
trial has provided answers to important questions.
‘Important’ may have a number of dimensions in
the context of trials funded by the MRC and HTA
Programme. For instance, will it have a beneficial
effect on patient care, either directly or indirectly?
Does the trial address major public health issues
for large numbers of people (as in HPS), or does it
help to clarify end-of-life decisions for a small
number of cancer sufferers (as in FOCUS)? Does it
add pieces to the jigsaw of cancer care, or is it
cutting-edge science? Does it help to reach
patients who are hard to bring in to trials (as in
ELEVATE and TOuCAN), and perhaps set up
networks of clinicians prepared to take part in
future trials?
Importance from the standpoint of Part B cannot
just be about finding positive answers, as only one
of the four trials (HPS) had reported results. With
the help of the HTA Programme and the MRC,
four exemplar trials were identified. In the
interviews for Part B, participants appeared to
agree that they were examples of successful trials.
They exuded a feeling of confidence in their
teams and shared enthusiasm about their trials.
Perhaps their self-belief was infectious and helped
them in ‘marketing their trials to their
collaborators and to their funders’.
These four trials were not unusual in returning to
funders for extensions: based on the findings from
Part A, this applies to around 50% of all trials,
most of which were awarded extra funding. It is
unclear whether this is because the trials are
underfunded in the first place, because applicants
are not able to predict the funding that will be
required, or because circumstances change
between the time of the application and the
recruitment phase of the trial, or because
investigators are strategically underbidding to get
a foot in the door to obtain some funding, even if
this is unlikely to be sufficient. Even though large
sums are spent by the MRC and HTA Programme
on trials (although the amount is small in relation
to the overall budget for the NHS), there is a
strong perception from trialists that money for
publicly funded trials is tight. Additional sources
of money were sought in three of the four Part B
trials. Although much of this was from the
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MRC and HTA Programme portfolio are for
research that industry is not interested in funding.
Dual funding brought concerns about clinical and
academic independence, and the effort to obtain
the additional funding represented an important
drain on the time and energies of the investigators.
STEPS suggested that the science and budget at
the application stage need to be complemented by
different capabilities for setting up and running
trials. Particularly in trials that may be
underfunded, the techniques of social marketing
(as used for charities), building on shared values,
may be helpful in motivating collaborators to
participate. Similarly, funders are mainly experts
in the scientific domains, but may be less skilled in
assessing the strength or weaknesses of the trial
processes.
Provisos
It should be noted that STEPS was based on MRC
and HTA Programme-funded trials. The
conclusions may therefore not generalise to other
funders of trials (e.g. charities and industry),
although some of the trials in both Parts A and B
had dual funders. In addition, the study was
conducted at a particular point in time, and 
the findings may become less relevant for future
trials. 
The research process
Multilensing
STEPS has used three different approaches to
investigate aspects of the same perceived problem
of poor recruitment in trials. At one level, these
approaches could be seen as setting down three
different roads that do not meet each other. In
practice, although some individuals were more
involved in one part than another, the three parts
have all been influenced by the different
perspectives of all those in the team, as well as the
research funders (MRC and HTA Programme).
Throughout the project, the team worked together
to develop and refine the questions and the
emerging conclusions. Bringing together this
collection of people has been a research process in
its own right, acting as a springboard for shaping
the research. This methodological pluralism
(multilensing) has resulted in a more informed
and more expert position. 
Barriers to this research
There were two main barriers to this research.
One was simply the amount of time and money
available to conduct the project. Working within
the constraints of a fixed one-year grant and a
fixed upper limit for funding, the present authors
no doubt did what they were finding the STEPS
trialists doing: making a good case for the work
they would carry out, but possibly being
unconsciously overambitious, in part to secure the
initial competitive funding. The team was also
working in the expectation, as stated in the
commissioning brief, that “continuation into a
second year may be possible, subject to review at 8
months based on emerging results”. In the event
this additional funding was not forthcoming.
The second major constraint related to the work
in Part B. As described in Chapter 3, this involved
telephone interviews with trial coordinating staff
and clinical investigators spread over the UK.
Considerable unanticipated delays occurred owing
to the need, first, to obtain MREC approval for
the study, and second, to obtain permission from
several trust R&D departments. (Again, this is
likely to have parallels with difficulties
experienced in trials that were reviewed, where
unpredicted and unpredictable problems may
have been caused by changes in the external
environment, which were often outside their
control.)
The need for MREC approval was unexpected and
time consuming, but at least only required one
central application. Permission from R&D
departments was also unexpected and even more
time consuming. It required a separate application
for each trust in which a potential interviewee was
based. The paperwork was extensive and non-
standard, and included applications for honorary
contracts and the need to provide references. The
checks verged on the ludicrous, including
completion of occupational health forms and even
a suggestion of police checks. The process was
labour intensive for the main Part B researcher,
and added at least 4 months’ delay to work on this
part. Clearly, this is disproportionate to this type
of research, which involves neither patients nor
face-to-face contact. The implications, however,
are that either this extra amount of time (and
therefore funding) needs to be built into grant
applications (and funders need to be aware of the
need to raise the funding level to take these
considerations into account), or these sorts of
studies involving a geographical spread of
interviewees will no longer be possible within
time-limited and budget-capped research projects.
This concern about disproportionate barriers to
research is not specific to STEPS (see recent
editorial100 and corresponding papers).
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trialists and funders
While not having sufficiently definitive results to
make strong recommendations, the authors
believe that the work in STEPS allows them to
make some tentative suggestions, that people
undertaking future trials ought at least to think
about the different phases in the life of trials, and
the need to put greater emphasis on the process of
actually doing trials. This implies learning lessons
from successful trial managers, with better training
facilities in this important area. Applicants could
be encouraged to predict more accurately the
feasibility of meeting their planned target sizes
and recruitment periods, and their needs for
funding.
Funders need reciprocally to encourage more
realistic applications, with the implication that, if
the same total amount of money were to be
available, fewer trials would be able to be funded,
but the ones that were should be less likely to need
further funding midway through the process. The
authors would urge that funders’ assessments
should take into account not only the science but
also the importance of the question and the
likelihood of its being answered, bearing in mind
the likely conduct of the trial. Part B suggested
that successful trials were those able to weather
storms that blew up, both because they had built
up a firm and stable structure that was unlikely to
be knocked off course, but also because they were
able to be flexible enough to adapt to unexpected
issues. Perhaps funders could assess this potential
for agility in much the same way as interviewees
for jobs are asked how they have dealt with or
would tackle a difficult situation. Arguably, the
trialists should also expect agility from funders.
The complexity of large trials means that
unanticipated difficulties are highly likely at some
time in every trial. Funders should recognise this
and be prepared to help, financially if necessary, if
the causes are beyond the trialists’ control. Both
the MRC and the HTA Programme have
developed increasingly proactive approaches to
trial monitoring, and this could be extending to
monitoring expenditure and remodelling funding
profiles in the light of developments and progress.
Funders may also need a formal process of
assessing the ‘payback’ of research101 or ‘the value
of the information’102 to be gained from funding
the trial, against other calls on scarce resources.
Ideally, this assessment would need to be kept
under observation by funders efficiently
monitoring ongoing trials.
Implications for further research
The original application for Part B had aimed to
look at a larger number of trials with different
recruitment patterns. In consultation with the
funders, the research team decided to concentrate
first on multiple voices from four exemplar trials.
To assess whether the conduct of the successful
trials might be able to provide lessons for how
other trials could be successful, further in-depth
investigation into trials with different recruitment
patterns (including ‘failures’) is necessary to
understand whether the patterns seen in the
successful trials differ or are similar. Furthermore,
although the perceptions of people intimately
involved with the trials are invaluable, the addition
of the voices of independent members of DMCs
and TSCs, who may be knowledgeable but have
sufficient distance to be more objective, could add
further insights. 
Another area for further research involves
extending the reference model developed in the
CRASH trial (in which patients were mainly
unconscious) to other settings, to see whether it
needs refinement and adaptation for other trials.
This may lead to the development of a checklist
that could be used as an audit tool for addressing
management factors. Research is also needed to
assess whether its application can help as a
diagnostic of any problem and hence to choose
strategies that are the most likely to increase
recruitment rates or other markers of the success
of a trial. Finally, these and other strategies need
to be formally evaluated for their effectiveness in a
range of trials.
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Draft template for steering committee agendas and reports
The Medical Research Council requires that independent steering committees are set up for every major
trial that it funds, and that these committees should meet at least once a year and submit a report to the
relevant research board. Presented below are guidelines on the information that should be provided by
triallists for discussion at steering committee meetings and included in the steering committee’s annual
report. It is suggested that the headings listed below should provide a basis for the agenda of the
meetings and form the template for the report. These headings may not be appropriate at every stage of
an individual trial or for all trials.
Target Achieved 
(date target set) (date achieved)
1. Name of trial
2. Grant no.
3. Sample size sought
4. Date recruitment started
5. Proposed date for recruitment end
6. Actual recruitment rate versus target rate 
(by month/quarter)
7. Acceptance rate, as a proportion of 
(i) those invited to participate and 
(ii) if known, all eligible participants
8. Quarterly/monthly forecasts of recruitment for the 
planned remainder of the trial
9. Losses to follow-up, 
(i) as a proportion of those entered and 
(ii) per month/quarter
10. No. for whom follow-up has been completed successfully 
(or still being successfully followed up)
11. Completeness of data collected
12. Any available results (pooled)
13. Any organisational problems
14. Issues specific to individual trials (to be specified by the 
steering committee)
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Appendix 1
Structure of current MRC and HTA
Programme progress reportsAppendix 1
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NHS R&D
National Coordinating
Centre for Health
Technology Assessment
(NCCHTA)
at the
Wessex Institute
for Health Research
and Development
Boldrewood
University of Southampton
Highfield
Southampton  SO16 7PX
Telephone 023 8059 5586
Fax 023 8059 5639
http://www.hta.nhsweb.nhs.uk
PROGRESS REPORT FOR A PRIMARY RESEARCH PROJECT
(All Sections Must Be Completed)
GENERAL
Project Number Lead Applicant
Project Title
Name & Address of Host Institution
Project Information
Start Date: End Date:
Details of any extensions granted:
Draft Final Report Due Date:
Progress Report Number: Progress Report Submission Date:Health Technology Assessment 2007; Vol. 11: No. 48
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PROGRESS
Summary of Project Progress to Date (specifically since the last report)
RECRUITMENT
Summary of Recruitment to Date (with respect to the project targets)
This report must be accompanied by a graphical presentation of recruitment showing actual
recruitment against target recruitment with fully labelled axes and data tablesRETENTION
Summary of Follow-up to Date (with respect to the project targets)
This report must be accompanied by a graphical presentation of retention showing actual
retention against target retention with fully labelled axes and data tables
ISSUES
Problems Encountered by the Project to Date (specifically since the last report)
Adverse Events Encountered by the Project to Date (specifically since the last report)
Appendix 1
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ORGANISATION
Changes to Protocol to Date (specifically since last report)
Changes to Project Staff to Date (specifically since the last report)
Trials Steering Committee and Data Monitoring & Ethics Committee
Does the Project have a Trials Steering Committee? No
Does the Project have a Data Monitoring & Ethics Committee? No
Yes
Yes
If  ‘No’ briefly explain why the committee has not been formed:
PUBLICATIONS
Project Outputs Submitted for Publication (specifically since last report)Appendix 1
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Conference Presentations and Media Interviews (specifically since the last report)
Acknowledgements
Have all outputs included the NHS Disclaimer?             Yes No
Yes No
Yes No
Have all outputs acknowledged HTA sponsorship?          
Have copies of all outputs been forwarded to the NCCHTA?
If ‘No’ briefly explain why:
REPORTING
Actions Recommended by the TSC/DMEC to Date (specifically since the last report)
Matters Relating to Consumer Involvement to Date (specifically since the last report)COMMENTS
Additional Comments Related to this Report
We regularly review our forms and your comments are highly valued – please pass on any
observations you may have regarding this form
Please return this form to: Hilary Bunce – Assistant Monitoring Manager
NCCHTA
Mailpoint 728 Boldrewood
University of Southampton
Southampton
SO16 7PX
E-mail: hd@soton.ac.uk
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Appendix 2
Part A: data extraction form
(see Appendix 3 for definitions)
A. TRIAL IDENTIFYING DETAILS
Title
Acronym
Grant no.
ISRCTN no.
(if available)
PI details
Name:
Address:
E-mail:
Tel: Fax:
B. ADMINISTRATIVE DETAILS
Day Month Year
/ Date of grant application submission:
/  Funding started:
/  Recruitment started:
/  Predicted recruitment closed:
/  Actual recruitment closed:
 Date of first MREC approval (if appropriate): /
/  Date of first LREC approval (if available): 
/
/
/
/
/
/
/
/
/ Date of last LREC approval (if available): Appendix 2
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C. TRIAL FEATURES
C1 Was there a pilot or feasibility phase? Yes No  Not clear
If yes, was this funded? Yes No  Not clear
C2 Was the recruitment strategy changed on the basis of the pilot? Yes No  Not clear
If yes, please give details
C3  Which disciplines did the applicants represent?
Economics Statistics HSR Consumers Other Medical
/Dental
Nursing
/PAMS
If other, please give details
C4 Where was the trial coordinated from?
Is this a Trials Unit? Yes No
C5 Was there a dedicated trial manager? Yes No Not clear
C6 Yes No Not clear Were there paid local trial staff?
Please give details about staffing (include disciplines, no. of sessions worked, etc.) Health Technology Assessment 2007; Vol. 11: No. 48
83
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C7 Were consumers involved? Yes No Not clear
If yes, please describe
If yes, at what stages  (e.g. grant application, protocol design, during retention period, throughout)?
C8 Were there any recruiting centres outside the UK? Yes No
(If subtrials within the one study split here)
C9 Design (preference, cross-over, parallel, factorial, Latin square, cluster)  
C10 Number of arms
C11 Clinical area (categories) 
C12  Which of these settings were crucial to recruitment?
Community General practice Hospital Mixed
C13  What was the geographical spread of the recruiting sites?
Regional Multiple
C14 Interventions (surgical, 
medical, etc.)
C15  Were all the interventions available outside the trial? Yes No  Not clear
C16 Inclusion criteria (age, etc.) 
D. RECRUITMENT
D1 What was the original recruitment target?
D2 Was the target revised during the trial? Yes No
If yes, what was the revised target?Appendix 2
84
D3 What was the final recruitment figure?
D4 Was the final recruitment figure? Over original target
To original target
Above revised target
To revised target
Under revised target
Under original target
Yes  No
D5 Was there a request made for an extension to the trial grant
to complete the original trial?
If yes, was there a time extension or supplementary grant to the
trial awarded?
If yes, was the extension time only?
supplementary grant only?
time and supplementary grant?
How many extensions were there?
Please give further details (length of extension, etc.) 
E. FINANCE
What was the original award? £
What was the supplementary award(s), if any £
£
£
£
£
F. DESCRIPTION OF COMPONENTS OF DELAY OR FAILURE TO REACH 
RECRUITMENT TARGET
CENTRE RECRUITMENT
F1 Was the overall start to recruitment delayed? Yes No
If yes, by how long?Health Technology Assessment 2007; Vol. 11: No. 48
85
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If yes, to what were any reasons related?
Funding issues R&D
Central staff Local research staff
MREC Local clinical arrangements
LRECs Other
No reason available
Please give details of reasons for delay and actions specified
F2 Were any centres pre-identified in the application? Yes No Not clear
(if no go to question F5)
IF YES, Yes   No Not appropriate
F3 Was there a failure to bring in any pre-planned centres
(after first had started)?
If yes, to what were any reasons related?
LREC Centre changed mind
R&D Other
Local research staff No reason available
Local clinical arrangements
Please give details of reasons for failure and actions specifiedAppendix 2
86
Yes  No
F4 Were there delays in bringing in any pre-planned centre (after first had started)? 
If yes, to what were any reasons related?
Yes  No
LREC Local clinical arrangements
R&D Other
Local research staff No reason available
Please give details of reasons for delay and actions specified
F5 Did new centres have to be recruited?
If yes, please give details (number of new centres, length of recruiting period, etc.).
What had to be done to bring in more?
F6 In total, how many centres finally ‘signed up’ to the trial?
F7 How many centres signed up but did not recruit any participants?
F8 How many centres had a delayed start?
Please describe these delays in startingHealth Technology Assessment 2007; Vol. 11: No. 48
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PARTICIPANT RECRUITMENT
F9 For the number of centres that were recruiting, was the initial (within approx. first 25% of recruiting time)
recruitment less (<80%) than expected?
No Yes, but unclear in how many sites Yes, in one site
Yes, in several sites Yes, in all sites
F10 IF YES,
a)  To what were the reasons related?
Eligible people missed Internal problem (e.g. staff)
Fewer eligible than expected External problem (e.g. publicity)
Small percentage agreeing to participate Other
No reason given
Please give details of reasons and actions specified
b)  Did all centres experience a low recruitment rate, or was there a difference between sites?
Yes No
F11 Is a recruitment graph available?
If yes, please tick to indicate that a copy has been taken.
F12 For the number of centres that were recruiting, was the later (within last approx. 75% of recruiting
time) recruitment less (<80%) than expected? 
No Yes, but unclear in how many sites Yes, in one site
Yes, in several sites Yes, in all sites
IF YES,
a)  To what were any reasons related?
Eligible people missed Internal problem (e.g. staff)
Fewer eligible than expected External problem (e.g. publicity)
Small percentage agreeing to participate Other
No reason givenAppendix 2
88
Please give details of reasons and actions specified
b)  If there was a difference between recruitment at different sites please give details
Yes  No
F13 Was overall recruitment lower than expected?
Yes  No
If yes, did this reflect early/later recruitment problems?
F14 Were there any marked changes in the recruitment rate over time?
If yes, please give details and indicate any reported reasons for this
F15 Was recruitment stopped early? No In several sites
In one site In all sites
Please give details and indicate any reported reasons for this (e.g. DMC decision)Health Technology Assessment 2007; Vol. 11: No. 48
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Yes  No Not clear
F16 Are there any records of attempts to improve recruitment?
Please give details
Any other comments/interesting featuresSection A: Trial identifying details
Descriptive details only
PI: the most recent contact details are recorded,
not necessarily those on the grant application.
Section B: Administrative details
Date of grant application submission – date that
PI signed the application.
MREC approval: date that the MREC first
approved the trial, not subsequent protocol
amendment approvals.
LREC approvals: date of first and last LREC
approvals. There could be quite a time lapse
between these dates if new centres were recruited.
Section C: Trial features
C1 Pilot phase: include either pilot or feasibility
phase that addressed anything to do with
recruitment (including changes to trial
documentation).
C3 Disciplines 
● medical, including dental
● PAMS: professions allied to medicine
(nurses, physiotherapists, occupational
therapists, etc.)
● HSR: including sociologists, psychologists
and generic methodologists
● consumers: including any representation by
consumers/consumer bodies 
● multidisciplinary: medical/dental/nursing
plus at least one other discipline.
C4 Trials unit: defined as a unit coordinating
more than one trial. 
C5 Trial manager: defined as a person
responsible for the day-to-day coordination.
C6 Local trial staff are paid, dedicated and
involved in recruitment.
C7 Consumer involvement is defined as what the
trial thought represented consumer
involvement.
C8 To be eligible for inclusion in the study, at
least one recruiting centre must be in the UK.
C9 Design: cluster trials excluded. 
C11 Clinical area: categories will be developed,
but likely to include cancer, child health,
primary health, complementary health,
mental health, cardiovascular and
cerebrovascular (see MRC disease areas at
end of document).
C13 Regional is one county/region only.
C16 Main inclusion criteria included.
Section D: Recruitment
D5 Include extensions to complete original trial
only. Extensions to carry out any
supplementary methodological work not
included. Include extensions to submit final
report if delay has been due to recruitment
phase being extended.
Section E: Finance
Section F: Components of
delay/failure to reach recruitment
target
F1 Once funding had started.
F2 Preplanned centres are defined as sites that
were identified at the time the grant was
awarded.
F5 New centres are those not identified at the
start of the trial.
F6 Based on what the trial treated as individual
sites.
F8 Centres with a delayed start: this is defined as
being relevant to their planned start, not
relative to the start of the trial.
F9 First 25% of recruiting time is approximate
only. It is specific to the early recruitment
period.
MRC disease areas
1. Cancer
2. Cardiovascular
3. Dental
4. Diabetes
5. Gastroenterology
6. Gerontology
7. Hearing research
8. HIV/AIDS
Health Technology Assessment 2007; Vol. 11: No. 48
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Appendix 3
Part A: data extraction form definitions9. Incontinence
10. Leukaemia
11. Multiple
12. Neurosciences/psychiatry
13. Obstetrics and gynaecology
14. Ophthalmology
15. Orthopaedics/rheumatology
16. Plastic surgery
17. Primary care
18. Public health/social medicine
19. Renal
20. Respiratory disease
21. Surgical
22. Training fellowship
23. Tropical medicine research 
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92MREC/03/4/102, version 2, 4th November 2003)
Address
Date
Dear Dr .........................
Re: Study recruitment to clinical trials
I am writing with regard to some research which involves staff previously or currently connected to the
XXX Unit at the YYY Hospital and involved in the ZZZ trial. The research assesses factors associated with
recruitment to randomized controlled trials and is funded by the Department of Health’s Health
Technology Assessment Programme and the Medical Research Council. It is being carried out by
researchers at the Universities of Aberdeen, London, Brighton and Cambridge. As part of this project we
are carrying out a qualitative sub-study to examine the views of those involved in a number of trials, one
of which is the ZZZ Trial. It involves interviews with medical staff who have had some experience of
recruiting to this trial. As you were involved in the recruitment of some patients to the ZZZ Trial we
would like to ask you to take part in the research.
The interviews will explore clinicians’ opinions about the trials, highlighting any specific features which
may have helped or hindered the recruitment process. The interview will not include discussion of
individual patients and we must ensure that there is no disclosure of information about individual
patients in the course of the interview. With your permission the interview would be tape-recorded. The
tape will be transcribed by a transcribing company which has been used and trusted by the researchers
for over 5 years. It would be marked confidential and a study number rather than your name would be
used to identify the tape. The opinions expressed in interview will be treated as confidential although of
course we would aim to use non-attributed comments in any publications that are written. You would be
asked after the interview to complete a one page demographic questionnaire.
There is a reply slip and prepaid envelope with this letter if you want to let me know whether or not you
are interested in taking part in the study. Alternatively you could email me if that is convenient, at
cms1000@cam.ac.uk. As we are working to a tight schedule, I will call you some time in the next week or
so unless I hear that you would prefer not to take part. In the meantime if you wish to know more about
the research you could call on the above number or email me and I would be happy to answer any
queries you have. 
Yours sincerely
Claire Snowdon 
Research Fellow .............................................................................................................................
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Appendix 4
Part B: letter for potential interviewees for
MREC application (adapted for each trial)Information Sheet (MREC/03/4/102, version 2,
4th November 2003)
A qualitative study of the professionals’ views of
recruitment patterns associated with four
MRC/HTA trials: in-depth analysis of
purposively selected case studies
You are being invited to take part in a research
study. Before you decide it is important for you to
understand why the research is being done and
what it will involve. Please take time to read the
following information carefully and discuss it with
others if you wish. Ask us if there is anything that
is not clear or if you would like more information.
Take time to decide whether or not you wish to
take part.
Thank you for reading this. 
What is the purpose of the study?
As part of a larger project which is assessing
factors associated with recruitment to trials, we are
carrying our a qualitative sub-study to examine the
views of those involved in a number of
randomised controlled trials, one of which is the
[name] Trial. The study is due for completion at
the end of March 2003.
Why have I been chosen and do I have to take
part?
The qualitative study involves interviews with
medical staff who have had some experience of
recruiting to this trial. As you were involved in the
recruitment of some patients to the [name] Trial
we would like to ask you to take part in the
research. Within the current funding we will be
carrying out approximately 30 interviews. It is up
to you to decide whether or not to take part. If
you do decide to take part you will be given this
information sheet to keep and be asked to sign a
consent form. If you decide to take part you are
still free to withdraw at any time and without
giving a reason.
What will happen to me if I take part?
The clinicians that decide to take part in the study
will be interviewed either by telephone or in
person. The interviews will explore clinicians’
opinions about the trials, highlighting any specific
features which may have helped or hindered the
recruitment process. The interview will not include
discussion of individual patients and we must
ensure that there is no disclosure of information
about individual patients in the course of the
interview. Interviewees would be asked to complete
a one page demographic questionnaire. Once the
interview and questionnaire are completed, no
further assistance with the study would be required.
With your permission the interview will be tape-
recorded. The tape will be transcribed by a
transcribing company which has been used and
trusted by the researchers for over 5 years. All
information which is collected about you during
the course of the research will be kept strictly
confidential. Any information about you which
leaves the Centre for Family Research will have
your name and address removed so that you
cannot be recognised from it. The opinions that
you express in interview will be treated as
confidential although of course we would aim to
use non-attributed comments in any publications
that are written. For individuals with specific roles
within trials, e.g. Principal Investigator or trial
manager, it is possible that you may be identified
because your name is connected with a specific
trial in the public domain. We will take every step
we can to use data sensitively for this study.
What will happen to the results of the research
study?
The results of this research are likely to be
published in 2004/5 although a report will be
available at an earlier date. Our usual policy is to
send a copy of the results to interviewees. If your
contact details are likely to change you may wish
to give us an alternative address if you do wish to
have a copy of the findings.
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Appendix 5
Part B: information sheet for potential 
interviewees for MREC application 
(adapted for each trial)Who is organising and funding the research?
The research is funded by the Health Technology
Assessment Programme and Medical Research
Council.
Who has reviewed the study?
The study has been reviewed by the Health
Technology Assessment Programme and the
Medical Research Council and their external
reviewers, and by Trent Multicentre Research
Ethics Committee, reference 03/4/102, date of
review 2/10/03.
Contact for Further Information
If you require any further information about the
study you can contact either of the following:
Claire Snowdon
Research Fellow
Centre for Family Research
Free School Lane
Cambridge CB1 8NL
Tel 01223 334508
cms1000@cam.ac.uk
Diana Elbourne
London School of Hygiene & Tropical Medicine
Keppel Street
London WC1E 7HT
Tel. 0207 927 2230
diana.elbourne@lshtm.ac.uk
What do I do now?
There are two copies of a consent form and
prepaid envelope with this letter. In accordance
with MREC approval, if you wish to take part in
the study you should sign and keep one copy of
the form, and sign and return the second copy to
me. If you do not wish to take part in the study
you could indicate this on the form, or email the
Research Fellow, Claire Snowdon, at
cms1000@cam.ac.uk, or call her on 01223
334508. As the study is working to a tight
schedule, she will aim to call you to discuss
possible participation in the study some time in
the next week or so, unless she hears from you
that you would prefer not to take part.
What if I have any concerns?
If you have any concerns or other questions about
this study or the way it has been carried out, you
should contact Professor Marion Campbell,
Principal Investigator for the study, or you may
contact Wendy Surridge at the London School of
Hygiene and Tropical Medicine. The contact
details are:
Marion Campbell
Health Services Research Unit (HSRU)
Polwarth Building
Foresterhill
University of Aberdeen
Aberdeen AB25 2ZD 
Tel. 01224 554480
m.k.campbell@abdn.ac.uk
Wendy Surridge
Registrar
London School of Hygiene & Tropical Medicine 
Keppel Street
London WC1E 7HT
Switchboard: +44 (0)20 7636 8636
Fax: +44 (0)20 7436 5389
This information sheet is for you to keep
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96CONSENT FORM
Centre Number::
Study Number: MREC/03/4/102, version 2, 4th November 2003
Interviewee Identification Number:
Title of Project: A qualitative study of the professionals’ views of recruitment patterns associated with
four MRC/HTA trials: in-depth analysis of purposively selected case studies 
(MREC/03/4/102, version 2, 4th November 2003)
Name of Researcher: Claire Snowdon
Please initial box
1. I confirm that I have read and understand the information sheet dated ............................ 
(version ............) for the above study and have had the opportunity to ask questions. [  ]
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my legal rights being affected.  [  ]
3. I agree/do not agree to take part in the above study (delete as appropriate).
________________________ ________________________
Name of interviewee Signature Date
________________________ ________________________
Researcher Signature Date
Please retain a copy for yourself and send a second copy to Claire Snowdon in the prepaid envelope provided
Other collaborators for Level 1 and Level 3 are:
Level 1
Vikki Entwistle
Reader/Programme Director (Participation in Health Care)
Health Services Research Unit, University of Aberdeen
email v.a.entwistle@abdn.ac.uk
Alison McDonald
Health Services Research Unit, University of Aberdeen
Tel. 01224 554338
email a.mcdonald@abdn.ac.uk
Rosemary Knight 
Research Co-ordinator
Medical Statistics Unit, London School of Hygiene and Tropical Medicine
Tel. 020 7927 2473
email rosemary.knight@lshtm.ac.uk
Level 3
David Francis
Brighton
email d.l.francis@brighton.ac.uk
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Appendix 6
Part B: consent form for potential 
interviewees for MREC application 
(adapted for each trial)Draft interview schedule for the
FOCUS trial central office staff
(PIs and trial managers)
This study involves four trials and there will be
specific areas of the interview that will be driven
by the individual conditions of those trials. The
study involves professionals with a variety of roles
within the trials, at the central trial office level
(principal investigators, trial managers) and a
recruiting centre level (local lead investigators,
local recruiters) and the questions will vary for
each of these individuals. Rather than producing
16 variants on the schedule, and given the semi-
structured nature of our approach, we will limit
the schedule to two approaches (trial office and
recruiting centre) and anticipate a degree of
flexibility within these. Although specific questions
are given in the schedule, it is likely that the
interview will develop over time. There is a school
of thought within qualitative methods which
permits adaptation of each interview in response
to the insights gained in the previous interview,
and so new lines of enquiry emerge as the
interviewer grows in their understanding of the
phenomenon.
We plan to interview professionals associated with
the FOCUS trial first, using a themed approach,
guided by the research recommendations in 
Ross et al. 1999 (Barriers review), of which one of
our team (Adrian Grant) is an author.
Ross et al. recommend that research is needed in
our areas and these are reflected in the schedule:
Area 1 – to identify robust scientific trial designs
which are compatible with routine
medical care and which are attractive to
clinicians and patients
Area 2 – to ascertain the optimum structure,
staffing and organisation for the
conduct of RCTs
Area 3 – to understand the problems experienced
and solutions experienced in current
RCTs
Area 4 – to understand more clearly the reasons
why clinicians and patients do or do not
take part in RCTs
The asterisks denote questions that are driven by
our findings from Level 1 (*) and from Level 3
(***) to allow some cross-reference and
comparison of data from the various parts of the
study.
Interview schedule 
Developmental stages of the trial
Would you briefly describe the early history of the
FOCUS trial, explaining why it was necessary and
what it was intended to achieve? *
How easy or difficult was it to gain support for the
trial in the developmental stages (i.e. academic,
clinical, financial support)? Were there any
particular methods you used? ***
At that stage, did you feel that there were any
factors which would aid the progress of this trial?
At that stage, what did you feel were the possible
obstacles for this trial which would have to be
overcome? ***
Were there any procedures put in place to deal
with these factors/obstacles? ***
Did you carry out a pilot study? If yes, was this
funded? If yes, did it result in any changes to your
recruitment strategies? *
Did you involve consumers in the developmental,
or any other stage, of the trial? *
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Appendix 7
Part B: interview schedule for the FOCUS the
central office staff (PIs and trial managers) for 
MREC application (adapted for each trial)Who is responsible for recruitment, and are they
paid to do so? (per recruitment/flat fee)*
Area 1: identify robust scientific trial designs
which are compatible with routine medical 
care and which are attractive to clinicians and
patients
What is the scientific design of the FOCUS trial?
(preference, parallel, multifactorial, other). How
many arms are there? 
Do you feel that this trial has a particularly robust
scientific design?
How does the design of the trial fit with routine
clinical care?
What is your impression of how clinicians view
– the scientific design of the trial 
– the importance of the trial
– the impact of the trial on their patients?
What is your impression of how patients view
– the scientific design of the trial
– the importance of the trial
– the impact of the trial on themselves?
For each trial at this point it would be appropriate to
insert questions which are relevant to what we will come
to know about each of the four trial designs, e.g. impact
of use of placebo/comparison with standard care, cross-
over designs, on recruitment.
Area 2: structure, staffing and organisation for
the conduct of the FOCUS trial
Could you describe how the trial works at a
central, trial office level, and at the level of the
local coordinators/recruiters?
Has this structure/organisation been successful?
How do you see the role of the
● PI
● trial manager
● local lead investigator
● local recruiter?
Who do you see as being responsible for
promotion of recruitment in the FOCUS trial?
How do you see the role of the
● PI
● trial manager
● local lead investigator
● local recruiter?
Do you think there is a general ‘trial ethos’ in your
centre? If yes, how does this manifest itself?
To what extent has communication between the
central trial office and the centres been successful? 
Area 3: to understand the problems experienced
and solutions experienced in current RCTs
What have been the biggest challenges for the
FOCUS trial?
How have these challenges been addressed? With
what degree of success?
We would like you to outline the progress of
recruitment to the trial, but first we need to place
the FOCUS trial in the same categories of
recruitment in trials as used in our
epidemiological review. Before describing the
progress of recruitment it would help if you could
simply state which category represents the FOCUS
trial.
● Recruitment lower/not lower than expected
● Marked change/no marked change in
recruitment
● Recruitment stopped early/finished on
time/required an extension
● Recruitment target revised/not revised during
the trial.*
Do you know what percentage of your original
target has been recruited?*
Now please expand on the progress of recruitment.
If you required an extension, please give details.
(If not covered by previous questions) Were there
any particular methods that you used to promote
recruitment? If yes, what was the basis of these
(research literature, previous experience, novel
approach)? How successful were they?*
How do you think this trial fitted with clinical
practice?
How do you think patients have responded to the
trial?
How do you see the process of recruitment itself
for the FOCUS trial? Do you think there have
been any factors which have helped or hindered?
(If not already covered) What do you feel have
been the key factors which have contributed to the
trial’s difficulties with or success in recruitment?
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why clinicians and patients do or do not take part
in RCTs
Why do you think clinical colleagues have elected
to participate in the FOCUS trial?
Why do you think patients have entered the trial?
We are interested to compare the views of our
interviewees on the relative importance of factors
which might be a barrier to recruitment in your
trial, as identified in a major review of the
literature. To allow a comparison could you give a
number, from 0 (not important) to 5 (very
important), as you would in a questionnaire, for
each of the factors listed. We would then like you
to expand on the reasons for your choice, which
we can discuss after you have identified a number.
In terms of the clinicians involved in the FOCUS
trial, how important a barrier to recruitment do
you think the following factors were/are:
● Time constraints
● Lack of staff and training
● Worry about the impact on the doctor/patient
relationship
● Concern for patients
● Loss of professional autonomy
● Difficulty with the consent procedure
● Lack of rewards and recognition
● Insufficiently interesting question?
In terms of the patients offered recruitment to the
FOCUS trial, how important a barrier to
recruitment were/are:
● Additional procedures and appointments for
the trial
● Travel problems and costs
● Patient preferences for a particular treatment
(or no treatment)
● Worry about uncertainty of treatment or trial
● Concern about information and consent
● Difficulties with the protocol
● The influence of their clinician?
Level 3 questions
For the STEPS Projects we have been investigating how
trials management may or may not benefit from theories
developed in a marketing context, i.e. how techniques
developed to improve marketing of organisations might
be used to improve accrual to trials. We would be
interested to know whether or not any of the ideas from
marketing are already being used, but possibly with a
different slant or label. We may already have covered
some of this material earlier in the interview in which
case you can just refer me back to our previous
discussion:
Could you tell us if you have used any of the
following approaches:
Did you ever define the distinctive contribution
that your trial would make?
If yes:
● Was this written down? 
● How and to whom was it communicated? 
● Did it have any effect on your planning of the
trial?
Did you have any methods of making sure that
your trial was seen as worthwhile?
Did you have any methods of maintaining its
profile among relevant groups?
How did you identify possible hindrances to the
trial, or areas where people may be resistant? How
did you deal with these problems and what was the
effect of your intervention?
Did you have particular individuals who represented
and defended the trial – in the world of marketing
they would be called sponsors or champions?
If yes:
● How did you enrol and motivate them?
● Was it successful?
Did you have any strategies for making the trial as
undemanding as possible for colleagues and
patient participants?
If yes:
● Did you experiment or modify any of the
procedures in the light of feedback? 
● By the end of the trial were you still using the
same procedures?
Optional prompt – Did you have any ways of making
it easy for clinicians and patients to incorporate
the requirements of the trial into their other
routines?
Did you involve any advertising or marketing
people for your trial?
Did you identify the points at which people could
opt in or opt out (decision points) of involvement
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increasing the likelihood that they would choose to
opt in to the trial?
Did you have any means of recognising or
rewarding professional and patient participation?
Retrospective and overview
What would you take from the FOCUS trial and
use in another setting? And why?
What would you not take from this trial and use in
another setting? And why?
What do you consider to be the key factors in the
success of this trial? And why?
This discussion has obviously focused on the
FOCUS trial, but I would be interested to hear
whether you think the FOCUS trial is very typical
of the trials you coordinate or whether you have
more general comments based on your experience
in other trials.
Reference
Ross S, Grant A, Counsell C, Gillespie W, Russell IT,
Prescott R. Barriers to participation in randomised
controlled trials: a systematic review. J Clin Epidemiol
1999;52:1143–56.
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FOCUS trial for recruiting centre
staff 
This study involves four trials and there will be
specific areas of the interview that will be driven
by the individual conditions of those trials. The
study involves professionals with a variety of roles
within the trials, at the central trial office level
(principal investigators, trial managers) and at
recruiting centre level (local lead investigators,
local recruiters) and the questions will vary for
each of these individuals. Rather than producing
16 variants on the schedule, and given the semi-
structured nature of our approach, we will limit
the schedule to two approaches (trial office and
recruiting centre) and anticipate a degree of
flexibility within these. Although specific questions
are given in the schedule, it is likely that the
interview will develop over time. There is a school
of thought within qualitative methods which
permits adaptation of each interview in response
to the insights gained in the previous interview,
and so new lines of enquiry emerge as the
interviewer grows in their understanding of the
phenomenon.
We plan to interview professionals associated with
the FOCUS trial first, using a themed approach,
guided by the research recommendations in 
Ross et al. 1999 (Barriers review), of which one of
our team (Adrian Grant) is an author.
Ross et al. recommend that research is needed 
in 4 areas and these are reflected in the 
schedule:
Area 1 – to identify robust scientific trial designs
which are compatible with routine
medical care and which are attractive to
clinicians and patients
Area 2 – to ascertain the optimum structure,
staffing and organisation for the
conduct of RCTs
Area 3 – to understand the problems experienced
and solutions experienced in current
RCTs
Area 4 – to understand more clearly the reasons
why clinicians and patients do or do not
take part in RCTs.
The asterisks denote questions that are driven by
our findings from Level 1 (*) and from Level 3
(***) to allow some cross-reference and comparison
of data from the various parts of the study.
Interview schedule 
Early stages of the trial
Would you briefly describe the FOCUS trial,
explaining why it was necessary and what it was
intended to achieve?
How easy or difficult was it to gain support for the
trial in your centre?
At that stage, did you feel that there were any
factors which would aid the progress of this 
trial?
At that stage, what did you feel were the possible
obstacles for this trial which would have to be
overcome?
Were there any procedures put in place to deal
with these factors/obstacles?
Area 1: identify robust scientific trial designs
which are compatible with routine medical care
and which are attractive to clinicians and
patients
What is the scientific design of the FOCUS trial?
(preference, parallel, multifactorial, other). How
many arms are there? 
Do you feel that this is a particularly robust
scientific design?
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Appendix 8
Part B: interview schedule for the FOCUS trial
recruiting centre staff for MREC application 
(adapted for each trial)How does the design of the trial fit with routine
clinical care?
What is your impression of how clinicians view
– the scientific design of the trial 
– the impact of the trial on their patients?
What is your impression of how patients view
– the scientific design of the trial
– the impact of the trial on themselves?
For each trial at this point it would be appropriate to
insert questions which are relevant to what we will come
to know about each of the four trial designs, e.g. impact
of use of placebo/comparison with standard care, cross-
over designs, on recruitment.
Area 2: structure, staffing and organisation for
the conduct of the FOCUS trial
Could you describe how the trial works at a
central, trial office level, and at the level of the
local coordinators/recruiters?
Has this structure/organisation been successful?
How do you see the role of the
● PI
● trial manager
● local lead investigator
● local recruiter?
Who do you see as being responsible for
promotion of recruitment in the FOCUS trial?
Do you think there a general ‘trial ethos’ in your
centre? If yes, how does this manifest itself?
To what extent has communication between the
central trial office and your centre been successful? 
Area 3: to understand the problems experienced
and solutions experienced in current RCTs
What have been the biggest challenges in your
centre for the FOCUS trial in your centre? Are
these different to the ones you feel were faced by
the trial more generally?
How have these challenges been addressed in your
centre? With what degree of success?
Would you outline the progress of recruitment to
the trial in your centre?
(If not covered by previous questions) Were there
any particular methods that you used to promote
recruitment? If yes, what was the basis of these
(research literature, previous experience, novel
approach)? How successful were they? Were these
independent of the trial office or in response to a
recruitment directive?
How has this trial fitted with your usual clinical
practice?
How have patients responded to the trial?
How have you found the process of recruitment
itself? Have there been any factors which helped
or hindered?
(If not already covered) What do you feel have
been the key factors which have contributed to
your own centre’s difficulties with or success in
recruitment?
Area: to understand more clearly the reasons why
clinicians and patients do or do not take part in
RCTs
Why did you elect to participate in the FOCUS trial?
Why do you think patients have entered the trial?
We are interested to compare the views of our
interviewees on the relative importance of factors
which might be a barrier to recruitment in your
trial, as identified in a major review of the
literature. To allow a comparison could you give a
number, from 0 (not important) to 5 (very
important), as you would in a questionnaire, for
each of the factors listed. If you wish to expand on
the reasons for your choice, we can discuss that
after you have identified a number
In terms of the clinicians involved in the FOCUS
trial in your centre, how important a barrier to
recruitment was/is:
● Time constraints
● Lack of staff and training
● Worry about the impact on the doctor/patient
relationship
● Concern for patients
● Loss of professional autonomy
● Difficulty with the consent procedure
● Lack of rewards and recognition
● Insufficiently interesting question?
In terms of the patients offered recruitment to the
FOCUS trial in your centre, how important a
barrier to recruitment was/is:
● Additional procedures and appointments for
the trial
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● Patient preferences for a particular treatment
(or no treatment)
● Worry about uncertainty of treatment or trial
● Concern about information and consent
● Difficulties with the protocol
● The influence of their clinician?
Retrospective and overview
What would you like to see taken from the FOCUS
trial and used in another setting? And why?
What would you not like to see taken from this
trial and used in another setting? And why?
What do you consider to be the key factors in the
success of this trial? And why?
This discussion has obviously focused on the
FOCUS trial, but I would be interested to hear
whether you think the FOCUS trial is very typical
of the trials that you are involved in or whether
you have more general comments based on your
experience in a range of trials.
Is there anything else that you would like to add
about the FOCUS trial?
Reference
Ross S, Grant A, Counsell C, Gillespie W, Russell IT,
Prescott R. Barriers to participation in randomised
controlled trials: a systematic review. J Clin Epidemiol
1999;52:1143–56.
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